REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
2Table of Contents  
1.0 DOCUMENT CONTROL  .................................................................................................................................... 4  
1.1  VERSION HISTORY  ........................................................................................................................................................... 4  
1.2  PROTOCOL APPROVAL PAGE ............................................................................................................................................. 7  
1.3  INVESTIGAT OR SIGNATURE PAGE ....................................................................................................................................... 8  
2.0 PROTOCOL SYNOPSIS  ...................................................................................................................................... 9  
3.0 STUDY CONTACTS  .......................................................................................................................................... 28 
4.0 INTRODUCTION  .............................................................................................................................................. 33 
4.1  BACKGROUND  .............................................................................................................................................................. 33 
4.2  RATIONALE  .................................................................................................................................................................. 39 
4.3  DEVICE DESCRIPTION  ..................................................................................................................................................... 39 
5.0 STUDY DESIGN  ............................................................................................................................................... 45 
5.1  STUDY DESIGN CHANGE AND RATIONALE  .......................................................................................................................... 45 
5.2  STUDY DESIGN OVERVIEW  .............................................................................................................................................. 45 
5.3  STUDY OBJECTIVES  ........................................................................................................................................................ 47 
5.4  STUDY ENDPOINTS  ........................................................................................................................................................ 47 
6.0 STUDY CONDUCT  ........................................................................................................................................... 53 
6.1  ENROLLMENT CRITERIA  .................................................................................................................................................. 53 
6.2  SUBJECT ENROLLMENT  ................................................................................................................................................... 54 
6.3  BLINDING  .................................................................................................................................................................... 56 
7.0 STUDY PROCEDURES  ...................................................................................................................................... 58 
7.1  STUDY SCHEDULE OF PROCEDURES AND ASSESSMENTS  ........................................................................................................ 58 
7.2  SCREENING / BASELINE  .................................................................................................................................................. 60 
7.3  CONCOMITANT THERAPIES  ............................................................................................................................................. 62 
7.4  TAVI  PROCEDURE ......................................................................................................................................................... 63 
7.5  POST-PROCEDURE FOLLOW -UP ........................................................................................................................................ 63 
7.6  ONE-MONTH FOLLOW -UP (CLINIC VISIT) ........................................................................................................................... 64  
7.7  THREE -MONTH FOLLOW -UP ............................................................................................................................................ 65 
8.0 DEVICE ACCOUNTABILITY ............................................................................................................................... 66 
9.0 ADVERSE EVENTS, SERIOUS ADVERSE EVENTS, AND END -POINTS POTE NTIALLY MEETING END -POINT 
CRITERIA  ...................................................................................................................................................................... 66 
9.1  ADVERSE EVENTS (AE) .................................................................................................................................................. 66 
9.2  SERIOUS ADVERSE EVENTS (SAE) .................................................................................................................................... 67 
9.3  ADVERSE DEVICE EFFECT (ADE) ...................................................................................................................................... 67 
9.4  SERIOUS ADVERSE DEVICE EFFECT (SADE) ........................................................................................................................ 67 
9.5  UNANTICIPATED ADVERSE DEVICE EFFECT (UADE)  ............................................................................................................. 67 
9.6  DEVICE DEFICIENCIES , MALFUNCTIONS , AND USE ERROR ...................................................................................................... 68 
9.7  END-POINTS  POTENTIALLY MEETING END-POINT CRITERIA  ................................................................................................... 68 
9.8  DOCUMENTATION  ......................................................................................................................................................... 68 
9.9  REPORTING .................................................................................................................................................................. 70 
9.10  EXPECTED ADVERSE EVENTS  ......................................................................................................................................... 72 
10.0  RISK/BENEFIT ANALYSI S ................................................................................................................................. 73 
10.1  POTENTIAL RISKS AND DISCOMFORTS  .......................................................................................................................... 73 
10.2  METHODS TO MINIMIZE RISKS ...................................................................................................................................... 73 
10.3  POTENTIAL BENEFITS  ................................................................................................................................................... 73 
11.0  STUDY C OMMITTEES  ...................................................................................................................................... 74 
11.1  PATIENT REVIEW COMMITTEE (PRC)  ............................................................................................................................. 74 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
3 
 11.2  CLINICAL EVENTS COMMITTEE (CEC)  ............................................................................................................................. 74 
11.3  DATA AND SAFETY MONITORING BOARD (DSMB)  ........................................................................................................... 75 
12.0  STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN  .................................................................................... 75 
12.1  GENERAL ANALYSIS DEFINITIONS  ................................................................................................................................... 75 
12.2  SAMPLE SIZE CALCULATION  .......................................................................................................................................... 76 
12.3  ANALYSIS POPULATIONS  .............................................................................................................................................. 85 
12.4  METHOD OF ANALYSIS AND REPORTING  .......................................................................................................................... 86 
13.0  PUBLICATION POLICY  ..................................................................................................................................... 96 
14.0  DATA COLLECTION AND MONITORING  .......................................................................................................... 97 
14.1  DATA COLLECTION AND MONITORING  ............................................................................................................................ 97 
14.2  SOURCE DOCUMENTATION AND VERIFICATION  ................................................................................................................. 98 
14.3  RECORD RETENTION  .................................................................................................................................................... 98 
15.0  ETHICAL AND REGULATORY CONSIDERATIONS  .............................................................................................. 98 
15.1  APPLICABLE REGULA TIONS  ........................................................................................................................................... 98 
15.2  INSTITUTIONAL REVIEW BOARD / MEDICAL ETHICS COMMITTEE  .......................................................................................... 98 
15.3  REGULATORY APPROVAL  .............................................................................................................................................. 99 
15.4  TRIAL REGISTRATION  ................................................................................................................................................... 99 
15.5  RECORDS AND REPORTS  ............................................................................................................................................... 99 
15.6  PROTOCOL AMENDMENTS  .......................................................................................................................................... 101 
15.7  INFORMED CONSENT  ................................................................................................................................................. 102 
15.8  TERMINATION OF THE STUDY  ...................................................................................................................................... 102 
15.9  AUDITING  ............................................................................................................................................................... 103 
15.10  PATIENT PRIVACY  ................................................................................................................................................... 103 
16.0  APPENDICES  ................................................................................................................................................. 104 
16.1  APPENDIX  I: DEFINITIONS  ........................................................................................................................................... 104 
16.2  APPENDIX II: ACRONYMS  ........................................................................................................................................... 122 
16.3  APPENDIX III: DECLARATION OF HELSINKI  ...................................................................................................................... 126 
16.4  APPENDIX IV: REFERENCES  ......................................................................................................................................... 129 
16.5  APPENDIX V: STRUCTURED INTERVIEW FOR THE MODIFIED RANKIN SCALE ........................................................................... 137 
16.6  APPENDIX VI: NIH  STROKE SCALE ............................................................................................................................... 138 
16.7  APPENDIX VII: NEUROPSYCHOLOGICAL TEST BATTERY  ..................................................................................................... 147 
16.8  APPENDIX VIII:  ANGIOGRAPHIC IMAGING ACQUISITION GUIDELINES  .................................................................................. 168 
16.9  APPENDIX IX: MAGNETIC RESONANCE IMAGING ACQUISITION PROTOCOL  ........................................................................... 170 
16.10  APPENDI X X: CT ANGIOGRAPHY IMAGING ACQUISITION GUIDELINES  ............................................................................... 182 
16.11  APPENDIX XI: SF-36 HEALTH SURVEY  ........................................................................................................................ 190 
 
  
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
41.0 Document Control  
1.1 Version History  
Version  Description 
1.0 
April 7 , 2014  Original version submitted to FDA  
2.0 
December 1 , 2014  Revised based on FDA Study Design Considerations  
3.0 
May 11, 2015  Revised based on FDA Study Design Considerations  
4.0 
July 6 , 2015  Revised based on FDA Study Design Considerations  
5.0 
December 14, 
2015  Updated description of device packaging; clarification of device 
regulatory status; clarification of CT imaging acquisition; minor 
additions to OUS adverse event reporting procedures ; minor 
administrative changes.  
6.0 
September 28, 2016 Addition of quality of life assessment and supplemental neurocognitive 
assessment; addition of CT core laboratory for evaluation of anatomic 
eligibility criteria; clarification of data to be captured from post -
procedure echocardiography performed as part of the standard of care; 
minor changes to study eligibility criteria (exclusion timeframe of prior 
stroke or TIA, range of concomitant vascular disease that would 
preclude delivery sheath access ); clarification of protocol requirements 
for study -specific  training for neurologist s performing assessments; 
minor administrative changes.  
7.0 
January 13, 2017 Primary efficacy endpoint revised to include more clinically meaningful 
threshold and evaluation time point for MoCA worsening; hypothesis -
driven second ary safety endpoints revised to add CNS infarction and 
total volume of cerebral ischemic lesions and omit stroke/TIA; 
additional prespecified exploratory analyses of primary and secondary 
efficacy endpoints; added NeuroARC -defined neurological events and 
“General Safety” composite to secondary safety endpoints; As Treated 
population modified to include all subjects exposed to the risks of the 
investigational device or procedure; mITT analysis population removed; 
revised assessment window for post -procedure NIHSS, mRS, and 
neuropsychological assessments to match post -procedure DW -MRI 
window; added frailty assessment at baseline and 90 days; added 
assessment of NYHA functional capacity, height, and weight at 
screening/baseline; eliminated select unnecessary bl ood chemistry 
tests from post -procedure assessment; updated device description to 
reflect changes to compatible commercially -available introducer 
sheaths; eliminated blinding of DSMC members based on DSMC 
request; updated Study Contacts; updated listing of  investigators and 
investigational sites; minor administrative changes.  
8.0 
March 1, 2017  Reverted previous change to blinding of DSMC members  (made in 
Version 7.0)  based on FDA recommendation  with DSMC agreement . 
DSMC members will be blinded to treatment  allocation per protocol . 
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
5The DSMC reserves the right to request unblinding  if deemed 
necessary to protect subject rights, welfare, or well -being . 
9.0 
May 1 9, 2017  Increased total sample size from up to 375 subjects (285 randomized, 
90 roll -in) to up to 495 subjects  (405 randomized, 90 roll -in). This 
prospective increase in the number of allowable randomized subjects 
is intended to prevent a delay in further enrollment if the interim analysis 
determines that additional subjects are required to ensure adequ ate 
study power. Anticipated study timelines revised; additional minor 
administrative changes.  
10.0 
June 20, 2017  Revised total sample size to 445 subjects (355 randomized, 90 roll -in) 
in response to FDA feedback.  The revised number of allowable 
randomized subjects  will be sufficient to prevent a delay in further 
enrollment if the interim analysis determines that additional subjects are 
required to ensure adequate study power.  
11.0 
December 6, 
2017- DSMB 
submission 
January
 22, 2018- 
FDA submission  Protoc ol amendments due to incorporation of a next iteration  device 
and following FDA feedback and DSMB comments on current protocol 
version.  
Changes includ e: 
Trial design - Addition of Phase II of the trial, incorporating a redesigned 
device (TriG UARD 3) into th e intervention arm and maintaining blinded 
data from the previous REFLECT trial  
Total number of expected subjects was updated to 53 3 including control 
patients from phase I . 
Randomization will be stratified by implanted valve type  (Medtronic vs. 
Edwards) . No single valve type will be implanted in more than 
approximately 70% of randomized patients  (phase II) . 
Event rate assumptions and sample size calculations - updated to 
reflect current RCT data and inclusion of controls from Phase I.  
Primary endpoint was updated- a new Tier 3 was added- Freedom from 
any MRI lesions to incorporate a meaningful clinical endpoint into the 
current hierarchy . 
MoCA assessment was excluded from this protocol as current data 
show inconclusive evidence concerning the validity and utility of this 
endpoint.  
90 days clinical visit was changed to a telephone call to assess death 
and stroke to reflect  that the  Cerebral Embolic Protection Device 
(CEPD ) is a peri -procedural device and should demonstrate its efficacy 
early . Assessment up to 30 days post procedure will ensure a correct 
balance between significant clinical efficacy and diminishing noise from 
other events such as atrial fibrillation.  
Other updates including fewer exclusion criteria due to next iteration 
device design, Cardiac bi omarkers measurements only when clinically 
indicated and updated antiplatelet treatment  recommendations  to 
reflect current standard of care.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
612.0 
July 20, 2018  
Post FDA - 
submission 
response  Protocol amendments following FDA feedback including:  
Event rate assumptions and sample size calculations - while event rates 
remained unch anged from the previous version, clarifications were 
added in regard to MRI findings and the comparison of lesion  sizes 
between patients  and to the FS methodology . 
Primary endpoints analysis  detailed and clarified. Secondary sensitivity 
analys es added.  
Adaptive design added.  
Revised Statistical Code . 
Power calculations were updated following a revised statistical code  
Study Contacts updated 
Minor grammatical and format modifications  
13.0 
November 1, 2018  
Post FDA 
Feedback on Version 12.0  Protocol amendments following FDA feedback , including:  
In Phase II, t he primary efficacy endpoint and hypothesis -driven 
secondary endpoint comparisons will be  one-sided with the level of 
significance set at  0.025.  Text was corrected to reflect a one- sided 
analysis.  
Further clarifications to the adaptive design plan per FDA request . 
Revised total Phase II sample size to 345 subjects (295 randomized, 
40-50 roll -in), from 275 subjects (225 randomized, 40-5 0 roll -in). The 
revised number of allowable randomized subjects will be sufficient to 
prevent a delay in further enrollment if the interim analysis determines 
that additional subjects are required to ensure adequate study power.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
8 
 1.3 Investigator Signature Page  
Study title:  The REFLECT Trial  
A randomized evaluation of the TriGuard™ HDH Cerebral 
Embol ic Protection  Device and the TriGUARD™ 3 Cerebral 
Embolic Protection Device  to reduce the impact of cerebral 
embolic lesions after transcatheter aortic valve implantation  
Protocol version:  13.0    
Protocol date:  November 1 , 2018  
Investigator’s Responsi bility  
Prior to participation in the REFLECT  Trial, as the site principal investigator, I understand 
that I must obtain written approval from my Institutional Review Board/ Ethics C ommittee. 
This approval must include my name and a copy must be provided to Keystone Heart Ltd. 
(or designee),  along with the approved Patient Information and Consent Form prior to the 
first enrol lment at my study site.   
As the site Principal Investigator, I must also:  
1. Conduct the study in accordance with the study protocol, the signed Clinical 
Investigation Agreement, applicable laws , 21 CFR Part 812 and  other applicable 
United States Food and Drug Administration (FDA)  regulations, any conditions of 
approval imposed by the FDA or IRB/EC, local regulations  where applicable,  
Intern ational Conference on Harmonization (ICH) Good Clinical Practice guidelines, 
and the Declaration of Helsinki, and ensure that all study personnel are appropriately trained prior to any study activities.  
2. Ensure that the study is not commenced until all approvals have been obtained.  
3. Supervise all use of the TriGuard HDH Cerebral Embolic Protection Device  and 
TriGUARD 3 Cerebral Embolic Protection Device  at my institution.  
4. Ensure that written informed consent is obtained from each subject prior to any data 
collection,  using the most recent Institutional Review Board/Ethics Committee 
approved Patient Information and Consent Form.  
5. Provide all required data and reports and agree to source document verification of 
study data with patient’s medical records by Keysto ne Heart Ltd. ( or designee) and 
any regulatory authorities.  
6. Allow Keystone Heart Ltd . personnel or its designees, as well as regulatory 
representatives, to inspect and copy any documents pertaining to this cl inical 
investigation according to national data protection laws.  
Investigator Signature  
I have read and understand the contents of the REFLECT  Trial protocol and agree to abide 
by the requirements set forth in this document.  
 
__________________________    __________________________   
Investigator Name (print)    Investigative Site (print)  
 
__________________________    ___________________________                         
Investigator Signature                                         Date   
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
9 
 2.0 Protocol Synopsis  
Title:  The REFLECT Trial  
A Randomized Evaluation oF the TriGuard™ HDH Cerebral Embolic 
Protection  Device and the TriGUARD™ 3 Cerebral Embolic Protection 
Device  to reduce the impact of cerebral embolic LEsions after trans Catheter 
aortic valve implan Tation  
Study device:  The Keystone Heart TriGuard™ HDH Cer ebral Embolic Protection  Device  
(CEPD) and TriGUARD™ 3 CEPD systems are  aortic embolism protection  
devices intended to reduce the amount of embolic material that may enter 
the carotid, subclavian, and vertebral arteries during transcatheter heart 
valve imp lantation.  
TriGuard HDH  
The TriGuard HDH consists of a temporary, sterile, single use, biocompatible 
filter, introduced transfemorally through a 9F sheath to the aortic arch. Under 
fluoroscopic guidance, the device is positioned in the aortic arch to cover  all 
3 major cerebral arteries (innominate, left carotid, and subclavian arteries), 
and is held in position by an atraumatic stabilizer in the innominate artery. 
Once the device is in position, emboli and particulate matter are diverted 
away from the cereb ral circulation and downstream to the descending aorta, 
where they are either harmless or can be treated effectively.  
The TriGuard HDH has received CE Mark and was commercially available 
in Europe and Israel  during phase I. Use of the device at European and 
Israeli sites in the REFLECT study was in accordance with its market 
approved use.  
In the United States, the TriGuard HDH was for investigational use only. The 
device has received IDE approval for use in the REFLECT study  (Phase I) .  
TriGUARD 3 
The TriG UARD 3 consists of a temporary, retrievable,  sterile, single use, 
biocompatible filter, introduced transfemorally through an 8F sheath to the 
aortic arch. The TriGUARD 3 CEPD filter includes a self -stabilizing frame 
design, a reduced pore size filter mesh,  and a redesigned delivery system  
intended for improved ease of use. Under fluoroscopic guidance, the device 
is positioned in the aortic arch to cover all major cerebral arteries (covering 
the innominate, left carotid, and left subclavian arteries), and is  held in 
position by the device’s circumferential pressure and the support of the nitinol 
shaft (external communicating device) in the aortic arch without the need for 
a stabilizer in the inominate artery . Once the device is in position, emboli and 
particu late matter are diverted away from the cerebral circulation and 
downstream to the descending aorta, where they are either harmless or can 
be treated effectively.  
The TriGUARD 3 device is for investigational use only.  
Objective:  To assess the safety and efficacy of the TriGuard HDH and TriGUARD 3 
cerebral embolic protection  device s in patients undergoing transcatheter 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
10 
 aortic valve implantation /replacement  (TAVI1), in comparison with a control 
group of patients undergoing unprotected TAVI.  
Study 
design2: This prospective, single -blind, three arm, randomized,  (2 device: 1 control),  
multicenter safety and efficacy trial is designed to enroll up to 603 total 
subjects in two consecutive phases: Phase I enrolled 258 subjects (including 
54 Roll -Ins) and utilized the TriGuard HDH and Phase II will enroll up to  345 
subjects (including 40-50 Roll- Ins) and will utilize the TriGUARD 3 (Figure 3b  
shows the patient flow/disposition).  
Phase I  
In phase I, a total of 204 evaluable subjects and 54 roll-in subjects were 
enrolled at 26 total investigational sites in the United States , Europe, and 
Israel , of which  20 sites  were  in the United States . A minimum of 50% of 
subjects were planned to be enrolled at US sites , and no single site was 
permitted to enroll more  than 20% of all subjects . 
Subjects with indications for TAVI and who met study eligibility criteria were  
randomized 2:1 (stratified by study site) to one of two treatment arms:  
• Intervention (Phase 1 Cohort)  – TAVI with the Tri Guard HDH CEPD  
• Control  – standard unprotected TAVI  
At sites where the investigator did not have  prior experience with the 
TriGuard device (minimum of 2 prior cases) , up to 3 roll-in subjects  were  
enrolled. Roll -in subjects were not  randomized, but underwent TAVI with the 
TriGuard HDH device. These cases were  proctored by a Sponsor 
representative. Investigational sites with ≥2 prior TriGuard cases were allowed to  enroll 1 roll -
in subject at the discretion of the site principal 
investigator.  
All subjects were to be followed clinically in -hospital and at 30 and 90 days, 
and to undergo  diffusion- weight ed MR imaging 2 to 5 days post -procedure, 
and neurologic  and neuropsychological testing pre- procedure, post-
procedure (2-5 days post -procedure) , and at 30 and 90 days.  
The initial randomized cohort expected  to enroll  up to 285 subjects.  
Note: Enrollment i n Phase I has been halted after enrolling a total of 258 
subjects (54 roll -ins and 204 randomized subjects including 63 controls)  
based on the recommendation of the Data Monitoring Committee following a 
review of interim 30- day data on 90 subjects at the p respecified interim 
analysis time point . A next iteration device designed for increased efficacy, 
ease of use, and improved safety will be  tested in Phase II (below).  
                                            
 
1 Throughout the protocol, the term TAVI will be used to signify TAVI in OUS and TAVR in US.  
2 REFLECT Version 10.0 intended to enroll up to 355 subjects and up to 90 roll -ins. Enrollment in this cohort 
(termed Phase I in this protocol version) was halted based on the recommmendation of the independent DSMB 
following interim data review at the prespecified interim analysis timepoint, as well as availability of the 
redesigned TriGuard 3 system, after 204 subjects were randomized and 54 roll -ins were enrolled.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
11 
 Phase II  
In Phase II, up to 295 randomized subjects and 40-50 roll-in subjects will be 
enrolled at up to 25 sites in the United States  (inclusive of sites enrolling 
subjects in Phase I) . No single site will be permitted to enroll more than 20% 
of all randomized subjects  in Phase II . 
Subjects with indications for TAVI and who meet study eligibi lity criteria will 
be randomized 2:1 (stratified by study site) to one of two treatment arms:  
• Intervention – TAVI with the TriGUARD 3 CEPD  
• Control  – standard unprotected TAVI . 
Randomization will be stratified by implanted valve type  (Medtronic vs. 
Edwards) . 
No single valve type will be implanted in more than approximately  70% of 
randomized patients (phase II).  
Roll-in subjects  (a minimum of 2 and a maximum of 3 Roll -ins per -site) will 
not be randomized, but will undergo TAVI with the TriGUARD 3  device. 
Thes e cases will be proctored by a Sponsor representative.  
All subjects will be followed clinically in -hospital and at 30 days, undergo 
diffusion -weighted MR imaging 2 to 5 days post -procedure, and undergo 
neurologic (NIHSS)  testing pre -procedure, post -procedure  (2-5 days post -
procedure) , and at 30 days.  A follow -up phone -call to assess  the occurrence 
of death  or stroke will be done at 90 days.  
The initial randomized cohort will consist of up to 225 subjects. After at least 
50% of the initial randomized cohort (approximately 112 subjects) have 
reached the 30 day primary efficacy endpoint  evaluation time point , a sample 
size reestimation will be performed in case the conditional power of the trial 
(assessed by the independent biostatistician) is > 40% but <80%, subject to 
approval by the Sponsor.  If this analysis determines that more than 225 
randomized subjects will be required to ensure adequate study power, 
enrollment may continue until the required number of subjects have been 
enrolled, or until the total subje ct limit for the study has been reached 
(whichever occurs first).  
Primary 
safety endpoint:  Combined safety endpoint (modified VARC 2 defined
1) at 30 days, defin ed 
as a composite of death, stroke, life- threatening or disabling bleeding, acute 
kidney injury (stage 2 or 3), coronary artery obstruction requiring intervention, 
major vascular complication, and valve- related dysfunction requiring repeat 
procedure.  
Primary efficacy endpoint:  
(Phase II):  
 Hierarchical composite efficacy endpoint , determined by pair -wise 
comparisons among all subjects according to the following pre- specified 
hierarchy of adverse outcomes:  
• All-cause mortality and/or any stroke (fatal and non- fatal, disabling or 
non-disabling) [evaluated at 30 days]  
o If both had a death/ stroke a time to event analysis by days will 
determine a win  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
12 
 o If both patients had a stroke at the same day the comparison 
moves to the next tier  
• NIHSS worsening (increase from baseline) [evaluated at 2 to 5 days 
post-procedure]  
• Freedom from any cerebral ischemic lesions detected by diffusion-
weighted magnetic resonance imaging (DW -MRI) 2 to 5 days post-
procedure  
• Total volume of cerebral ischemic lesions detected by diffusion-weighted magnetic resonance imaging (DW -MRI) 2 to 5 days post -
procedure  
Each subject in the intervention group will be compared with each and every 
subject  from the control group based on the above hierarchy  according to the 
Finkelstein -Schoenfeld method .
2 For example, if Subject A dies or has stroke 
and Subject B survives free of stroke to 30 days, Subject B wins (score +1) 
and Subject A loses (score -1). If both subjects die or have a stroke, the 
patient with the later event will be the winner. If both have death/stroke on 
same day it is equilibrium (score 0). If both subjects are alive and have a 
stroke on the same day, the comparison moves to the next tier of th e 
hierarchy (NIHSS worsening). If both subjects survive free of stroke to 30 
days , the comparison also moves to the next tier of the hierarchy.  After all 
between- subject comparisons have been performed, scores are summed to 
obtain a cumulative score for each subject, and outcomes between treatment groups are then compared.  
Secondary endpoints:  
 
           SECONDARY SAFETY ENDPOINTS  
The following safety endpoints will be evaluated in- hospital and at 30 days . 
Overall event rates will be reported by treatmen t group . In the Intervention 
and Roll -In groups, all safety endpoints will be adjudicated for their 
relationship to the investigational device and/or the investigational procedure 
by an independent Clinical Events Committee.  
In-hospital procedural safety, defined as the composite of the following 
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE):  
• All-cause mortality  
• All stroke (disabling and non- disabling)  
• Life-threatening (or disabling) bleeding  
• Acute kidney injury – Stage 2 or 3 (including r enal replacement 
therapy)  
• Major vascular complications  
TAVI device success  (VARC), evaluated in- hospital, defined as:  
• Absence of procedural mortality AND  
• Correct positioning of a single prosthetic heart valve into the proper 
anatomical location AND  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
13 
 • Intende d performance of the prosthetic heart valve (no prosthesis -
patient mismatch (VARC -defined) and mean aortic valve gradient 
<20 mm Hg or peak velocity <3 m/s, AND no moderate or severe 
prosthetic valve regurgitation (VARC -defined)  (site-reported)  
General  Safety, defined as the composite of the following adverse events:  
• All-cause mortality  
• All stroke (disabling and non- disabling)  
• Acute kidney injury  – Stage 3 (including renal replacement therapy)  
Mortality:  [evaluated in -hospital and at 30 and 90 days]  
• All-cau se mortality  
o Cardiovascular mortality  
 Neurologic event related mortality  
o Non-cardiovascular mortality  
Myocardial infarction:  
• Peri-procedural MI (≤72 hours after the index procedure)  
• Spontaneous MI (>72 hours after the index procedure)  
Neurological Events (component and composite):  
• Stroke  (VARC -2 defined ) [evaluated in -hospital and at 30 and 90 
days]  
o Ischemic stroke  
o Hemorrhagic s troke  
o Undetermined  
• Disabling Stroke  (VARC -2 defined) [evaluated in -hospital and at 
30 and 90 days]  
• Non-disabling stroke (VARC -2 defined) [evaluated in -hospital 
and at 30 and 90 days]  
• Transient ischemic attack (TIA)  (VARC -2 defined ) 
• Overt CNS Injury (NeuroA RC3 defined  Type 1) [evaluated in -
hospital and at 30 and 90 days]  
• Covert CNS Injury (NeuroARC defined Type 2) 
• Neurological dysfunction without CNS injury (NeuroARC defined  
Type 3) 
• CNS infarction (NeuroARC defined composite neurological 
endpoint ) 
• CNS hemorrhage (NeuroARC defined composite neurological 
endpoint ) 
Bleeding Complications:  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
14 
 • Life-threatening  bleeding  (VARC -2) 
• Major bleeding  
• Minor bleeding  
Acute Kidney Injury (AKIN Classification):  
• Stage 2  
• Stage 3  
Vascular Complications:  
• Major vascular complications  
• M ajor vascular complications  related to TriGUARD 3 
SECONDARY EFFICACY ENDPOINTS 
Hypothesis -driven Secondary Endpoints  (Phase II)  
For the following secondary endpoints, a test for superiority of each  
intervention group to the control group will be performed. To address the 
issue of multiple tests among these secondary endpoints, sequential testing  
is pla nned. Secondary endpoints will be formally tested if and only if the 
primary study hypotheses are confirmed. The secondary endpoints will be 
tested individually, in the order in which they are listed as follows:  
• All stroke [evaluated at 7 days in the e ITT population] 
• NIHSS worsening, defined as any NIHSS score increase from 
baseline  [evaluated at 2 to 5 days post-procedure in the efficacy 
Intention to Treat (eITT) analysis population] . A sensitivity analysis will 
further compare >2 points NIHSS worsening [evaluated at 2-5 days 
post-procedure in the efficacy Intention to Treat (eITT) analysis 
population]  
• Composite of all -cause mortality and all stroke [evaluated at 7 
days in the eITT population] 
• CNS Infarction  (NeuroARC defined) [evaluated at 30 days in the eITT 
analysis population]  
• Total volume of cerebral ischemic lesions detected by DW-MRI, 
[evaluated 2 to 5 days post -procedure in the efficacy Intention to Treat 
(eITT) analysis population]  
The above endpoints will be tested by this pre- specified sequence, until the 
first non -significant difference is found between the two treatment groups. 
After that, other treatment comparisons will be examined in an exploratory 
manner.  
Phase I: Hierarchical composite efficacy endpoint , determined by pair -
wise comparisons among all subjects according to the following pre- specified 
hierarchy of adverse outcomes:  
• All-cause mortality or any stroke (disabling or non- disabling) 
[evaluated at 30 days]  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
15 
 • NIHSS worsening (increase from baseline) [evaluated at 2-5 days 
post-procedure]  or Montreal Cognitive Assessment worsening 
(decrease of 3 or more points from baseline) [evaluated at 30 days]  
• Total volume of cerebral ischemic lesions detected by diffusion-
weighted magnetic resonance imaging (DW -MRI) 2 to 5 days post -
procedure  
Each subject in the  intervention group will be compared with each and every 
subject from the control group based on the above hierarchy according to the 
Finkelstein -Schoenfeld method.2 For example, if Subject A dies or has stroke 
and Subject B survives free of stroke to 30 days, Subject B wins (score +1) 
and Subject A loses (score -1). If both subjects die or have a stroke, it is 
equilibrium (score 0). If both subjects survive free of stroke to 30 days, the 
comparison moves to the next tier of the hierarchy.  
After all between- subject comparisons have been performed, scores are 
summed to obtain a cumulative score for each subject, and outcomes 
between treatment groups are then compared.  
Imaging Efficacy Endpoints  (Phase I and II)  
• Presence of cerebral ischemic lesions detected by DW -MRI, 
evaluated 2 to 5 days post -procedure  
• Number of cerebral ischemic lesions detected by DW -MRI, 
evaluated 2 to 5 days post -procedure  
• Per-patient average single cerebral ischemic lesion volume 
detected by DW -MRI, evaluated 2 to 5 days post -procedure  
• Single cerebral ischemic lesion volume (lesion -level analysis)  
detected by DW -MRI, evaluated 2 to 5 days post -procedure  
• Total volume of cerebral ischemic lesions detected by DW-MRI, 
evaluated 2 to 5 days post -procedure    
Neurologic Efficacy Endpoints  (Phase I and II)  
• NIHSS worsening, defined as an NIHSS score increase from baseline [baseline score compared with score evaluated  at 2-5 
days post -procedure and at 30 days ] 
• New neurologic impairment , defined as NIHSS worsening from 
baseline accompanied by the presence of cerebral ischemic lesions [evaluated at 2-5 days post-procedure and at 30 days ]  
 
SECONDARY PERFORMANCE ENDPOINTS  
The following perform ance endpoints will be evaluated post -procedure in the 
Intervention group ( Roll-Ins
 excluded)  (TriGuard HDH and TriGUARD 3 
reported individually):  
• Successful device deployment, defined as ability to access the 
aortic arch with the TriGuard HDH or TriGUARD 3 delivery catheter 
and deploy the device from the delivery catheter into the aortic arch  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
16 
 • Device positioning, defined as ability to position the TriGuard 
HDH or TriGUARD 3 device in the aortic arch to cover all major 
cerebral arteries, with proper position ing maintained (verified by 
fluoroscopy ) until the following time points:  
o Final deployment of the first prosthetic valve 
o Final procedure (after any additional post -dilatation or 
additional valve implantations have been completed, and 
the TAVR delivery syst em has been removed)  
Extent of cerebral artery coverage will be reported as:  
o Complete (coverage of all 3 cerebral artery branches)  
o Partial (coverage of 1- 2 cerebral artery branches)  
o None  
Note:  Maintenance of device positioning to each time point and 
extent  of cerebral artery coverage will be evaluated by the 
Angiographic Core Laboratory.   
• Device interference , defined as interaction of the TriGuard HDH 
or TriGUARD 3  device with the TAVI system leading to:  
o Inability to advance or manipulate the TAVI delivery  system 
or valve prosthesis, OR  
o Inability to deploy the TAVI valve prosthesis, OR  
o Inability to retrieve the valve prosthesis or delivery system  
• Successful device retrieval , defined as ability to retrieve the 
TriGuard HDH or TriGUARD 3 CEPD.  
• Technical success, defined as successful device deployment, 
device positioning, and successful device retrieval in the absence 
of device interference  
• Procedure success , defined as technical success in the absence 
of any investigational device- related or investigational  procedure-
related in- hospital procedural safety events  
Other measures:  The following additional measures will also be reported (TriGuard HDH and 
TriGUARD 3 reported individually) : 
o Device deployment time − Time elapsed between insertion of the 
TriGuard HDH or TriGUARD 3 device into the groin access point  and 
successful device deployment [evaluated post -procedure]  
o Total procedural time  − Time elapsed between first arterial access 
and removal of the last catheter from the arterial access sheath  
[evaluated post -procedure]  
o Total fluoroscopy time  [evaluated post -procedure]  
o Total contrast utilization [evaluated post -procedure]  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
17 
 o Health -related quality of life, as measured by the SF -36 Health 
Survey [evaluated at baseline and at 30 days , Phase I only ].  
Patient 
population:  The study  will enroll  up to 603 subjects ( 499 randomized subjects and up to 
104 roll-in subjects ) meeting approved indications for transcatheter aortic 
valve implantation.  Of these , up to 295  will be randomized in Phase II , with 
an additional 40-50 roll in patients.  
Patient Follow -Up: Phase I: All subjects were  followed clinically in -hospital and at 30 and 90 
days, underwent  diffusion- weighted MR imaging 2 to 5 days post -procedure, 
and underwent  neurologic and neuropsychological testing pre- procedure, 
post-procedure  (2-5 days post -procedure) , and at 30 and 90 days.  
Phase II: All subjects will be followed clinically in -hospital and at 30 days, 
undergo diffusion- weighted MR imaging 2 to 5 days post -procedure, and 
undergo neurologic testing pre- procedure, post -procedure (2-5 days post -
procedure) , and at 30 days.  90 days  phone -call follow -up will assess the 
occurrence of death and/or stroke.  
Study Committees:  Patient Review Committee  
A Patient Review Committee (PRC) will evaluate each potential ly eligible  
subject (Includes confirmation  that subject  meets selected anatomic eligibility 
criteria  based on imaging analysis by an independent CT core laboratory ). 
All subjects must be approved by the PRC prior  to enrollment in the trial .  
Clinical Events Committee 
An independent Clinical Events Committee (CEC) will adjudicate all site-reported cardiovascular adverse events  and all site -reported adverse events 
potential ly meeting  endpoint criteria , in an ongoing  fashion during the trial. In 
the Intervention and Roll -
In groups, relationship to the investigational device 
or investigational procedure will also be adjudicated.  
Data and Safety Monitoring Board  
An independent Data and Safety Monitoring Board ( DSM B) will be 
responsible for the oversight and safety monitoring of the study. The DSM B 
will advise the Sponsor regarding the continuing safety of the trial subjects 
and those yet to be recruited to the trial, as well as the continuing validity and 
scientific mer it of the trial. 
Antiplatelet Therapy:  Selection and dosing of antiplatelet therapy will be performed according to 
physician standard practice, in accordance with local standards of care and 
published guidelines  for TAVI procedures. Each site is encouraged to commit 
to a consistent antiplatelet regimen to be applied to all subjects enrolled in 
the trial, independent of treatment group.  
The investigators recommend (but do not require) the following antiplatelet 
regimen, and further recommend that all subjects receive dual anti -platelet 
therapy for a minimum of 6 months in the absence of contraindications:  
• ASA 75 -100 mg maintenance dose indefinitely, and  
• Clopidogrel 75 mg daily maintenance dose  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
18 
 • If the patient is on warfarin therapy prior to the procedure t he 
following is recommended:  
o Discontinue warfarin three days prior to the procedure  
o Confirm that the INR is <1.8 prior to the procedure  
o C lopidogrel 75 mg for 3 days or ASA 75 -100 mg prior to the 
procedure  
• If the patient is on warfarin therapy post -procedure  
      it is recommended that the patient is prescribed either daily aspirin 
(75-100 mg) or daily clopidogrel (75 mg)  
Minimum recommended maintenance dosages can be higher based on 
physician’s discretion.  
Inclusion 
criteria:  Subjects must meet ALL of the following criteria:  
General Inclusion Criteria  
1. The patient is a male or non- pregnant female ≥18 years of age  
2. The patient meets indications for TAVI  
3. The patient is willing to comply with protocol -specified follow -up 
evaluations  
4. The patient, or legally a uthorized representative, has been informed of 
the nature of the study, agrees to its provisions and has provided written 
informed consent, approved by the appropriate Institutional Review 
Board (IRB) or Ethics Committee (EC).  
Exclusion criteria:  Potenti al subjects will be excluded if ANY of the following criteria apply:  
General Exclusion Criteria  
1. Patients undergoing TAVI via the trans -apical, trans -axillary, trans -
subclavian, or trans -aortic route (applicable to Phase II)  
2. Patients undergoing TAVI via the trans -apical approach due to friable or 
mobile atherosclerotic plaque in the aortic arch (Phase I only ) 
3. Patients with a previously implanted prosthetic aortic valve (i.e., planned 
valve -in-valve TAVI)  
4. Pregnant or nursing subjects and those who plan pregna ncy in the 
period up to 1 year following index procedure. Female subjects of child-
bearing potential must have a negative pregnancy test done within 14 
days prior to index procedure per site standard test  
5. Patients with known diagnosis of acute myocardial i nfarction (AMI) within 
72 hours preceding the index procedure (according to definition) or AMI 
>72 hours preceding the index procedure, in whom CK and CK -MB have 
not returned to within normal limits at the time of procedure, or patients 
who are currently experiencing clinical symptoms consistent with new -
onset AMI, such as nitrate- unresponsive prolonged chest pain  
6. Patients with a history of bleeding diathesis or coagulopathy or patients 
in whom anti -platelet and/or anticoagulant therapy is contraindicated, 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
19 
 patients who will refuse transfusion, or patients with an active peptic 
ulcer or history of upper gastrointestinal (GI) bleeding within the prior 3 
months   
7. Patients with known mental or physical illness or known history of 
substance abuse that may cause non- compliance with the protocol, 
confound the data interpretation, or is associated with a life expectancy 
of less than one year  
8. Patients with severe allergy or known hypersensitivity or contraindication 
to aspirin, heparin/bivalirudin, clopidogrel, nitinol , stainless steel alloy, 
and/or contrast sensitivity that cannot be adequately pre- medicated  
9. Patients with a history of a stroke or transient ischemic attack (TIA) within 
the prior 6 months  
10. Patients with renal failure (estimated Glomerular Filtration Rate [eGFR] 
<30 mL/min calculated from serum creatinine by the Cockcroft -Gault 
formula or MDRD - Modification of Diet in Renal Disease formula) 
11. Patients with hepatic failure (Child- Pugh class C)   
12. Patients with hypercoagulable states that cannot be corrected by 
additional peri -procedural heparin  
13. Patients presenting with cardiogenic shock at the time of the index 
procedure  
14. Patients with severe peripheral arterial , abdominal aortic, or thoracic 
aortic  disease that precludes delivery sheath vascular access  
15. Patients in whom the aortic arch (Phase I and II ), innominate artery 
ostium  (Phase I only) , or proximal innominate artery  (Phase I only ) are 
heavily calcified, severely atheromatous, or severely tortuous  
16. Patients with an innominate artery ostium diameter <10 mm or  >25 mm  
(Phase I only ) 
17. Patients with a transverse aortic diameter >43 mm (Phase I only ) 
18. Patients with anatomic irregularities of the innominate artery that could 
prevent positioning of the TriGuard upper stabilizer and compromise 
stability of the device (Phase I only ) 
19. Patients with any other condition that would prevent adherence to the 
TriGuard HDH (Phase I) or TriGUARD 3 (Phase II)  Instructions for Use  
20. Patients with contraindication to cerebral MRI  
21. Patients who have a planned treatment with any other investigational 
device or procedure during the study period  
22. Patients planned to undergo any other cardiac surgical or interventional 
procedure (e.g., concurrent coronary revascularization) during the TAVI 
procedure or within 10 days prior to the TAVI procedure . NOTE: 
Diagnostic cardiac catheterization is permitted within 10 days prior to the 
TAVI procedure.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
20 
 Blinding This is a single -blind study. The following individuals will be blinded to the 
subject’s treatment allocation:  
• Subject and his/her family members  
• Site personnel administering neurological evaluations (NIHSS  or mRS  
and/or neuropsychological test battery  in Phase I ); these individuals 
will also be blinded to DW -MRI results  
• Members of the Data and Safety Monitoring Board  
• MRI Core Laboratory personnel  performing imaging analysis  
Un-blinding will occur only after the database has been locked for the 
analysis of the primary endpoint or to protect subject rights, welfare, or well -
being at the request of the DSM B. 
Analysis 
Plan:  Primary Endpoint Analysis  
Primary Safety Endpoint Analysis 
(Phase I and II3 reported individually)  
The primary safety hypothesis is that the rate of the VARC 2 Combined 
Safety Endpoint (defined as the composite of death, stroke, life -threatening 
or disabling bleeding, AKI [Stage 2/3 ], coronary artery obstruction requiring 
intervention, major vascular complication, and valve- related dysfunction 
requiring repeat procedure) at 30 days in the group undergoing TAVI with 
either protection device system (Intervention groups) is significantl y less in 
each device group (TriGuard HDH and TriGUARD 3) compared separately 
to the Performance Goal (PG) . 
The PG has been determined based on published literature reporting the 
VARC -2 combined safety endpoint in patients undergoing TAVI with 
Medtronic or  Edwards Valves. Based on an expected event rate of 25% and 
a relative non- inferiority delta of 37.5% (absolute delta 9.4%), the PG will be 
set at 34.4% (25% + 9.4%). A sample size of 179 evaluable subjects in the 
intervention group will provide 85% power to demonstrate that the 
intervention group event rate is significantly less than the PG at the 
alpha=0.05 level. After accounting for a potential 5% loss to clinical follow -
up at 30 days (including subjects who do not meet As Treated population 
criteria), the total required intervention group sample size is 190 subjects  in 
each Phase. For Phase II , the 150 subjects randomized to the TriGUARD 3 
and 40-5 0 roll -ins will constitute the primary safety population.  
The primary analysis population for the primary s afety endpoint will be the 
As Treated ( AT) population. The AT population is defined by the treatment 
actually received, regardless of the assigned treatment. In the AT population,  
subjects  in whom vascular access in the contralateral femoral artery has 
been established for the intended deployment of the TriGuard HDH or 
TriGUARD 3 device  will be assigned to the Intervention group, and subjects 
                                            
 
3 Safety power calculation was done for TriGUARD 3 independently.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
21 
 in whom the TAVI procedure is initiated (but no vascular access for intended 
deployment of the TriGuard HDH or TriGU ARD 3  is established ) will be 
assigned to the Control group.  As a secondary analysis, the primary safety 
endpoint will be evaluated in the Intention To Treat (ITT) population of 
evaluable subjects (Roll -In patients are excluded).  
 
Primary Efficacy Endpoint  Analysis  
Phase II:  
The primary efficacy hypothesis is that TAVI with the TriGUARD 3 system is 
superior to standard (unprotected) TAVI for the primary hierarchical 
composite efficacy endpoint  of all -cause mortality or any stroke at 30 days  
(Tier 1), NIHSS worsening 2-5 days post-procedure (Tier 2) , freedom from 
any cerebral ischemic lesions detected by diffusion- weighted magnetic 
resonance imaging (DW -MRI) 2 to 5 days post -procedure (Tier 3), and total 
volume of post-procedure cerebral ischemic lesions detected by DW -MRI 
(Tier 4). In tier 1 death/ stroke will be analyzed as time to event by days.   
Each subject in the intervention group of phase II  will be compared with every 
control subject (from phases I and II)  based on the pre- specified hierarchy of 
advers e outcomes  according to the Finkelstein -Schoenfeld method.2 For 
example, if Subject A dies or has stroke and Subject B survives free of stroke 
to 30 days, Subject B wins (score +1) and Subject A loses (score -1). If both 
subjects die or have a stroke  on the same day , it is equilibrium (score 0 , 
otherwise the patient with the later (by at least a day) death/stroke will be the 
winner. If both patients had a stroke on the same day the comparison will 
move to the next tier of the hierarchy.   
If neithe r subject experiences a Tier 1 event, the comparison moves to the 
next tier of the hierarchy. After all between- subject comparisons have been 
performed, scores are summed to obtain a cumulative score for each subject, 
and outcomes between treatment groups are then compared by the chi-
square test. 
Based on published clinical data from randomized controlled trials of subjects 
undergoing TAVI4-7 as well as data from the DEFLECT III randomized trial of 
TriGuard  HDH vs. unprotected TAVI8 and the r ecent SENTINEL9 trial we 
assume the following hierarchical event rates:  
Assumed Event Rates Phase II  
  Assumed 
Control Rates  Assumed 
TriGUARD 3 Rates  
Death or Stroke 11% 6% 
Worsening NIHSS  9% 6% 
Freedom from MRI Findings  
(Lesion Volume 0  mm3) 11% 27% 
Lesion Volume  (mm3)   
>0-50 7% 19% 
>50-150 33% 7.5%  
> 150  48% 46% 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
22 
 15% Missing in MRI Follow -up and 5% missing for all other parameters  
Type I Error = 5%    
Among subjects who reach third tier of the comparison hierarchy, we assume 
a 15% loss to DW -MRI follow -up (due to contraindications to post -procedure 
DW-MRI [e.g., pacemaker implantation] or subject non- compliance).  
Given these assumptions, the initial randomized cohort  sample size of 225 
subjects (2:1 randomization with 150  Intervention and 75 new control 
patients) will provide a power of >80% to demonstrate superiority ( 1-sided 
α=0.025 ) of the intervention group over the control  group for the primary 
efficac y endpoint. Notably, i n several simulations, considering different 
distributions for lesion volume and different distributions for death/ stroke, the 
study power remained greater than 80%. Adding  the 63 control  subjects 
already enrolled in REFLECT phase I for a total of 138 control subjects would 
increase the power to at least 92% to demonstrate superiority of the primary 
efficacy endpoint; poolability of the Phase I and Phase II control subject s will 
be assessed at the time of the primary analysis and the results will determine 
the control population used for the primary analysis of the primary efficacy 
endpoint . 5% loss to clinical follow  up at 30 days is included.   
As a primary efficacy analysis, the primary efficacy endpoint will be evaluated 
in the effi cacy Intention to Treat (eITT) population. The eITT population is 
defined as:  
• Subjects who are enrolled in the trial and randomized to a treatment 
group, regardless of treatment actually received AND  
• Who do not have conversion to surgery or prolonged cardiac arrest 
(>3 minutes) prior to the post -procedure DW -MRI 
Selection of the eITT population as the primary analysis population for the 
primary efficacy endpoint ensures that, should a small number of subjects 
experience an adverse event due to circumstances  unrelated to procedural 
neuroprotection (i.e., c onversion to surgery or prolonged cardiac arrest prior 
to the post -procedure DW -MRI) , the study will remain powered to detect a 
clinically -meaningful treatment effect, particularly regarding the volume of 
subclinical cerebral ischemic lesions on DW -MRI.  
If the primary endpoint is met in the primary (eITT) analysis population, 
sequential testing of the primary efficacy hypothesis will be conducted in the 
Intention to Treat (ITT) analysis population of evaluabl e subjects (Roll -In 
patients are excluded). As a secondary analysis, the primary efficacy 
endpoint and its components will be evaluated in the Intention To Treat (ITT) 
analysis population of evaluable subjects (Roll -In patients are excluded). The 
ITT popul ation is defined as all subjects who are enrolled the study, by 
assigned treatment, regardless of the treatment actually received.  An 
additional analysis will also be performed in the Per Treatment (PT) 
Population.  
The PT population is defined as subjects in the Intervention group in whom 
device positioning is maintained until final procedure with complete cerebral 
coverage, and all Control group subjects.  An additional analysis of the 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
23 
 primary efficacy endpoint with adjustment for pre -existing cerebral lesi on 
volume will also be performed in the primary eITT analysis population.  
Secondary Endpoints Analysis  (Phase I)  
The efficacy hypothesis for phase I was that TAVI with the TriGuard HDH 
system is superior to standard (unprotected) TAVI for the phase I hierarchical 
composite efficacy endpoint of all -cause mortality or any stroke at 30 days 
(Tier 1), NIHSS worsening  2-5 days  post-procedure or MoCA worsening at 
30 days (Tier 2), and total volume of post -procedure cerebral ischemic 
lesions detected by DW -MRI (Ti er 3).  
Each subject in the intervention group was to be compared with every subject 
from the control group based on the pre- specified hierarchy of adverse 
outcomes according to the Finkelstein- Schoenfeld method2. For example, if 
Subject A dies or has stroke and Subject B survives free of stroke to 30 days, 
Subject B wins (score +1) and Subject A loses (score -1). If both subjects die 
or have a stroke, it is equ ilibrium (score 0). If neither subject experiences a 
Tier 1 event, the comparison moves to the next tier of the hierarchy. After all 
between- subject comparisons have been performed, scores were to be 
summed to obtain a cumulative score for each subject, th en outcomes 
between treatment (TriGuard HDH and control ) groups were to be compared 
by the Mann- Whitney test.  
Based on published clinical data from randomized controlled trials of subjects 
undergoing TAVI  as well as data from the DEFLECT III randomized tri al of 
TriGuard vs. unprotected TAVI, we assumed the following hierarchical event 
rates:  
Event  Intervention  Control  
Death or stroke  7% 8% 
NIHSS or MoCA worsening  10% 15% 
Total Lesion Volume  70 mm3 100 mm3 
In addition, among subjects who reach Tier 3 of  the comparison hierarchy, 
we assume a 20%  loss to DW -MRI follow -up (due to contraindications to 
post-procedure DW -MRI [e.g., pacemaker implantation] or subject non-
compliance).  
Given these assumptions, a sample size of 270 evaluable subjects (180 
Intervention and 90 Control) would provide >90%  power to demonstrate 
superiority (2- sided α=0.049) of the Intervention group to the Control group 
for the primary efficacy endpoint. Therefore, the total sample size of  the initial 
randomized cohort of  285 subjects ( 190 Intervention and 95 Control) will 
provide sufficient power to evaluate the primary efficacy endpoint, even in 
the event that up to 5% of trial subjects do not meet criteria for inclusion in 
the primary efficacy analysis population**  
** Enrollment in th is cohort (termed Phase I in this protocol version) was 
halted after 204 subjects were randomized and 54 roll -ins were enrolled).  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
24 
  
Secondary Safety Endpoints  
All secondary safety endpoints will be reported by treatment group in the AT 
population of evaluab le subjects using appropriate descriptive statistics 
(sample size, mean, standard deviation, median, minimum, and maximum 
for continuous characteristics; counts and percentages of patients for 
dichotomous characteristics). No formal hypothesis testing will  be performed, 
and there is no plan to adjust alpha to account for multiple testing of 
exploratory secondary endpoints.  
The AT analysis will be considered primary. As a secondary analysis, all 
secondary safety endpoints will be evaluated in the ITT populat ion of 
evaluable subjects.  
For safety endpoints occurring in the Intervention and Roll -In groups, 
relationship to the investigational device/investigational procedure (as 
determined by an independent Clinical Events Committee) will also be 
reported.  
Seco ndary Efficacy Endpoints  
Imaging Efficacy Endpoints  
All secondary imaging efficacy endpoints will be reported by treatment group 
in the eITT p opulation of evaluable subjects (Roll -In subjects are excluded) 
with interpretable DW -MRI data using descriptive s tatistics. 
No formal hypothesis testing will be performed, and there is no plan to adjust 
alpha to account for multiple testing of exploratory secondary endpoints. 
Statistics for continuous variables will include mean, median, quartiles, 
standard deviation , minimum, maximum, and sample size for each treatment 
group. Binary variables will be summarized using frequencies, percentages, 
and sample size for each treatment group. 
The analysis of the eITT population of subject s with available DW -MRI data 
will be c onsidered primary. As a secondary analysis, all secondary imaging 
efficacy endpoints will be evaluated in the ITT population of evaluable 
subjects. An additional analysis will also be performed in the PT population . 
An additional analysis of secondary imag ing efficacy endpoints with 
adjustment for pre- existing cerebral lesion volume will also be performed in 
the primary eITT analysis population.  
Neurologic Efficacy Endpoints  
All secondary neurologic efficacy endpoints will be reported by treatment 
group in the eITT Population of evaluable subjects (Roll -In subjects are 
excluded) using descriptive statistics. No formal hypothesis testing will be 
performed, and there is no plan to adjust alpha to account for multiple testing 
of exploratory secondary endpoints.  Statistics for continuous variables will 
include mean, median, quartiles, standard deviation, minimum, maximum, 
and sample size for each treatment group. Binary variables will be 
summarized using frequencies, percentages, and sample size for each 
treatmen t group  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
25 
 The analysis of the eITT population will be considered primary. As a 
secondary analysis, all secondary neurologic and cognitive efficacy 
endpoints will be evaluated in the ITT population of evaluable subjects. An 
additional analysi s will also be performed in the PT population.  An additional 
analysis of secondary neurologic and cognitive efficacy endpoints with 
adjustment for pre- existing cerebral lesion volume will also be performed in 
the primary eITT analysis population.  
Secondary Performance Endpoints  
All secondary performance endpoints will be reported by treatment group in 
the ITT population of evaluable subjects (Roll -In subjects are excluded) using 
appropriate descriptive statistics (sample size, mean, standard deviation, 
median, minimum, maxi mum for continuous characteristics; counts and 
percentages of patients for dichotomous characteristics). No formal 
hypothesis testing will be performed, and there is no plan to adjust alpha to 
account for multiple testing of exploratory secondary endpoints . 
The ITT analysis will be considered primary. As an additional analysis, all 
secondary performance endpoints will be evaluated in the AT population of 
evaluable subjects.  
Other Measures  
Other Measures will be reported by treatment group in the ITT population of 
evaluable subjects (Roll -In subjects are excluded) using descriptive 
statistics. No formal hypothesis testing will be performed.  
The ITT analysis will be considered primary. As a secondary analysis, Other 
Measures will be evaluated in the AT population of evaluable subjects. An 
additional analysis will also be performed in the PT population.  
Subgroup Analyses  
Subgroup analyses will be performed for all primary and secondary 
endpoints in their respective primary analysis populations for the following  
subgroups , and results will be reported by treatment group using descriptive 
statistics: 
• Subjects with paroxysmal or persistent atrial fibrillation (AF) at 
baseline  
• Subjects by valve prosthesis type (Edwards vs. Medtronic)  
Roll-In Population Analysis  
The Phase II Roll -In population will be pooled with the Phase II intervention 
group for the primary analysis of the primary safety endpoint. The Roll- In 
patient population will also be used for a separate analysis of all primary and 
secondary endpoints and other measures . Additional analyses will evaluate 
primary and secondary endpoints in the pooled population of Roll -In Subjects 
plus Evaluable Subjects.  
Analysis Timing and Adjustment  
Interim Analysis  (Phase I only)  
The assumptions for powering the primary efficacy endpoint were  based on 
neurologic, cognitive, and imaging data from a limited number of subjects in 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
26 
 the DEFLECT III Trial.  Due to uncertainty regarding the primary efficacy 
endpoint, an unblinded interim analysis was planned to be conducted to re-
evaluate the sample size required to demonstrate superiority of the 
Intervention group to the Control group.  
The unblinded interim analysis was to  be conducted when 90 subjects total 
(approximately 60 Intervention group subjects and 30 Control group 
subject s) who meet the eITT population definition have completed the 30 -
day follow -up visit . At the interim analysis, the trial sample size would have 
been re-calculated, if necessary, to ensure 80% conditional power to 
demonstrate superiority (overall 2- sided α= 0.05) of the Intervention group to 
the control group for the primary efficacy endpoint, taking into account the 
interim unblinded results, according to the eITT population definition (there 
was to  be no imputation of missing data in this interim analysis; i.e., missing 
data will be excluded). The conditional power and sample size re- calculation 
for the final analysis was planned to be ascertained by computer simulations 
and by established methodology outlined in Chen, DeMets and Lan.10 
Specifically, at the interim stage, Monte Carlo simulations were to be used to 
assess the conditional power of achieving a significant Mann- Whitney test by 
the end of the study, conditioned on the distribution of the observed interim 
data. If the conditional power was found to be 50% - 80% (the “promising 
zone” according to Chen, DeMets and Lan), the plan was to use simulations 
to ascertain the increase in sample size that is required to yield 80% 
conditional power for the Mann -Whitney  test. If the interim analysis 
determined that more than 285 randomized subjects will be required to 
ensure adequate study power, enrollment would have continue d until the 
required number of subjects have been enrolled, or until the total subject limit 
for the study has been reached (whichever occur ed first).  If the conditional 
power was found to be  <50% or >80%, the study would have proceeded  as 
is without a sample size adjustment  (i.e., only the initial randomized cohort 
of 285 subjects would have been enrolled) .  
There was no intention to stop the study for overwhelming efficacy at the 
interim analysis. However, as a precautionary measure and to be 
conservative (due to the presence of an unblinded interim analysis), the 
O’Brien Fleming alpha spending method was to be used to calculate an alpha 
penalty for the final analysis regardless of whether a sample size increase is 
needed (final analysis two- sided alpha = 0.049).  
Note: Enrollment in Phase I (TriGuard HDH CEPD ) has been halted after 
enrolling a total of 258 subjects (54 roll -ins and 204 randomized subjects 
including 63 controls)  based on a recommendation of the DSMB following 
data review at the prespecified interm analysis time point . A next iteration  
device (TriGUARD 3) designed for incr eased efficacy, ease of use, and 
improved safety will be tested in Phase II.  
Adaptive Design (Phase II)  
Once at least 50% of the Phase II cohort has been enrolled and has reached 
the 30 day primary efficacy endpoint  evaluation time point, the independent 
unblinded statistician will perform a conditional power analysis. If the trial, 
based on the results at that point is either ≤ 40% powered to achieve success 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
27 
 in meeting the primary endpoint or is ≥80% powered to achieve the primary 
endpoint , no sample size reestimation will be required. If the conditional 
power of the study is >40% but <80% the independent unblinded statistician 
will recommend a sample size reestimation, subject to approval by the 
Sponsor.  
Promising zone computation  
After the trial has enrolled 50% of the originally planned sample size of the 
initial randomized cohort  (approximately 112 subjects ), an independent 
statistician will estimate all 4 levels of the Finkelstein -Schoenfeld hierarchy 
for device and control, and use these estimates to re-calculate the trial’s 
power given the originally planned 225 Phase II patients.   
If the trial power is between >40% and <80%, the trial will be considered 
promising and the trial will readjust the sample size to attain 80% power. If 
on the other hand t he power falls to ≤ 40% or to ≥ 80%, the sample size will 
not be adjusted.  
Conditional power computation  
The conditional power will estimate all four Finkelstein- Schoenfeld levels and 
use these estimates to simulate future enrolled patients. The power 
simulation will fol low exactly the same algorithm as used to power the original 
Phase II study with updated estimates of effect size.  
Alpha spending and controlling type I error  
Since the study leadership and sponsor do not conduct any formal statistical 
hypothesis  test, this design will not incur any alpha penalty or affect the 
overall type I error. As detailed by Mehta and Pocock11 and based on the 
work of Chen10 as long as the sample size reestimation occurs only when  
the conditional power falls in the promising zone, no additional alpha spend 
is required and the overall type I error is preserved.   
Anticipated 
timelines:  Phase I  
Initial Enrollment:  
Last Enrollment:  
30 days follow -up: 
90 days follow -up: 
Phase II  
Initial Phase II Enrollment:  
Last Enrollment:  
30 days follow -up: 
90 days follow -up:  
June 2016  
July 2017  
September  2017 
November  2017  
 
June 2018  
December  2018  
January  2019 
March  2019  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
28 
 3.0 Study Contacts  
Sponsor  Keystone Heart Ltd.  
Keystone Heart , Ltd.   
3000 Bayport Drive, Suite 980   
Tampa, FL 33607  USA 
 Keystone Heart Research and Development Ltd.  
15 Halamish St.  
P.O. Box 3170  
Caesarea Business Park 3088900  
Israel  
Contact s: 
M. Pauliina Margolis, MD, PhD  
Chief Medical Officer  
Tel: 305.972.8447  
email: pauliina.margolis@keystoneheart.com
  
Ron Nitzan, PhD  
Vice President, Regulatory and Quality Affairs  
Tel: +972 4 615 8005  
Fax: +972 4 615 8099  
email: ron.nitzan@keystoneheart.com  
  
Study Chairman  Jeffrey W. Moses, MD  
Director, Cardiovascular Interventions  
New York Presbyterian Hospital/ Columbia University Medical Center  
161 Fort Washington Ave., 5
th Fl. 
New York, NY 10032 USA  
Tel:  (212) 342- 3601  
email: jm2456@cumc.columbia.edu   
 
Principal Investigator  Tamim M. Nazif, MD  
Director of Clinical Services for the Structural Heart & Valve Center, Director of Clinical Research for the Center  for Interventional 
Vascular  Therapy,  New York Presbyterian 
Hospital/ Columbia University Medical Center  
161 Fort Washington Ave., 5
th Fl. 
New York, NY 10032 USA  
Tel:  (212) 342- 0444  
email: tmn31@cumc.columbia.edu  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
29 
 US Co -Principal Investigator  Alexandra J. Lansky, MD  
Associate Professor of Cardiology  
Director, Yale Cardiovascular Research Group  
Co-Director, Yale Valve Program  
Yale University School of Medicine  
135 College Street, Suite 101  
New Haven CT 06510 USA  
Tel: (212) 737- 2142 
email: alexandra.lansky@yale.edu   
US Co -Principal Investigator  
 Rajendra Makkar, MD  
Director, Interventional Cardiology and Cardiac 
Catheterization Laboratory  
Co-Director, Interventional Cardiology Research 
Program Cedars -Sinai Medical Center  
127 S. San Vicente Blvd, Advanced Health Sciences Pavilion, Third Floor, A3600  
Los Angeles, CA 90048 USA 
Tel: (310) 423- 3871 
Email: raj.makkar@cshs.org
  
EU Co -Principal Investigator / 
Coordinating Investigator  
(Phase I)  Andreas Baumbach, MD  
Chair for Device Innovation  
Queen Mary University London  
Consultant Cardiologist and Director of Interventional Research Barts Heart Cent re, St. Bartholomew’s Hospital  
West Smithfield  
London EC1A 7BE UK  
email: a.baumbach@qmul.ac.uk
  
  
EU Co -Principal Investigator / 
Coordinating Investigator  
(Phase I)  Joachim Schofer, MD  
Medical Director, Medical Care Center  
Hamburg University Cardiovascular Center  
Wördemanns Weg 25 -27 
Hamburg 22527, DE  
Tel: +49 (0 40) 889009-0 
email: schofer@herz -hh.de   
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
30 
 Regulatory, Angiographic Core 
Laboratory, Clinical Events 
Committee, Data Safety Monitoring Committee  
(phase I)  
  Yale Cardiovascular Research Group  
Yale University School o f Medicine  
135 College Street, Suite 101  
New Haven CT 06510 USA  
Contacts:  
Alexandra J. Lansky, MD  
Director  
Tel: (203) 737- 2142 
Fax: (203) 737- 7457  
email: alexandra.lansky@yale.edu  
Louise Gambone, RN  
Directo r of Operations  
Tel: (203) 737- 3427 
Fax:(203) 737- 7457 
e-mail: louise.gambone@yale.edu  
Angiographic Core Laboratory, 
(Phase II)  Cardiovascular Research Foundation  
Clinical Trials Center  
1700 Broadway, 9th Floor  
New York, NY 10019  
Tel: ( 646) 434-4500 
Fax: (646) 434- 4711  
e-mail: info@crf.org  
 
Contacts:  
Ivana Jankovic, MD  
Director , Core Lab Operations  
Tel: (646) 434-4388 
Fax: (646) 434-471 
e-mail: ijankovic@crf.org  
Clinical Ev ents Committee , 
Biostatistics  
(Phase II)  
 Cardiovascular Research Foundation  
Clinical Trials Center  
1700 Broadway, 9th Floor  
New York, NY 10019  
Tel: ( 646) 434-4500 
Fax: (646) 434- 4711  
e-mail: info@crf.org  
Data Safety Mo nitoring Committee  
(Phase II)  Yale Cardiovascular Research Group  
Yale University School of Medicine  
135 College Street, Suite 101  
New Haven CT 06510 USA  
Contacts:  
Louise Gambone, RN  
Director of Operations  
Tel: (203) 737- 3427 
Fax:(203) 737- 7457 
e-mail: louise.gambone@yale.edu  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
31 
 MRI Core Laboratory , CT Core 
Laboratory, Monitoring (US), Data 
Management  Global Institute for Research, LLC  
14701 Village Square Place, Suite B  
Midlothian, VA 23112 USA  
 
Contacts : 
Szilar d Voros, MD  
Chief Medical Officer  
email:  szilard.voros@globalifr.com   
Brad ley Brown , MS, MBA  
Chief Executive Officer  
Tel: +1 804 638 8598  
Fax: +1 804 884 3885  
email:  brad.brown@globalifr.com   
  
Monitoring ( OUS ) (Phase I)  genae N.V.  
Europaallee 41  
8021 Zürich , Switzerland  
Tel: +32 3 290 0306  
Fax: +32 3 290 0307  
 Contact:  
Evert Verbraak, PhD  
Director, Operations  
email: evert.verbraak@genae.com
 
Biostatistics  (Phase I)  CardioMed Device Consultants, LLC  
5523 Research Park Drive, Suite 205  
Baltimore, MD 21228 USA  
 Contact:  
Victor Novack, MD, PhD Tel: (410) 674- 2060 
Fax: (410) 674- 2133  
Email: vnovack@cardiomedllc.com
  
  
Biostatistics  (Phase II)  Cardiovascular Research Foundation  
Clinical Trials Center  
CRF Imaging Core Labs  
1700 Broadway, 9th Floor  
New York, NY 10019, USA  
 Contact:  
Thomas McAndrew, PhD  
Tel: ( 646) 434-4570 
Fax: (646) 434- 4711  
e-mail: tmcandrew@crf.org
 
 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
32 
 Patient Review Committee  Cedars Sinai Medical Center Heart Institute  
CT Core Laboratory  
127 S San Vicente Blvd 
Advanced Health Sciences Pavil ion, 3rd Floor  
Los Angeles, CA 90058 USA  
 Contact:  
Rahul P. Sharma, MD  
Email: Rahul.Sharma@cshs.org   
  
 
  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
33 
 4.0 Introduction  
4.1 Background  
4.1.1  Periprocedural Stroke  
Stroke is a dreaded complication of endovascular procedures due to its association with an 
extreme morbidity and mortality burden.12, 13 Periprocedural stroke rates increase with the 
complexi ty of cardiac surgery, ranging from 1-5% for coronary artery bypass graft surgery 
(CABG) or isolated aortic valve replacement to as high as 7.4% for combined CABG and valve surgery and 9.7% for multiple valve surgery.
14 Periprocedural stroke during catheter -
based cardiovascular procedures is also a major concern. While stroke after left heart catheterization or percutaneous coronary intervention (PCI) is rare (<0.5%),
15 it is associated 
with significant morbidity and an in- hospital mortality rate of 25% to 30%.16, 17 
Cerebral microembolism is the primary mechanism of periprocedural stroke during catheter -
based interventions, and is primarily caused by embolization of aortic plaque dislodged during  
retrograde instrumentation of the aortic arch.18 In particular, retrograde catheterization with 
crossing of the aortic valve has been associated with focal diffusion- imaging abnormalities 
suggesting cerebral embolic events in 22% of patients, in addition to a 3% rate of clinical neurological deficits.
19  
Given the frequency and dire implications of periprocedural stroke, methods to reduce cerebral embolism during cardiac interventions are sorely needed.  
4.1.2  Transcatheter Aortic Valve Implantation and Cerebral  Injury  
4.1.2.1.1  TAVI and Periprocedural Stroke  
Transcatheter aortic valve implantation (TAVI) has emerged as an important alternative to surgical aortic valve replacement ( SAVR) for high -risk and moderate -risk patients with aortic 
stenosis, offering overall less morbidity, similar mortality and significantly reduced recovery 
time.
4, 20-22 However, periprocedural neurological injury remains an important limitation of 
TAVI. In high -risk surgical candidates in the randomized PARTNER trial, TAV I was 
associated with an approximately two- fold increased risk of stroke or TIA (5.5% vs. 2.4%, 
p=0.04) compared with SAVR at 30 day s.4 In inoperable subjects, stroke or TIA occurred in 
6.7% of TAVI patients at 30 days, with 5.0% of subjects suffering a major stroke.5 A meta-
analysis of 10,037 published TAVI patients found an overall 30- day stroke rate of 3.3±1.8%, 
with the majority being major strokes (2.9±1.8%).23 In this study, stroke was associated with 
a more than 3.5- fold increase in 30- day mortality (25.5±21.9% vs. 6.9±4.2%).  
In the more recent PARTNER 2 trial, the rates of any stroke in moderate risk patients with AS after TAVI were similar to the rates after SAVR: 5.5% vs. 6.1% at 30 days and as high as 9.5% vs. 8.9% at 2 years, for TAVI and SAVR respectively.
22 
The timing of stroke after TAV I follows a bimodal distribution. The risk of stroke during an 
early high -peaking hazard phase (within 2 days of the procedure) is primarily procedure -
related (TAV I versus SAVR).24 More than 50% of strokes in TAV I patients occur during this 
early phase. During a later constant hazard phase (1 to 12 months post-procedure), pati ent 
factors including generalized heavy atherosclerotic burden, recent cerebral ischemic event, and higher NYHA class appear to be the primary determinants of risk.  
As during other types of cardiac procedures, periprocedural stroke during TAVI is generally  
ischemic and embolic.
25 TAVI patients have several high- risk features that make cerebral 
embolization particularly common. First, the prevalence of severe aortic atherosclerosis increases across grades of AS, which when combined with the large- caliber catheters 
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
34necessar
y for TAVI, make dislodgement  of aortic debris more likely .26 Second, disruption of 
aortic valvular and annular calcification during TAV I is an additional source of embolic 
material; procedural transcranial Doppler monitoring indicates that the valve itself is the 
primary source of cerebral emboli following TAV I, and that most emboli are c omposed of 
debris dislodged during direct manipulation of the calcified aortic valve and crushing of the 
leaflets and aortic annulus during implantation.27  
4.1.3  TAVI and Silent Cerebral Ischemia 
In addition to clinical stroke, there is increasing recognition of the impo rtance of subclinical 
manifestations of periprocedural cerebral embolization in cardiac procedures in general and 
TAVI in particular.28-30 A growing body of evi dence indicates that clinically silent cerebral 
ischemia  is common after TAVI and may have an important impact on clinical and 
neurocognitive outcomes.  
Diffusion -weighted magnetic resonance imaging (DW -MRI) is a highly sensitive and specific 
technique to visualize acute ischemia.31 Acute ischemia presents on DW -MRI as a 
hyperintense area against the dark background of normal tissue, allowing detection of even small lesions. MRI -based methods have greater sensitivity to detect cerebral infarcts, 
particularly small lesions, compared with computed tomography (CT) due to stronger field magnets, thinner slices, and different pulse sequences.
32 DW-MRI has an average sensitivity 
of 94% and specificity of 97% in detecting stroke in humans.33 It has been used extensively 
as a surrogate for cerebral embolization after catheter -based and surgical cardiovascular 
interventions.31, 34 In addition, standardized endpoint definitions  for TAVI trials (VARC -2)  
include MRI or computed tomographic  neuroimaging as an important  supplement to the 
clinical diagnosis of stroke and TIA, as well as a requisite for diagnosing stroke in patients with non- focal global encephalopathy.
35  
Several small  studies (Tables 1 -4) have reported DW -MRI data after unprotected TAVI. Foci 
of restricted cerebral perfusion on DW-MRI (cerebral ischemic  lesions) are present in 
approximately 77% of patients (reported range 58% to 93%) after TAVI (Table 1). Most 
patients have multiple lesions (mean 4.6) ( Table 2) , distributed bilaterally in a pattern 
suggesting cerebral embolization. Several studies have reported the volume of single (Table 3) and total per -patient (Tables 4 and 5) lesion volumes after TAVI, with wide variance
between studies; the relative degree to which this variation is attributable to methodological 
and patient -level differences in the extent of affected cerebral tissue is unclear .  
Table 1.  Reported Incidence of Ischemic Lesions on Post -TAVI DW -MRI
Study  Sample Size (N) Subjects with 
Lesions (n)  Proportion with 
Lesions (n/N)  
Arnold 201036 25 17 68% 
Astarci 201337†* 44 41 93% 
Fairbairn 201238 31 24 77% 
Ghanem 201339† 39 28 72% 
Kahlert 201040 * 32 27 84% 
Knipp 201341 12 7 58% 
Rodes -Cabau 201120* 60 41 68% 
Uddin 201342 45 37 82% 
Average  36 28 75% 
Weighted Mean  -- -- 77% 
† Multiple publications with overlapping data. Data from the most recent (and largest) reports are provided.  
* Data from studies reporting sepa rate results from multiple study arms were pooled.
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
35 
  
Table 2. Reported Number of Ischemic Lesions on Post -TAVI DW-MRI 
Study  N Lesion Count  
Range (min, 
max)  Mean  SD Median  IQR [25 -75] 
Astarci 201337†* 44 -- 7.9 -- -- -- 
Fairbairn 201238 31 -- 4.2 6.5 2 1-5 
Ghanem 201043‡ 22 0, 19  3.4 5.1 1.5 0.25-4 
Kahlert 201040* 32 0, 19  3.6 -- -- -- 
Knipp 201341 12 0, 5 1.8 1.9 1.5 -- 
Onsea 201 244 20 -- 7.2 -- -- -- 
Rodes -Cabau  201120* 60 1, 36  4.2 -- 3 2-8 
Average  31.5 0, 20  4.6 -- 2 1-6 
† Multiple publications with overlapping data. Data from the most recen t (and largest) report is provided.  
* Data from studies reporting separate results from multiple study arms were pooled.  
‡Multiple publications with overlapping data. Data from the first report were used because patient -level 
data was provided, allowing ca lculation of SD, median, and IQR.  
 
Table 3.  Reported Single -lesion Volume on Post -TAVI DW-MRI 
Study  N Per Lesion Volume (cm3) 
Range (min, max)  Mean  SD Median  IQR [25 -75] 
Astarci 201337†* 44 -- 0.17 -- -- -- 
Fairbairn 201238 31 -- 0.49 -- -- -- 
Ghanem 201043‡ 22 0, 11.7  0.76 2.47 0.15 0.025 -0.33 
Kahlert 201040* 32 0.059, 0.094  0.075  -- -- -- 
Knipp 201341 12 0.015, 1.21  0.172  0.283  -- -- 
Average  28.2 0.025, 4.33  0.334  -- 0.15 -- 
† Multiple publications with overlapping data. Data from the most recent (and largest) report is provided.  
* Data from studies reporting separate results from multiple study arms were pooled.  
‡Multiple publications with overlapping data. Data from the first report were used because patient -level 
data was provided, allowing calculation of SD, median, and IQR.  
 Table 4.  Reported Total Lesion Volume (Per -Subject) on Post -TAVI DW-MRI 
Study  N Per Patient Lesion  Volume (cm3) 
Range (min, max)  Mean  SD** Median  IQR [25 -75] 
Astarci 201337†* 44 -- 1.65 -- -- -- 
Fairbairn 201238 31 -- 2.05 3.50 -- -- 
Ghanem 201043‡ 22 0, 70.3  4.3 14.9 0.30 0.025 -1.23 
Uddin 201342 45 -- 1.74 2.8 -- -- 
Average  36 -- 2.44 5.5 -- -- 
Weighted Average  -- -- 2.18 4.5 -- -- 
† Multiple publications with overlapping data. Data from the most recent (and largest) report is provided.  
* Data from studies reporting separate results from multiple study arms were pooled.  
‡Multiple pu blications with overlapping data. Data from the first report were used because patient -level data 
was provided, allowing calculation of SD, median, and IQR for per -patient total lesion volume.  
** Average and weighted average Standard Deviations calculated using SD per unit method  
 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
36 
 Table 5.  Reported Total Lesion Volume (Per -Subject) on Post -TAVI DW-MRI - Excluding 
Subjects Who Experienced a Stroke  
Study  N Per Patient Lesion Volume (cm3) 
Range (min, max)  Mean  SD**  Median  IQR [25 -75] 
Astarci 201337†* 44 -- 1.65 -- -- -- 
Fairbairn 201238¥ 29 -- 1.1 1.1 -- -- 
Ghanem 201043‡¥ 21 0, 7.8  1.16 2.08 0.30 0-1.00 
Uddin 201342 45 -- 1.74 2.8 -- -- 
Average  35 -- 1.41 2.07 -- -- 
Weighted Average  -- -- 1.49 2.18 -- -- 
† Multiple publications with overla pping data. Data from the most recent (and largest) report is provided.  
* Data from studies reporting separate results from multiple study arms were pooled.  
‡Multiple publications with overlapping data. Data from the first report were used because patient -level data 
was provided, allowing calculation of SD, median, and IQR for per -patient total lesion volume.  
** Average and weighted average Standard Deviations calculated using SD per unit method  
¥ Strokes excluded  where possible (1 subject with a major stroke [Ghanem 2010] and 2 subjects 
with unspecified stroke [Fairbairn 2012])  
The clinical significance of asymptomatic DW-MRI lesions is incompletely characterized. 
However, in  population -based studies  the presence of clinically silent brain infarcts has bee n 
associated with frailty, declines in physical function, reduced cognitive ability, depressive 
symptoms, and an increased risk of subsequent stroke  or TIA .32, 45, 46 Several studies have 
found an association between DW-MRI lesions and neuropsychological deficits after 
conventional valve surgery,47, 48 and DW-MRI lesions have also been associated with 
chemical markers of neuronal damage that in turn correlate with postoperative cognitive deficits and embolic stroke.
49  
Thus far, small studies of DW-MRI lesions after TAV I have failed to detect an association 
between post -procedural ischemic lesions  and risk of future neurological events36, 50, 51 or 
measurable impairments of neurocognitive function (using the Mini Mental State Examination).
20, 40, 43, 52 However, concerns remain about the potential impact of even 
transient and asymptomatic ischemic lesions on long -term cognitive outcomes and other 
neurological syndromes.33, 53- 57  
DW-MRI studies examining neurocognitive outcomes after TAVI have been exploratory (not 
powered to detect clinically meaningful neurocognitive changes) and lack long term follow -
up. Furthermore, while routine clinical examination can reliably detect focal neurological abnormalities and deficits, more subtle evidence of global neurological dysfunction such as cognitive decline, memory and mood disturbances, reduction of psychomotor speed, and personality changes require specific testing for diagnosis and may be missed. The MMSE, 
the most frequently used cognitive test in these studies, is relatively insensitive to mild cognitive impairment and declines in non- memory domains .
58 These issues are likely to 
receive increased attention as the indications for TAVI are expanded to younger populations 
with increased life expectancy.  
4.1.4  Stroke Assessment - National Institute of Health Stroke Scale- 
NIHSS  
The NIHSS w as first derived by Brott et al.  to assess stroke severity in a naloxone trial59 and 
later modified and utilized in a tPA trial  by the NINDS60. While t he scale has been shown to 
have prognostic implications61-64, the timing of conducting the NIHSS assessment and the 
number of points considered as ‘true worsening’ differs between trials65-71. Previous Cerebral 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
37 
 Embolic Protection Device ( CEPD) trials (DEFLECT III8, EMBOL -X72, MISTRAL -C73, and 
CLEAN -TAVI74) hav e used a cut -off of 1 point (See below).   
4.1.5  Prevention of Periprocedural Cerebral Embolism  
The devastating consequences of periprocedural stroke during TAVI, as well as concern 
regarding  potential long -term neurocognitive sequelae of subclinical  cerebral embolic events, 
have prompted investigation into methods to minimize or prevent periprocedural cerebral 
embolism during cardiac surgery and endovascular interventions.  Because atheromatous 
and calcific embolic are substantial contributors to cerebral embolism  during TAVI, a 
mechanical means of preventing such material from reaching the cerebral circulation could 
be an effective approach. Because approximately 50% of TAV I-related neurological events 
are directly procedure- related,23 such devices could have a meaningful impact on stroke and 
other cerebral embolic events in TAVI patients.  
The DEFLECT I Trial (NCT01448 421) of the  first-generation TriGuard cerebral embolic 
protection device (CEPD)  (from which the TriGuard HDH  device and the TriGUARD 3  device  
used in the present study were  developed) demonstrated good procedural success and 
safety, as well as a reduction in total per -patient cerebral ischemic lesion volume after TAVI 
with embolic protection compared with a historical control of unprotected TAVI.75  
Table 6. Comparison of Post -TAVI DW-MRI Lesion Data for TAVI Without vs. With Embolic 
Protection  
Parameter  Unprotected TAV I 
Historical Average  TAVI with Embolic 
Protection  
Incidence of lesions  
[proportion of patients]  77% 78.6% 
Number of lesions  
[mean (range)]  4.6 (0- 36) 5.1±6.1 (0-28) 
Single lesion volume  
[mean (range)]  0.33 (0. 075 – 0.76) 0.13±0.13 (0 – 0.47) 
Total lesion volume  
[mean (range)]  2.18±4.5  (1.65 – 4.3) cm3 0.77±0.96 (0 – 3.94) cm3 
Results of the DEFLECT I trial of the first -generation TriGuard device (n=28 subjects with p aired DW -
MRI)  compared with Historical Average (Tables 1 -4 above)  
 
Thus far, several randomized control trials have addressed the issue of embolic protection 
device during TAVI.  
The DEFLECT  III trial8 included 85 patients and evaluated the efficacy of the TriGuard HDH 
device. Complete cerebral vessel coverage was achieved in 89% of subjects. Device use was associated with greater freedom from ischemic brain lesions  and a shift towards smaller 
lesion volumes compared to controls.  Clinically, device protection afforded better 
neurocognitive function and numerically lower rates of death and stroke.  
The EMBOL -X trial
72 included 30 patients , with half of the patients randomized to protection 
with the EMBOL -X device (self -expandable mesh placed in the aorta). Protected patients had 
fewer lesions and the authors  reported statistically significant smaller lesion  volumes in the 
supply region of the MCA.  No mortality was observed in this trial in both groups.  
Mistral - C73 included 55 patients with 1:1 randomization to protection with the SENTINEL 
device (2 cone shaped filters placed into the brachiocephalic trunk and the left common 
carotid artery). Patients with SENTINEL protection had numerically fewer lesions and a 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
38 
 smaller total lesion vol ume.  Neurocognitive deterioration was present in 4% of patients with 
device protection and 27% of patients without (p=0.017). Mortality was also reduced in the 
device arm (not statistically significant).  
CLEAN -TAVI74 published in 2016 included 100 patients  with 50 patients randomized to 
device protection with Claret (2 cone shaped filters described above). The trial showed a 
statistically significant reduction in the number of lesions and total lesion volume in the device arm. Stroke rates were similar between groups and one death occurred in the control group.  
Finally, the  recently published SENTIN EL trial
9 included 119 controls and 242 device patients 
(including 123 safety patients). Patients in the device arm had smaller lesion volumes and a lower number of lesions.  Stroke rates were reduced in the device arm but no differ ence was 
noted in neurocognitive function between groups.  
* MRI and other clinical results in the trial s above were not statistically significant unless 
otherwise mentioned.  
Major trials and their MRI findings are summarized in table 6a.  A comparison of t he different 
clinical endpoints assessed in these trials is presented in table 6b.  
Table 6a . MRI findings in RCTs using device protection in TAVI.  
Trial*  N Percent of patients 
with MRI lesions  Median Number 
of MRI lesions  Median Total Lesion 
Volume (mm^3)** * 
Device  Control  Device  Control  Device  Control  
DEFLECT III8 2015  85 78.8%  88.46%  7 4 100.9**** 110****  
EMBOL -X72 2015  30 57.14%  68.75%  1.28**  2** -- -- 
MISTRAL -C73 2016  65 72.73%  86.67%  -- -- 95 197 
CLEAN TAVI74 2016  100 97.96%  97.78%  5 10 205 472 
SENTINEL9 2017  363 -- -- 3 5 294 309.8  
* Based on published results where  available.  CLEAN -TAVI results of number of lesions and volume were 
statistically significant.  
** Unclear calculation methodology in the paper.  
*** Total lesion volume in all territories  
**** Results  by per treatment.  
Table 6 b. Clinical endpoints in RCTs using device protection in TAVI  
Trial N Death at 30 days  Stroke at 30 
days  Any worsening 
NIHSS  
Device  Control  Device  Control  Device  Control  
DEFLECT III8 2015 85 2.17%  5.13%  4.35%  5.13%  3.8%*  4.5%*  
EMBOL -X72 2015  30 0% 0% -- -- 3.8%*  4.5%*  
MISTRAL -C73 2016  65 3.12%  9.09%  0% 6.06%  0%**  5%**  
CLEAN TAVI74 2016  100 0% 2% 8% 8% 17.9%*  22.5%*  
SENTINEL9 2017  363 1.28%  1.8%  5.63%  9.09%  -- -- 
* At 30 days  
** At discharge, data from presentation at TCT 2015, not presented in published paper.   
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
39 
 4.1.6  Study Population- Minorities  
CEPD trials enrolled patients referred for TAVI, hence patient demographics are similar to 
current TAVI enrollment practices. Table 6c summarizes the distribution of age and sex in 
current CEPD trials. Racial disparities in TAVI have been previously repor ted76. Race  was 
not reported in the abov e-mentioned CEPD  trials but is expected to reflect rates similar to 
TAVI trials.  In this trial sites will be encouraged to enroll minorities.  
Table 6c. Sex and age distribution in current CEPD trials.  
Trial N Age (years)  
mean +SD or median (IQR)  Female N(%)  
Device  Control  Device  Control  
DEFLECT III8 2015  85 82.5+6.5 82.3+6.0 56.5% ** 48.7% ** 
EMBOL -X72 2015  30 81.0+5.0 82.1+4.1 10 (71.4%)  8 (50.0%)  
MISTRAL -C73 2016  65 82 (79 -84) 82 (77 -86) 15 (47%)  16 (49%)  
CLEAN TAVI74 2016  100 80.0+5.1 79.3+4.1 29 (58%)  28 (56%)  
SENTINEL9 2017  240* 85.0 (78.4 -89.4)  83.1 (77.2 -87.2)  58 (48.7%)  63 (52%)  
* Safety population not included  
** N not reported  
4.2 Rational e  
The incidence of stroke and subclinical cerebral ischemic lesions, and their association with post-procedural neurological deficits, indicate that methods to prevent or reduce cerebral 
embolization are vital to optimizing TAVI procedures and improving the outcomes of patients with severe aortic stenosis. The first -generation TriGuard device has been demonstrated to  
safely reduce the total cerebral ischemic lesion volume after TAVI  compared with historical 
controls . This  prospective, randomized trial will  provide more comprehensive evaluation of 
the safety and efficacy of the TriGuard HDH  and TriGUARD 3 device s compared with a 
concurrent active control of unprotected T AVI.  
By employing standardized image acquisition and analysis parameters and detailed 
neuro logical testing, the REFLECT  trial will also advance  the understanding of subclinical 
neurological events and their relationship with neurocognitive function in patients undergoing 
cardiovascular interventions.  
4.3 Device Description  
The following is a summary description of the Investigational Devices. For additional information, please refer to the Instructions for Use.  
4.3.1  Devices Summary  
4.3.1.1.1  Phase I - TriGuard HDH  
The Keystone Heart  TriGuard HDH CEPD  (Figure 1) is a temporary, sterile, single use, 
biocompatible filter, introduced transfemorally through a 9F sheath to the aortic arch. Under 
fluoroscopic guidance, the device is positioned in the aortic arch to cover all 3 major cerebral arteries (innominate, left carotid, and subclavian arteries), and is held in position by an 
atraumatic stabilizer in the innominate artery  (Figure 2). Once the device is in position, emboli 
and particulate matter are diverted away from the cerebral circulation and downstream to the descending aorta, where they are either harmless or can be treated effectively.   
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
40 
  
Figure 1. The TriGuard HD H CEPD  
 
Figure 2.  TriGuard HD H device positioning in the aortic arch.  
The TriGuard HDH CEPD  is available in a single size, and is composed of a structural nitinol 
frame, lower stabilizer legs that push it towards the upper wall of the aortic arch, an upper 
stabilizer that protrudes into the innominate artery ostium, and a nitinol mesh . The frame 
includes 4 radiopaque markers to increase CEPD  visualization under fluoroscopy, and ends 
in a 60 mm tail c omprised of braided nitinol wires with a Duraskin™ -coated coil on top of it. 
A connector with 180° of rotational freedom connects the CEPD  frame to the delivery tether.  
The CEPD  filter consists of a thin and durable nitinol mesh (nominal pore size 130 X 2 50 µm) 
attached to the frame, allowing maximal blood flow while diverting clinically significant emboli 
toward the descending aorta. The CEPD  is heparin coated to reduce thrombogenicity and 
increase lubricity. The chemical and physical properties of this immobilized, biocompatible, hydrophilic, ultrathin polymeric coating reduce the likelihood of blood component adherence and activation, reducing the formation of thrombi or emboli.  
The CEPD filter  unit is connected to a delivery tether  that serves for pushi ng, maintaining and 
retrieving  the filter from the aortic arch. In addition to the filter, the TriGuard System includes 
a delivery subsystem for crimping and loading the device into commercially -available 7F and 

REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
41 
 9F sheaths  (please refer to the TriGuard HDH  Instructions for Use for a listing of compatible 
introducer sheaths) .  
Device deployment is accomplished by pre- loading (crimping) the CEPD  through the 
dedicated crimper into the distal end of a commercially -available 7F sheath delivery system. 
Under fluoroscopy, the 7F  sheath is pushed via a commercially -available 9F sheath delivery 
system, already inserted through a femoral artery access site. The device is then de-
sheathed into the 9F introducer and the 7F introducer is removed.  
4.3.1.1.2  Phase II- TriGUARD 3 CEPD 
The Keystone Heart TriGUARD 3 CEPD  (Figures 1a , 1b and 2a) is a temporary, retrievable,  
sterile, single use, biocompatible filter, introduced transfemorally through an 8F sheath to the aortic arch. Under fluoroscopic guidance, the device is positioned in the aortic arch (Figure 
2a) to cover all 3 major cerebral arteries (covering the innominate, left carotid, and left 
subclavian arteries), and is held in position by the device’s circumferential pressure and the 
support of the nitinol shaft (external communicating device) in the aortic arch. Once the device is in position, emboli and particulate matter are diverted away from the cerebral circulation and downstream to the descending aorta, where they are either harmless or can be treated effectively . 
The TriGUARD 3 CEPD  is available in a single size, and is composed of a structural nitinol 
frame that push es it towards the upper wall of the aortic arch, and a Polymer  mesh. The 
frame is radiopaque to increase device visualization under fluoroscopy. A nitinol connector 
connects the device frame to the delivery system . 
The CEPD  filter consists of a thin and durable Polymer  mesh (nominal pore size 115 X 145 
µm) attached to the frame, allowing maximal blood flow while diverting clinically significant emboli toward the descending aorta. The filter is heparin coated to reduce thrombogenicity 
and increase lubricity. The chemical and physical properties of this immobilized, biocompatible, hydrophilic, ultrathin polymeric coating reduce the likelihood of blood component adherence and activation, reducing the formation of thrombi or emboli.  
The CEPD filter  unit is connected to a delivery system  that serves for pushing, maintaining 
and retrieving  the filter from the aortic arch. In addition to the filter, the TriG UARD 3 System 
includes a delivery subsystem for crimping and loading the device into a commercially 
available 8F braided sheath.  
Device deployment is accomplished by pre- loading (crimping) the CEPD  through the 
dedicated crimper into the distal end of the 8 F delivery  system. Under fluoroscopy, the 8F 
sheath is advanced over the wire already inserted through a femoral artery access site. The device is then de- sheathed and exposed to the blood stream.  
 
 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
42 
  
Figure 1 a. The TriGUARD 3 CEPD  
 
 
Figure 1b.  TriGUARD 3 system o verview.  
 
Figure 2a. TriGUARD 3  device  positioned in the aortic arch 

REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
43 
 4.3.2  Regulatory Status  
The TriGuard HDH has received CE Mark and is commercially available in Europe and Israel . 
Use of the device at European and Israeli sites in the REFLECT study is in accordance with 
its market approved use.  
In the United States, the TriGuard HDH and the TriGUARD  3 are for investigational use only.  
4.3.3  Device Packaging  
4.3.3.1.1  Phase I- TriGuard HDH  
The device is supplied pre- assembled in a single rigid inner blister tray (Figure 3) containing 
the TriGuard HDH CEPD , a 9F delivery sheath extension (including a loading tube with a 
double hemostasis valve), a crimper (to load the CEPD  into the delivery system), and 
Instructions for Use. The inner blister tray is placed in a sterility barrier consisting of a 
thermoformed blister tray with a Tyvek lid, which is placed in a cardboard box. The entire package is sterilized using Gamma irradiation.  
 
Figure 3.  The TriGuard HDH System  
 
4.3.3.1.2  Phase I I- TriGUARD 3 
The device is supplied pre- assembled in a single rigid blister tray (Figure 3a ) containing the 
TriGUARD 3 CEPD filter , a crimper (to load the filter into the delivery system), and 
Instructions for Use. The inner blister t ray is placed in a sterility barrier consisting of a 
thermoformed sealed Tyvek pouch, which is placed in a cardboard box. The entire package is sterilized using EtO. 
 
  

REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
44 
 Figure 3a. TriGUARD 3  System  Packaging  
  
 
4.3.4  Comparison between Device Generations  
The TriGuard HDH device and the TriGUARD 3 device share the same basic principles of 
operation and intended use and are manufactured under the same Quality System. Design 
changes between the TriGuard HDH and TriGUARD 3 are expected to improve device safety, 
effectiveness,  performance, and ease of use (Table 6d) and will be tested in Phase II .  
In comparison with TriGuard HDH  system , the TriGUARD 3 system includes the following 
design changes : 
• A simplified self -positioning, self-stabilizing frame design that utilizes circumferential 
pressure and the support of the nitinol delivery shaft  to improve vessel wall apposition 
and eliminate the need for dedicated stabilizer elements in the innominate artery and 
aortic arch, improving device safety, particle deflection efficacy, and ease of deployment and positioning. In addition, the revised device design permits the use of cerebral protection in a broader anatomic subset of patients because it is not limited by aortic arch or innominate artery ostium diameter or the presence of calcification, atheroma, or tortuosity in the innominate artery.  
• R educed filter mesh pore size ( 115 × 145 µm vs. 130 × 250 µm) for deflection of 
smaller particles, achieved via a different mesh material ( Polymer vs. nitinol);  
• An increased filter area of 68.3 cm
2 vs. 20.9 cm2. 
• A frame that is fully visible via fluoroscop y (eliminating the need for radiopaque marker 
bands) for improved monitoring during deployment and positioning; and  
• A refined delivery subsystem that reduces the delivery profile (8 F vs. 9 F ) expected 
to improve safety, reduce the number of procedural steps required for deployment, 
and allow over-the-wire introduction and positioning for better ease of use.  
 
Table 6d. Comparison between devices  
TriGuard HDH  TriGUARD 3 
Nitinol frame with upper and lower 
stabilizers  Self-positioning, self -stabilizing nitino l 
frame, fully visible via fluoroscopy  
Nitinol mesh (pore size 130 x 250 µm) Polymer  mesh (pore size 115 x 145 µm) 
Filter area = 20.9 cm2 Filter area = 68.3 cm2 
9 Fr delivery  8 Fr OTW delivery  
 

REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
45 
 4.3.5  Intended Use  
The Keystone Heart TriGuard ™ HDH and TriGUAR D 3 are aortic CEPDs  designed to reduce 
the amount of embolic material that may enter the cerebral blood circulation  during 
transcatheter heart valve replacement or implantation.  
5.0 Study Design  
5.1 Study Design Change and Rational e 
REFLECT Version 10.0 was a prospective, single- blind, randomized, multicenter safety and 
efficacy trial. The study was intended to enroll up to 355 subjects and up to 90 roll -ins. 
Enrollment in this cohort (termed Phase I in this protocol version) was halted after 204 
subjects were randomized and 54 roll -ins were enrolled)  based on a recommendation of the 
DSMB following interim data review at the prespecified interm analysis timepoint . A next 
iteration  device (TriGUARD 3) designed for increased efficacy, ease of use, and improved 
safety will be tested in Phase II.  
5.1.1  Rational e for Phase II  
This amendment to the protocol is intended to allow the evaluation of the TriGUARD 3. This  
next iteration of the  device will be  the only m anufactured and available TriGuard device.  
The proposed modific ations to the ongoing REFLECT trial will allow a scientifically valid 
evaluation of the safety, effectiveness, and performance of the TriGUARD 3 device by 
leveraging the engagement of existing US sites and operators who are familiar with the prior generati on device, as well as blinded clinical data already collected from Phase I control 
patients. This approach will minimize the total number of study subjects exposed to any risks associated with the investigational device, maximize the value of the contributions of subjects 
already enrolled in the trial, and potentially speed market availability of the TriGUARD 3 
device.  
Analysis will include poolability assessment and data validity of the old controls with the new 
ones and between sites in US and OUS  as det ailed in the SAP.  
5.2 Study Design Overview  
This study is a prospective, single -blind, three arm, randomized (2 device: 1 control) , 
multicenter  safety and efficacy trial designed to enroll  up to 603 evaluable subjects in two 
consecutive phases: Phase I, which evaluated the TriGuard HDH device enrolled 258 
subjects (including 54 Roll -Ins) prior to enrollment suspension at the recommendation of the 
independent DSMB following an interim data review at the prespecified interim analysis time point . Phase II will enr oll up to 345 subjects (including up to 50 Roll -Ins) and will utilize the 
TriGUARD 3 (Figure 3b shows the patient flow/disposition).  
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
46Figure 3b. REFLECT Phase I and Phase II Trial Design (Note: The depicted Phase II design reflects the 
sample 
size of 
the initial randomized cohort, not including a possible adaptive design sample siz e increase)
Phase I:  
In phase 1, a total of 204 evaluable subjects and 54 roll-in subjects were enrolled at 26 total 
investigational sites in the United States, Europe, and Israel, including 20 sites in the United 
States. A minimum of 50% of subjects were planned to be enrolled at US sites, and no single 
site was permitted to enroll more than 20% of all subjects.  
Subjects with indications for TAVI and who meet study eligibility criter ia were randomized 2:1 
(stratified by study site) to one of two treatment arms:  
•Intervention (Phase I Cohort)  – TAVI with the TriGuard HDH CEPD
•Control  – standard unprotected TAVI
At sites where the investigator did not have prior experience with the TriGuard device 
(minimum of 2 prior cases) , up to 3  roll-in subject s were  enrolled. Roll -in subjects were not 
randomized, but  underwent  TAVI with the TriGuard HDH  device. These cases were  proctored 
by a Sponsor representative. Investigational sites with ≥ 2 prior TriGuard cases were allowed 
to enroll 1 roll -in subject at the discretion of the site principal investigator . 
All subjects were to be followed clinically in -hospital and at 30 and 90 days, undergo diffusion -
weighted MR i maging 2 to 5 days post -procedure, and undergo neurologic and 
neuropsychological testing pre- procedure,  post-procedure (2-5 days post -procedure) , and at 
30 and 90 days.  
The initial randomized cohort was planned to enroll  up to 285 subjects. 
Note: 
Enrollment in Phase I has been halted after enrolling a total of 258 subjects (54 roll -ins 
and 204 randomized subjects including 63 controls) based on a recommendation of the DSMB following interim data review at the prespecified interm analysis timepoint . A new 
generation device designed for increased efficacy, ease of use, and improved safety which  
will be  tested in Phase II (below).  
Phase II  
In Phase II, up to 295 randomized subjects and 40-50 roll-in subjects  will be enrolled at up to 
25 sites in the United St ates (inclusive of sites enrolling subjects in Phase I) . No single site 
will be permitted to enroll more than 20% of all randomized subjects  in Phase II . 

REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
47 
 Subjects with indications for TAVI and who meet study eligibility criteria will be randomized 
2:1 (str atified by study site) to one of two treatment arms:  
• Intervention – TAVI with the TriGUARD 3 CEPD  
• Control  – standard unprotected TAVI . 
Randomization will be stratified by implanted valve type  (Medtronic vs. Edwards) . 
No single valve type will be implanted in more than approximately 70% of randomized 
patients (phase II).  
Roll-in subjects (a minimum of 2 and a maximum of 3 Roll-ins per -site) will not be randomized, 
but will undergo TAVI with the TriGUARD 3 device. These cases will be proctored by a 
Sponsor representative.  
All subjects will be followed clinically in -hospital and at 30 days, undergo diffusion- weighted 
MR imaging 2 to 5 days post -procedure, and undergo neurologic (NIHSS)  testing pre -
procedure, post -procedure (2-5 days post -procedure) , and at 30 days.  A follow -up phone -call 
to assess  the occurrence of death or stroke will be done at 90 days.    
The initial randomized cohort will consist of up to 225 subjects. After at least 50% of the initial 
randomized cohort (approximately 112 subjects)  have reached the 30 day primary efficacy 
endpoint  evaluation time point,  a sample size re- estimation will be performed in case the 
conditional power of the trial (assessed by the independent biostatistician) is > 40% but <80%, 
subject to approval by the Sponsor.  If this analysis determines that more than 225 
randomized subjects will be required to ensure adequate study power, enrollment may continue until the required number of subjects have been enrolled, or until the total subject limit for the study has been reached (whichever occurs first).  
5.3 Study Objectives  
The objective of the REFLECT  trial is to evaluate the safety and efficacy of  the TriGuard HD H 
and TriGUARD 3 CEPDs  in patients TAVI , in comparison with an active control group of 
patients undergoing unprotected TAVI.  
The study will also report additional secondary safety,  efficacy, and performance endpoints 
evaluating the TriGuard HDH and TriGUARD 3 in patients undergoing transcatheter a ortic 
valve implantation (TAVI)  in comparison with patients undergoing unprotected TAVI. Other 
measures related to the effect of embolic protection  on TAVI  procedural time and radiation 
exposure will also be collected.  
5.4 Study Endpoints  
5.4.1  Primary  Endpoint s 
5.4.1.1.1  Primary Safety Endpoint  
The primary safety endpoint of the study is combined s afety at 30 days, defined according 
to modified VARC -2 1 (“TAVI early safety”) as the composite of:  
• All-cause mortality  
• All stroke (disabling and non- disabling)  
• Life-threatening or disabling bleeding  
• Acute kidney injury – Stage 2 or 3 (including renal replacement therapy)  
• Coronary artery obstruction requiring intervention  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
48 
 • Major vascular complication  
• Valve -related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)  
 
5.4.1.1.2  Primary Efficacy Endpoint - Phase II  
The primary efficacy endpoint of the study is  the hierarchical composite efficacy endpoint , 
determined by pair -wise comparisons among all subjects according to the following pre-
specified hierarchy of adverse outcomes:  
• All-cause mortality and/or any stroke (fatal and non- fatal, disabling or non- disabling) 
[evaluated at 30 days]  
o If both had a death/ stroke , a time to event analysis by days will determine a win  
o If both patients had a stroke at the same day the comparison moves to the next 
tier 
• NIHSS worsening  (increase from baseline)  [evaluated at  2 to 5 days  post-procedure]   
• Freedom from any cerebral ischemic lesions detected by diffusion- weighted magnetic 
resonance imaging (DW -MRI) 2 to 5 days post-procedure  
• T otal volume of cerebral ischemic lesions detected by diffusion- weighted magnetic 
resonance imaging (DW -MRI) 2 to 5 days post -procedure.  
Each subject in the intervention group will be compared with each and every subject from 
the control group based on the above hierarchy  according to the Finkelstein- Schoenfeld 
method.2 For example, if Subject A dies or has stroke and Subject B survives free of 
stroke to 30 days, Subject B wins (score +1) and Subject A loses (score -1). If both 
subjects die or both have a stroke on the same day, it is equilibrium (score 0). If both 
subjects survive free of stroke to 30 days, the comparison moves to the next tier of the 
hierarchy. A lack of an event is given a +1 score. An event which is less severe than the 
comparison gets a 0 score (for example death vs. stroke) 
After all between- subject comparisons have been performed, scores are summed to 
obtain a cumulative score for each subject, and outcomes between treatment groups are 
then compared.  
5.4.2  Secondary Endpoints  
5.4.2.1.1  Hypothesis -driven secondary endpoints  
For the following secondary endpoints, a test for superiority of each intervention group to the control group will be performed. To address t he issue of multiple tests among these 
secondary endpoints, sequential testing is planned. Secondary endpoints will be formally tested if and only if the primary study hypotheses are confirmed. The secondary endpoints will be tested individually, in the order in which they are listed as follows:  
• All stroke [evaluated at 7 days in the eITT population]  
• NIHSS worsening, defined as any NIHSS score increase from baseline [evaluated at 
2 to 5 days post -procedure in the efficacy Intention to Treat (eITT) analysis population]. 
A sensitivity analysis will further compare >2 points NIHSS worsening [evaluated at 2-
5 days post -procedure in the efficacy Intention to Treat (eITT) analysis population]  
• Composite of all -cause mortality and all stroke [evaluated at 7 days in the eITT 
population]  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
49 
 • CNS Infarction  (NeuroARC defined) [evaluated at 30 days in the eITT analysis 
population]  
• Total volume of cerebral ischemic lesions  detected by DW -MRI, [evaluated 2 to 5 
days post -procedure in the efficacy Intention to Treat (eITT) analysis population]  
The above endpoints will be tested by this pre- specified sequence, until the first non-
significant difference is found between the two treatment groups. After that, other treatment 
comparisons will be examined in an exploratory manner.  
 
5.4.2.1.2  Secondary Safety  Endpoints  
The following safety endpoints will be evaluated in- hospital and at 30 days. Overall event 
rates will be reported by treatment group. In the Intervention and Roll -In groups, all safety 
endpoints will be adjudicated for their relationship to the investigational device and/or the 
investigational procedure by an independent Clinical Events Committee ( §11.1):  
• In-hospital procedural safety, defined as the composite of the 
following Major Adverse Cardiovascular and Cerebrovascular Events (MACCE):  
• All-cause mortality  
• All stroke (disabling and non- disabling)  
• Life threatening (or disabling) bleeding  
• Acute kidney injury – Stage 2 or 3 (including renal replacement 
therapy)  
• Major vascular complications  
• TAVI device success (VARC), evaluated in- hospital, defined as:  
• Absence of procedural mortality AND  
• Correct positioning of a single prosthetic heart valve into th e 
proper anatomical location AND  
• Intended performance of the prosthetic heart valve (no prosthesis -patient mismatch (VARC -defined) and mean aortic 
valve gradient <20 mm Hg or peak velocity <3 m/s, AND no moderate or severe prosthetic valve regurgitation (V ARC-
defined)  (site-reported)  
• General safety, defined as the composite of the following adverse events ( each VARC -2 defined):  
• All-cause mortality   
• All stroke (disabling and non- disabling)  
• Acute kidney injury  – Stage 3 (including renal replacement 
therapy)  
• M ortality  [evaluated in- hospital and at 30 and 90 days] : 
• All-cause mortality  
o Cardiovascular mortality  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
50 
  Neurologic event related mortality  
o Non-cardiovascular mortality  
• Myocardial infarction:  
• Peri-procedural MI (≤72 hours after the index procedure)  
• Spontaneous MI (>72 hours after the index procedure)  
• Neurological Events (component and composite):  
• Stroke  (VARC -2 defined)  [evaluated in -hospital and at 30 and 
90 days]  
o Ischemic stroke  
o Hemorrhagic s troke  
o Undetermined  
• Disabling Stroke  (VARC -2 defined)  [evaluated in -hospital and 
at 30 and 90 days]  
• Non-disabling stroke (VARC -2 defined)  [evaluated in -hospital 
and at 30 and 90 days]  
• Transient ischemic attack  (TIA)  (VARC -2 defined)  
• Overt CNS Injury (NeuroA RC defined  Type 1 ) [evaluated in -
hospital and at 30 and 90 days]  
• Covert CNS Injury (NeuroARC defined  Type 2) 
• Neurological dysfunction without CNS injury (NeuroARC defined  
Type 3) 
• CNS infarction (NeuroARC defined composite neurological 
endpoint ) 
• CNS hemorrhage (NeuroARC defined composite neurological 
endpoint ) 
• Bleeding Complications:  
• Life-threatening  bleeding (VARC -2) 
• Major bleeding  
• Minor bleeding  
• Acute Kidney Injury (AKIN Classification):  
• Stage 2  
• Stage 3  
• Vascular Complications:  
• Major vascular complications  
• Major  vascular complications  related to device 
 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
51 
  
5.4.2.1.3  Secondary Efficacy Endpoints  
5.4.2.1.4  Phase I: Hierarchical composite efficacy endpoint, determined by 
pair-wise comparisons among all subjects according to the following pre-
specified hierarchy of adverse outcomes:  
• All-cause mortality or any stroke (disabling or non- disabling) 
[evaluated at 30 days]  
• NIHSS worsening (increase from baseline) [evaluated at 2-5 days 
post-procedure] or Montreal Cognitive Assessment worsening 
(decrease of 3 or more points from baseline) [evaluated at 30 days]  
• Total volume of cerebral ischemic lesions detected by diffusion-
weighted magnetic resonance imaging (DW -MRI) 2 to 5 days post -
procedure  
Each subject in the intervention group will be compared with each and 
every subject  from the control group based on the above hierarchy 
according to the Finkelstein- Schoenfeld method.2 For example, if Subject 
A dies or has stroke and Subject B survives free of stroke to 30 days, Subject B wins (score +1) and Subject A loses (score -1). If both subjects 
die or have a stroke, it is equilibrium (score 0). If both subjects survive free of stroke to 30 days, the comparison moves to the next tier of the hierarchy.  
After all between- subject comparisons have been performed, scores are 
summed to obtain a cumulative score for each subject, and outcomes between treatment groups are then compared.  
5.4.2.1.5  Imaging Efficacy Endpoints  (Phase I and Phase II) : 
• Presence of cerebral ischemic lesions detected by DW -MRI, 
evaluated 2 to 5 days  post-procedure  
• N umber of cerebral ischemic lesions detected by DW -MRI, 
evaluated 2 to 5 days  post-procedure  
• Per-patient average single cerebral ischemic lesion volume 
detected by DW -MRI, evaluated 2 to 5 days  post-procedure  
• Single cerebral ischemic lesion volume (lesion -level analysis) 
detected by DW -MRI, evaluated at 2 to 5 days  post-procedure  
• Total volume of cerebral ischemic lesions detected by DW -MRI, 
evaluated 2 to 5 days post -procedure   
5.4.2.1.6  Neur ologic Efficacy Endpoints  (Phase I and Phase II) : 
• NIHSS worsening, defined as an NIHSS score increase from baseline [baseline score compared with score evaluated at 2-5 days 
post-procedure  and at 30 days]  
• New neurologic  impairment, defined as an NIHSS scor e increase 
from baseline accompanied by the presence of cerebral ischemic 
lesions [evaluated at 2-5 days post-procedure and at 30 days ]  
 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
52 
  
5.4.2.1.7  Secondary Performance Endpoints  
The following performance endpoints will be evaluated post -procedure in 
the Intervent ion group ( Roll-Ins excluded) . TriGuard HDH and TriGUARD 3 
reported individually:  
• Successful device deployment, defined as ability to access the aortic 
arch with the TriGuard HDH or TriGUARD 3 delivery catheter and 
deploy the device from the delivery catheter into the aortic arch  
• Successful device positioning, defined as ability to position the TriGuard HDH or TriGUARD 3 device in the aortic arch to cover all  
major cerebral arteries, with proper positioning maintained (verified 
by fluoroscopy ) until the following time points:  
o Final deployment of the first prosthetic valve 
o Final procedure (after any additional post -dilatation or additional 
valve implantations have been completed, and the TAVR delivery system has been removed)  
• Extent of cerebral artery coverage will be reported as:  
o Complete (coverage of all 3 cerebral artery branches)  
o Partial (coverage of 1- 2 cerebral artery branches)  
o None  
Note:  Maintenance of device positioning to each time point and extent of 
cerebral artery coverage will be evaluated by the Angiographic Core Laboratory.  
• Device interference, defined as interaction of the TriGuard HDH or 
TriGUARD 3 device with the TAVI system leading to:  
o Inability to advance or manipulate the TAVI delivery system or valve prosthesis, OR  
o Inability to deploy the  TAVI valve prosthesis, OR  
o Inability to retrieve the valve prosthesis or delivery system  
• Successful device retrieval, defined as ability to retrieve the 
TriGuard HDH or TriGUARD 3 CEPD.  
• Technical success, defined as successful device deployment, 
device positioning, and successful device retrieval in the absence of 
device interference  
• Procedure success, defined as technical success in the absence of any investigational device- related or investigational procedure-
related in- hospital procedural safety events  
5.4.3  Other Measures  
The following additional measures will also be evaluated (TriGuard HDH and TriGUARD 3 
reported individually) : 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
53 
 5.4.3.1.1  Device deployment time − Time elapsed between insertion of the 
TriGuard HDH or TriGUARD 3 device into the groin access point  and s uccessful 
device deployment [evaluated post -procedure]  
5.4.3.1.2  Total procedural time  − Time elapsed between first arterial access 
and removal of the last catheter from the arterial access sheath  [evaluated post -
procedure]  
5.4.3.1.3  Total fluoroscopy time  [evaluated post -procedure]  
5.4.3.1.4  Total contrast utilization [evaluated post -procedure]  
6.0 Study Conduct  
6.1 Enrollment Criteria  
6.1.1  General Inclusion Criteria  
Subjects must meet ALL of the following criteria to be eligible for enrollment into the study:  
6.1.1.1.1  The patient  is a male or non- pregnant female ≥18 years of age  
6.1.1.1.2  The patient meets indications for TAVI  
6.1.1.1.3  The patient is willing to comply with protocol -specified follow -up 
evaluations  
6.1.1.1.4  The patient, or legally authorized representative, has been informed 
of the nature of the study, agrees to its provisions and has provided written 
informed consent, approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC)   
6.1.2  General Exclusion Criteria  
Potential subjects will be excluded if ANY of the following criteria apply:  
6.1.2.1.1  Patients  under going TAVI via the trans - apical, trans  -axillary, trans -
subclavian, or trans -aortic route (applicable to Phase II)  
6.1.2.1.2  Patients undergoing TAVI via the transapical approach due to friable 
or mobile atherosclerotic plaque in the aortic arch (Phase I only ) 
6.1.2.1.3  Patients with a previously implanted prosthetic aortic valve (i.e., 
planned valve- in-valve TAVI)  
6.1.2.1.4  Pregnant or nursing subjects and those who plan pregnancy in the 
period up to 1 year following index procedure. Female subjects of child- bearing 
potential must hav e a negative pregnancy test done within 14 days prior to 
index procedure per site standard test . 
6.1.2.1.5  Patients with known diagnosis of acute myocardial infarction (AMI) 
within 72 hours preceding the index procedure (according to definition) or AMI >72 hours preceding the index procedure, in whom CK and CK -MB have not 
returned to within normal limits at the time of procedure, or patients who are 
currently experiencing clinical symptoms consistent with new -onset AMI, such 
as nitrate- unresponsive prolonged chest pain.  
6.1.2.1.6  Patients with a history of bleeding diathesis or coagulopathy or 
patients in whom anti -platelet and/or anticoagulant therapy is contraindicated, 
patients who will refuse transfusion, or patients with an active peptic ulcer or 
history of upper gastrointestinal (GI) bleeding within the prior 3 months.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
54 
 6.1.2.1.7  Patients with known mental or physical illness or known history of 
substance abuse that may cause non- compliance with the protocol, confound 
the data interpretation, or is associated with a life expectancy o f less than one 
year 
6.1.2.1.8  Patients with severe allergy to heparin or known hypersensitivity or 
contraindication to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless 
steel alloy, and/or contrast sensitivity that cannot be adequately pre- medicated 
6.1.2.1.9  Patients with a history of a stroke or transient ischemic attack (TIA) 
within the prior 6 months  
6.1.2.1.10  Patients with renal failure (estimated Glomerular Filtration Rate 
[eGFR] <30 mL/min, calculated from serum creatinine by the Cockcroft -Gault 
formula or MDRD - Modi fication of Diet in Renal Disease formula ) 
6.1.2.1.11  Patients with hepatic failure (Child -Pugh class C)   
6.1.2.1.12  Patients with h ypercoagulable states that cannot be corrected by 
additional periprocedural heparin  
6.1.2.1.13  Patients presenting with cardiogenic shock at the time of the index 
procedure  
6.1.2.1.14  Patients with severe peripheral arterial , abdominal aortic, or thoracic 
aortic  disease that precludes delivery sheath vascular access  
6.1.2.1.15  Patients in whom the aortic arch (Phase I and II ), innominate artery 
ostium  (Phase I only ), or proximal innominate artery  (Phase I only ) are heavily 
calcified, severely atheromatous, or severely tortuous  
6.1.2.1.16  Patients with an innominate artery ostium diameter <10  mm or >25 
mm (Phase I only ) 
6.1.2.1.17  Patients with a transverse aortic diameter >4 3 mm (Phase I only ) 
6.1.2.1.18  Patients with anatomic irregularities of the innominate artery that 
could prevent positioning of the TriGuard upper stabilizer and compromise 
stability of the device (Phase I only ) 
6.1.2.1.19  Patients with any other condition that would prevent adherence to 
the TriGuard HDH  (Phase I ) or TriGUARD 3 (Phase II)  Instructions for Use  
6.1.2.1.20  Patients with contraindication to cerebral MRI  
6.1.2.1.21  Patients who have a planned treatment with any other investigational 
device or procedure during the study period  
6.1.2.1.22  Patients planned to undergo any other cardiac surgical or 
interventional procedure during the TAVI procedure (e.g., concurrent coronary 
revascularization) or within 10 days  prior to the TAVI proce dure. NOTE: 
Diagnostic cardiac catheterization is permitted within 10 days prior to the TAVI 
procedure.  
6.2 Subject Enrollment  
6.2.1  Screening and Enrollment  
Patients meeting indications for TAVI will be pre-screened for study eligibility by a member 
of the research team, including a review of the patient’s  medical history  and any existing 
diagnostic imaging testing that has been performed as a part of the patient’s normal medical 
care.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
55 
 Based on the results of pre- screening, potentially eligible patients will be asked to provide 
written informed consent. Informed consent must be documented prior to the performance of 
any study -specific screening procedures or assessments.  Following receipt of informed 
consent, a baseline screening assessment will be conducted to verify eligibility; the required 
documentation must also be provided to the Patient Review Committee (§ 11.1) to determine 
anatomic eligibility for the trial.  
The patient will be considered enrolled in the study when all the following criteria have been 
met: 
• The patient has provided written informed consent  
• Baseline screening has been conducted and: 
o The Patient Review Committee has determined that the patient meets the evaluated anatomic  eligibility criteria  (based on imaging analysis by 
independent CT core laboratory)  AND  
o The investigator has determined that the patient meets all applicable remaining 
inclusion and no exclusion criteria  
• The point of enrollment has been reached:  
o For evaluable subjects  (Intervention and Control groups), the point of 
enrollment is the moment of randomization. Randomization will occur:  
 Within 72 hours  prior to the scheduled initiation of the TAV I procedure  
AND 
 After the investigator has confirmed the subject meets all anatomic  
eligibility criteria  
o For Roll -In subjects , the point of enrollment is the introduction of the TriGuard 
HDH or TriGUARD 3 device into the bloodstream . 
A screening log will be completed to document the enrollment and subject number, or reason for non- enrollment of subjects screened but not enrolled in the study.  All enrolled subjects 
are required to complete all assigned follow -up ass essments. No single site was permitted to 
enroll more than 20% of the total number of evaluable subjects (i.e., no single site may enroll more than 57 evaluable subjects  in the initial  randomized cohort  [in addition to any roll -in 
subjects ] in Phase I, and  no more than 45 randomized subjects  in the initial randomized 
cohort  [in addition to any roll -in subjects] in Phase II .  
Randomization will be stratified by implanted valve type (Medtronic vs. Edwards).  
No single valve type will be implanted in more than approximately 70% of randomized 
patients (phase II).  
After at least 50% of the patients in the initial randomized cohort (approximately 112 subjects) have reached the 30 day primary efficacy endpoint evaluation time point, a sample size 
reestimation will b e performed in case the conditional power of the trial (assessed by the 
independent biostatistician) is > 40% but <80%, subject to approval by the Sponsor.  If this 
analysis determines that more than 225 randomized subjects will be required to ensure adequat e study power, enrollment may continue until the required number of subjects have 
been enrolled, or until the total subject limit for the study has been reached (whichever occurs first).  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
56 
 6.2.2  Roll-In Subjects  
Sites will enroll a minimum of  2 and a maximum of 3 Roll-In subjects . Roll- In subjects will not 
be randomized to a treatment arm, but will undergo TAVI with the TriGUARD 3 CEPD  and 
will undergo all protocol -specified follow -ups. These cases will be proctored by a Sponsor 
representative.  
For the purposes of analysis, a subject is considered enrolled in the Roll -In phase of the study 
when:  
• The patient has been judged to meet all inclusion and no exclusion criteria (including 
approval by the PRC), and has signed a Patient Informed Consent form  
• The TriGuard HDH or TriGUARD 3 device has been introduced into the patient’s 
bloodstream  
6.2.3  Withdrawal and Replacement of Patients  
Subjects  can withdraw from the study at any time; the reason(s) for withdrawal (if given) will 
be docum ented. All data available at the time of withdrawal (if any) will be used for analysis. 
There will be no further follow -up (per this study protocol) on a subject  who has withdrawn. 
Subjects  who withdraw from the study will not be replaced. The withdrawal of a subject  can 
be initiated by the Inves tigator if he/ she determines it is in the best interest of the patient . 
6.2.4  Protocol Deviations  
All deviations from the requirements of this Clinical Investigation Plan will be considered 
protocol deviations.  
A major protocol  deviation is a protocol deviation that may affect the scientific soundness of 
the protocol or the rights, safety, or welfare of the patients. Major protocol deviations  require 
urgent reporting to the Study Monitor and the Institutional Review Board/ Ethics Committee .  
Patient -level deviations are those that occur in direct association with a specific study patient. 
These include, but are not limited to, deviations from informed consent procedures, 
inclusion/ex clusion criteria, protocol -specified procedures and assessments,  and device 
handl ing and usage. 
Site-level deviations are those that occur at the study center but are not directly related to a 
study specific patient. All efforts should be made to avoid any protocol deviation.  
6.3 Blinding  
This is a single -blind study. The following individuals will be blinded to the subject’s treatment 
allocation:  
• Subject and his/her family members  
• Site personnel administering neurological evaluations (NIHSS  and mRS) ; these 
individuals will also be blinded to DW -MRI results  
• Members of the Data Safety Moni toring Committee  
• MRI Core Laboratory personnel  performing imaging analysis  
Un-blinding will occur only after the database has been locked for the analysis of the primary 
endpoint or to protect subject rights, welfare, or well -being at the request of the DSMB. The 
circumstances under which the DSMB may request unblinding to treatment allocation will be 
outlined in the DSMB charter prior to the onset of the trial.   
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
57 
 If a site investigator determines it is necessary to reveal treatment allocation to the subjec t 
as a result of complication or injury, he or she is requested to notify the S ponsor.  
  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
58 
 7.0 Study Procedures  
7.1 Study Schedule of Procedures and Assessments  
Table 7. Study Schedule of Procedures and Assessments - Phase I  (TriGuard HDH)  
 
 
 Screening/  
Baseline  Procedure  
(day 0)  Post -Procedure 
/ Pre -Discharge  30-day 
Follow -up 
(30 ± 7 days)  90-day 
Follow -up 
(90 ± 14 days)   
Written Informed Consent  X     
Medical History  X     
Physical Examination1 X  X X X 
Review of Eligibility Criteria2 X X    
Clinical Frailty S cale X    X 
12-lead ECG3 X  X   
Concomitant Medications  X X X X X 
Pregnancy Test4 X     
Hematology/Chemistry5 X  X   
Cardiac Enzymes6 X  X   
CT Imaging7 X     
Cerebral DW -MRI8   X   
NIH Stroke Scale9 X  X X X 
Modified Rankin Scale9 X  X X X 
Neuro psychological test 
battery10 X  X X X 
SF-36 Health Survey11 X   X X 
TAVI   X    
Echocardiography (SOC)12   X   
TriGuard HDH deployment   X    
Adverse Events   X X X X 
1 Physical examination to include heart rate , blood pressure , and ischemic / anginal s tatus (CCS or silent 
ischemia) . The screening/baseline assessment must also include NYHA functional capacity, height, and 
weight.  
2 If the full screening/baseline review of eligibility criteria is conducted before the day of enrollment, t he 
following repeat review of selected eligibility criteria should be performed on the day of  enrollment and 
randomization (§6.2.1) to confirm study eligibility, using the most recent available laboratory values and 
clinical assessments: 1.) Ensure that the subject has not had symptoms or chemistry results indicating acute myocardial infarction (§6.1.2.1.5); 2.) Ensure that the most recent eGFR remains ≥30 (§6.1.2.1.10); 3.) 
Ensure that there are no signs of cardiogenic shock or severe hypotension (systolic blood pressure <90 mm Hg) (§ 6.1.2.1.13); and 4.) Review the planned approach for TAVI, as certain approaches will make the 
subject ineligible for the study (§ 6.1.2.1.1, § 6.1.2.1.2) 
3 Screening/baseline ECG may be performed up to 30 days prior to procedure, as long as there have been 
no intervening signs or symptoms of myocardial ischemia (in which case the ECG should be performed within 24 hours prior to enrol lment ). The post -procedure ECG must be performed within 24 hours of the  
procedure or prior to hospital discharge (whichever occurs first).  
4 Female patients of childbearing potential must have a pregnancy test within 14 days prior to the procedure  
5 Hematology and chemistry within 14 days prior to the procedure  are defined i n §7.2. 
6 For the screening/baseline assessment, cardiac enzymes (CK), isoenzymes CK -MB or troponins obtained 
up to 14 days prior to the procedure (or on current admission) are acceptable, provided there has been no intervening episode of myocardial ischemia (in which case cardiac enzymes should be confirmed within 24 hours prior to enrol lment ). Post -procedure, CK/CKMB or troponin (preferably CKMB isoenzyme) will be 
measured at 12- 24 hours post -procedure, at 24±3 hours after the first measurement, and again at 72±6 
hours post -procedure or at discharge (whichever occurs first). If cardiac biomarkers are elevated, they should 
be repeated daily until values show a decline.  
R E F L E C T – U S I D E Tri al [ CI P -0 9 ( v 1 3. 0)]             K e y st o n e H e art Lt d.  
5 9  
 7 M ulti -sli c e C T a n gi o gr a p h y of t h e l eft h e art,  a ort a, gr e at v e s s el s a n d p eri p h er al a c c e s s v e s s el s p erf or m e d 
u p t o 1 y e ar pri or t o pr o c e d ur e  s h o ul d b e s u b mitt e d f or r e vi e w .  
8 D W -M RI m u st b e p erf or m e d 2 t o 5 d a y s ( ≥ 4 8 t o < 1 4 4 h o ur s) p o st -pr o c e d ur e.  
9 T h e NI H S S a n d m R S (i n a d diti o n t o t h e n e ur o p s y c h ol o gi c al t e st b att er y) m u st b e p erf or m e d 2 t o 5 d a y s 
( ≥ 4 8 t o < 1 4 4 h o ur s) p o st -pr o c e d ur e  b y  a n e ur ol o gi st  or a cli ni c al d e si g n e e ( e. g.  n e ur ol o g y f ell o w ). A f ull 
n e ur ol o gi c al e v al u ati o n s h o ul d b e p erf or m e d b y a n e ur ol o gi st i n all p ati e nt s i n w h o m a str o k e or TI A i s 
s u s p e ct e d o n t h e b a si s of t h e NI H S S, m R S, or ot h er si g n s or s y m pt o m s.  
1 0  A bri ef p a p er -a n d -p e n cil n e ur o p s y c h ol o gi c al t e st b att er y ( § 16. 7 ), will b e a d mi ni st er e d u p t o  3 0 d a y s pri or t o 
pr o c e d ur e, 2 t o 5 d a y s ( ≥ 4 8 t o < 1 4 4 h o ur s) p o st -pr o c e d ur e , a n d at t h e 3 0 - a n d 9 0 -d a y cli ni c vi sit s.  
1 1  T h e S h ort F or m 3 6 H e alt h S ur v e y ( S F -3 6) ( § 1 6. 1 1 ) will b e a d mi ni st er e d u p t o 3 0 d a y s pri or t o pr o c e d ur e 
a n d at t h e 3 0 - a n d 9 0 -d a y cli ni c vi sit s.  W h e n a d mi ni st er e d d uri n g a vi sit t h at i n cl u d e s ot h er a s s e s s m e nt s, t h e 
S F -3 6 s h o ul d b e p erf or m e d fir st.   
1 2  If e c h o c ar di o gr a p h y (tr a n st h or a ci c or tr a n s e s o p h a g e al) w a s p erf or m e d aft er T A V R pr o st h e si s i m pl a nt ati o n  
a s p art of t h e st a n d ar d of c ar e, t h e r el e v a nt p ar a m et er s (i n cl u di n g m e a n a orti c v al v e gr a di e nt, p e a k v el o cit y, 
a n d d e gr e e of pr o st h eti c a orti c v al v e r e g ur git ati o n) m u st b e c a pt ur e d o n t h e e C R F f or e v al u ati o n i n -h o s pit al 
T A VI d e v i c e s u c c e s s  ( § ). 
 
T a bl e 7 a.  St u d y S c h e d ul e of Pr o c e d ur e s a n d A s s e s s m e nt s - P h a s e II  ( Tri G U A R D 3) 
 
 
 S cr e e ni n g/  
B a s eli n e  Pr o c e d ur e  
( d a y 0)  P o st -
Pr o c e d ur e  3 0 -d a y 
F oll o w -u p  
( 3 0 ± 7 d a y s)  9 0 -d a y 
F oll o w -u p  
( 9 0 ± 1 4 d a y s)   
Writt e n I nf or m e d C o n s e nt  X     
M e di c al Hi st or y  X     
P h y si c al E x a mi n ati o n 1 X  X X  
R e vi e w of Eli gi bilit y Crit eri a 2 X X    
Cli ni c al Fr ailt y S c al e  X     
1 2 -l e a d E C G 3 X  X   
C o n c o mit a nt M e di c ati o n s  X X X X  
Pr e g n a n c y T e st 4 X     
H e m at ol o g y/ C h e mi str y 5 X  X   
C ar di a c E n z y m e s 6 X6  X6   
C T I m a gi n g 7 X     
C er e br al D W -M RI 8   X   
NI H Str o k e S c al e 9 X  X X  
M o difi e d R a n ki n S c al e 9 X  X X  
T A VI   X    
E c h o c ar di o gr a p h y ( S O C) 1 0    X   
D e vi c e  d e pl o y m e nt   X    
A d v er s e E v e nt s   X X X  
P h o n e c all t o a s s e s s m ort alit y/ Str o k e      X  
1 P h y si c al  e x a mi n ati o n  t o  i n cl u d e  h e art  r at e,  bl o o d  pr e s s ur e,  a n d  i s c h e mi c/ a n gi n al  st at u s  ( C C S  or  sil e nt 
i s c h e mi a). T h e s cr e e ni n g/ b a s eli n e a s s e s s m e nt m u st al s o i n cl u d e N Y H A f u n cti o n al c a p a cit y, h ei g ht, a n d w ei g ht.  
2 If t h e f ull s cr e e ni n g/ b a s eli n e r e vi e w of eli gi bilit y crit eri a i s c o n d u ct e d b ef or e t h e d a y of e nr oll m e nt, t h e f oll o wi n g 
r e p e at r e vi e w of s el e ct e d eli gi bilit y crit eri a s h o ul d b e p erf or m e d o n t h e d a y of e nr oll m e nt a n d r a n d o mi z ati o n 
( § 6. 2. 1 ) t o c o nfir m st u d y eli gi bilit y, u si n g t h e m o st r e c e nt a v ail a bl e l a b or at or y v al u e s a n d cli ni c al a s s e s s m e nt s: 
1) E n s ur e t h at t h e s u bj e ct h a s n ot h a d s y m pt o m s or c h e mi str y r e s ult s i n di c ati n g a c ut e m y o c ar di al i nf ar cti o n 
( § 6. 1. 2. 1. 5 ); 2) E n s ur e t h at t h e m o st r e c e nt e G F R r e m ai n s ≥ 3 0 ( § 6. 1. 2. 1. 1 0 ); 3) E n s ur e t h at t h er e ar e n o si g n s 
of c ar di o g e ni c s h o c k ( § 6. 1. 2. 1. 1 3 ); a n d 4) R e vi e w t h e pl a n n e d a p pr o a c h f or T A VI, a s c ert ai n a p pr o a c h e s will 
m a k e t h e s u bj e ct i n eli gi bl e f or t h e st u d y ( § 6. 1. 2. 1. 1 ) 
3 S cr e e ni n g/ b a s eli n e E C G m a y b e p erf or m e d u p t o 3 0 d a y s pri or t o pr o c e d ur e, a s l o n g a s t h er e h a v e b e e n n o 
i nt er v e ni n g si g n s or s y m pt o m s of m y o c ar di al i s c h e mi a (i n w hi c h c a s e t h e E C G s h o ul d b e p erf or m e d wit hi n 2 4 
h o ur s pri or t o e nr oll m e nt). T h e p o st -pr o c e d ur e E C G m u st b e p erf or m e d wit hi n 2 4 h o ur s of t h e pr o c e d ur e or 
pri or t o h o s pit al di s c h ar g e ( w hi c h e v er o c c ur s fir st).  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
60 
 4 Female patients of childbearing po tential must have a pregnancy test within 14 days prior to the procedure  
5 Hematology and chemistry within 14 days prior to the procedure are defined in §7.2. 
6 For the screening/baseline assessment, cardiac enzymes (CK), isoen zymes CK -MB or troponins obtained 
up to 14 days prior to the procedure (or on current admission) are acceptable, provided there has been no 
intervening episode of myocardial ischemia (in which case cardiac enzymes should be confirmed within 24 hours prior to enrollment ). Post-procedure CK/CKMB or troponin (preferably CKMB isoenzyme) will be 
measured post procedure when clinically indicated . If cardiac biomarkers are elevated, they should be 
repeated per local standard of care.  
7 Multi- slice CT angiography of the left heart, aorta, great vessels and peripheral access vessels performed 
up to 1 year prior to procedure should be submitted for review .  
8 DW-MRI must be performed 2 to 5 days (≥48 to <144 hours) post-procedure.  
9 The NIHSS and mRS  must be performed 2 to 5 days (≥48 to <144 hours) post -procedure by a neurologist  or 
a clinical designee ( e.g. neurology fellow ). A full neurological evaluation should be performed by a neurologist 
in all patients in whom a stroke or TIA is suspected on the basis of the NIHSS, mRS, or other signs or symptoms.  
10 If echocardiography (transthoracic or transesophageal) was performed after TAVI prosthesis implantation 
as part of the standard of care, the relevant parameters (including mean aortic valve gradient, peak velocity,  
and degree of prosthetic aortic valve regurgitation) must be captured on the eCRF for evaluation in- hospital 
TAVI device success. 
 
 
7.2 Screening / Baseline  
The following tests and examinations must be performed prior to the procedure to verify 
eligibility a nd to collect baseline study data:  
• Relevant medical history and patient demographic information , including STS Risk 
Score  and EuroSCORE II risk evaluations  
• Physical examination including ischemic / anginal status (CCS or silent ischemia) , 
NYHA functional c apacity, heart rate,  blood pressure, height, and weight   
• Frailty assessment with the Clinical Frailty Scale  
• C oncomitant medication  documentation  
• Review of the study eligibility criteria (inclusion  and exclusion) . NOTE: If the full 
screening/baseline review  of eligibility criteria is conducted before the day of 
enrollment , the following repeat review of selected eligibility criteria should be 
performed on the day of enrollment and randomization (§ 6.2.1 ) to confirm study 
eligibility, using the most recent available laboratory values and clinical assessments:  
o Ensure that the subject has not had symptoms or chemistry results indicating 
acute myocardial infarction (§ 6.1.2.1.5) 
o Ensure that the most recent eGFR remains ≥30 (§ 6.1.2.1.10) 
o Ensure that there are no signs of cardiogenic shock (§ 6.1.2.1.13) 
o Review the planned approach for TAVI, as certain approaches will make the subject ineligible for the study (§ 6.1.2.1.1 , §6.1.2.1.2) 
• Routine laboratory tests including:  
o Hematology - hemoglobin, hematocrit, platelet count, white blood cell count 
within 14 days  prior to the procedure  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
61 
 o Chemistry  - creatinine, ALT/serum glutamic -pyruvic transaminase (SGPT), and 
AST/serum glutamic -oxaloacetic acid transaminase (SGOT) within 14 days  
prior to the procedure,  
o Cardiac enzymes (CK), isoenzymes CK -MB or troponins  should be obtained 
when clinically indica ted (for example if there is a suspected ischemic event) .  
o Female patients of childbearing potential  must  also have a pregnancy test 
within 14 days prior to the procedure.   
• At the investigator’s discretion and according to site standard practice, subjects 
requiring warfarin therapy may undergo a pre- procedure Coagulation Panel including 
prothrombin time, partial thromboplastin time (PTT) and International Normalized Ratio (INR) to ensure compliance with the concomitant therapy recommendations (§7.3). 
• A 12-lead electrocardiogram.  An ECG performed within 30 days prior to the procedure 
may be used as the baseline ECG provided there have been no signs or symptoms of myocardial ischemia between the time of the ECG and enrollment  (in which case the 
ECG should be performed within 24 hours prior to enrol lment ). 
• CT imaging (standard and contrast -enhanced angiography  preferred ) of the left heart, 
aorta, great vessels, and peripheral  access vessels performed up to 1 year prior to the 
procedure should be submitted for review.  
• NIH Stroke Scale (NIHSS) up to 14 days prior to procedure. Neurologic status 
evaluation using the NIH stroke scale shall also be performed 2-5 days post-procedure  
and during each follow -up assessment. The e xamination must be performed by a 
neurologist , or a clinical designee (e.g . neurology fellow) . 
• Modified Rankin Scale  (mRS) up to 14 days prior to procedure . The mRS will also  be 
performed 2-5 days post-procedure  and during each follow -up assessment. The 
assessment must be performed by  a neurologist  or a clinical designee (e.g. neurology 
fellow) .  
• A full neurological evaluation should be performed by a neurologist  in all patients in 
whom a stroke or TIA is suspected on the basis of the NIHSS, mRS, or other signs or symptoms.  
• A neuro psychological  test battery (§16.7) will be administered up to 30 days prior to 
procedure by a qualified individual, and will be re- administered  2-5 days  post-
procedure and at 30 and 90 days.  The test battery includes : (Phase I only)  
o Montreal Cognitive Assessment (MoCA)  - A cognitive screening instrument that 
includes tasks that assess attention and concentration, executive functions, memory, language, visuoconstructional abilities, abstraction, calculations, and orientation.  It t akes approximately 10 minutes to administer and is available in 
several languages.  
o Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)  
- A comprehensive, but brief, neuropsychological battery that includes 
assessment of immediate memory, visuospatial/constructional abilities, language, attention, and delayed memory . The RBANS is available in many 
different languages and typically takes less than 30 minutes to administer.  
Alternate forms of the tests are used for repeat testing.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
62 
 o Trail Making Test Parts A & B. These tests evaluate attention, psychomotor  
speed, and mental flexibility.  In Part A, the subject  connects 25 encircled 
numbers in ascending order as quickly as possible. In Part B, the subject  
connects encircled numbers and letters in ascending order, alternating betwee n 
the two (i.e., 1 -A-2-B- etc.). The total administration time is less than 10 minutes.   
• The Short Form 36 Health Survey (SF -36v2) will be administered up to 30 days prior 
to procedure, and will be re- administered at 30. The SF -36 is a 36- item questionnaire 
that measures health- related quality of life across 8 physical and mental domains.  It is 
available in many different languages and takes approximately 10 minutes to 
administer.  When administered during  a visit that includes other assessments, the SF -
36 should be performed first  (Phase I only) . 
7.3 Concomitant Therapies  
Selection and dosing of procedural and post -procedural concomitant therapies, including 
antiplatelet and anticoagulant therapies, will be performed according to physician standard practice, in accordance with local standards of care and published guidelines. Each site is encouraged to commit to a consistent antiplatelet regimen to be applied to all subjects enrolled in the trial, independent of treatment gr oup. 
The investigators recommend (but do not require) that all subjects receive the medication 
regimen listed below  (Table 8). All medications administered should be recorded in the 
patient’s medical record and the CRF.  
Table 8: Concomitant Medications  
Timing  Medication  Recommended Doses  
Prior to 
Procedure  IV Heparin or low molecular 
weight heparin or bivalirudin  Per routine hospital practice  
During 
Procedure  IV Heparin or low molecular 
weight heparin or bivalirudin  Per routine hospital practice. It  is 
recommended to maintain an ACT > 250 seconds .
† 
Post 
Procedure * Acetylsalicylic acid (ASA)  75-100 mg QD indefinitely  
Clopidogrel  
 75 mg QD for a minimum of 6 months or 
longer based on local guidelines.  
†Peak and nadir intraprocedural ACT measuremen ts must be recorded in the CRF for all subjects.  
*Note for patients receiving warfarin therapy:  
• If the patient is on warfarin therapy prior to the procedure, the following is recommended:  
o Discontinue warfarin three days prior to the procedure  
o Confirm that  the INR is <1.8 prior to the procedure 
o ASA 75 -100 mg or clopidogrel 75 mg for 3 days prior to the procedure  
• If the patient is on warfarin therapy post- procedure, it is recommended that the patient is 
prescribed either daily aspirin (75- 100 mg) or daily clopidogrel (75 mg).  
Minimum recommended maintenance dosages can be higher based on physician’s 
discretion.  
 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
63 
 7.4 TAVI  Procedure  
TAVI  will be performed according to standard institutional practice under local or general 
anesthesia and via the transfemoral approach at the discretion of the investigator .  
In subjects in the Intervention or Roll -in Groups, the TriGuard HDH or TriGUARD 3 device 
will be advanced and deployed across the aortic arch to cover the ostia of the 3 major vessel 
takeoffs ( innominate, left ca rotid and subclavian arteries ) at the initiation of the TAVI 
procedure and withdrawn at the completion of the procedure. Please refer to the TriGuard 
HDH or TriGUARD 3  Instructions For Use for additional information.  
Device coverage and positioning must be verified by fluoroscopy  (a steep left anterior oblique 
[LAO] view is recommended),  with particular attention paid to 1.) Device coverage after initial 
deployment, 2.) Device positioning after final deployment of the first prosthetic valve, and 3.) 
Device positioning after the procedure is complete (i.e., after any additional post -dilatation or 
additional valve implantations have been completed, and the TAVR delivery system has been 
removed) . All imaging should be forwarded to the Angiographic Core Laboratory for analysis. 
For additional details, please refer to the Angiographic Imaging Acquisition Guidelines  
(§16.8).  
7.5 Post -procedure Follow -up 
The procedure is considered complete once the last guiding catheter has been removed fr om 
the patient and the patient is off the table. Thereafter, if a guiding catheter is re- introduced, 
this is considered a repeat intervention, which must be documented.   
The post -procedure follow up will consist of:  
• Physical examination including ischemic  / anginal status (CCS or silent ischemia), 
heart rate, and blood pressure  
• Documentation of any adverse events/ serious adverse events occurring since the point of enrollment  
• Current concomitant medications  documentation, including antiplatelet and 
antic oagulant therapy  
• Routine laboratory tests including:  
o Hematology - hemoglobin, hematocrit, platelet count, white blood cell count  
o Chemistry - creatinine. Serum creatinine should be measured within  48 hours 
post-procedure in all subjects. Subjects with elev ated serum creatinine (≥1.5x 
baseline OR >0.3 mg/dL [>26.4 mmol/L]) should have continued assessments to 7 days post -procedure or until discharge (whichever occurs first) to assess 
acute kidney injury.  
o Cardiac enzymes: CK/CKMB or Troponin (preferably CKMB isoenzyme) will be measured when clinically indicated. If cardiac biomarkers are elevated, they 
should be repeated per local standard of care .   
• A 12 -lead ECG , to be completed within 24 hours post -procedure or prior to hospital 
discharge (whichever occurs first) 
• If echocardiography (transthoracic or transesophageal) was performed after TAVR prosthesis implantation as part of the standard of care, the relevant parameters (including mean aortic valve gradient, peak velocity, and degree of prosthetic aortic 
R E F L E C T – U S I D E Tri al [ CI P -0 9 ( v 1 3. 0)]             K e y st o n e H e art Lt d.  
6 4  
 v a l v e  r e g ur git ati o n)  m u st  b e  c a pt ur e d  o n  t h e  e C R F  f or  e v al u ati o n  i n -h o s pit al  T A VI 
d e vi c e s u c c e s s ( § ) 
• Diff u si o n -w ei g ht e d M RI of t h e br ai n 2 t o 5 d a y s ( ≥ 4 8 t o < 1 4 4 h o ur s)  p o st -pr o c e d ur e  
• NI H Str o k e S c al e ( NI H S S) . N e ur ol o gi c st at u s  e v al u ati o n u si n g t h e NI H str o k e s c al e 
s h all b e p erf or m e d 2 t o 5 d a y s ( ≥ 4 8 t o < 1 4 4 h o ur s) p o st -pr o c e d ur e  a n d d u ri n g e a c h 
f oll o w -u p  a s s e s s m e nt. T h e  e x a mi n ati o n  m u st  b e p erf or m e d b y a  n e ur ol o gi st  or a 
cli ni c al d e si g n e e ( e. g. n e ur ol o g y f ell o w) . 
• M o difi e d R a n ki n S c al e  ( m R S) s h all b e p erf or m e d 2 t o 5 d a y s ( ≥ 4 8 t o < 1 4 4 h o ur s) p o st -
pr o c e d ur e  a n d  d uri n g  e a c h  f oll o w -u p  a s s e s s m e nt.  T h e  a s s e s s m e nt  m u st  b e 
p erf or m e d b y  a n e ur ol o gi st or a cli ni c al d e si g n e e ( e. g.  n e ur ol o g y f ell o w).  
• A f ull n e ur ol o gi c al e v al u ati o n s h o ul d b e  p erf or m e d b y a n e ur ol o gi st i n all p ati e nt s i n 
w h o m a str o k e or TI A i s s u s p e ct e d o n t h e b a si s of t h e NI H S S, m R S, or ot h er si g n s or 
s y m pt o m s.  
• A n e ur o p s y c h ol o gi c al  t e st b att er y ( § 1 6. 7 ) will b e a d mi ni st er e d 2 t o 5 d a y s ( ≥ 4 8 t o < 1 4 4 
h o ur s)  p o st -pr o c e d ur e  b y  a  q u alifi e d  i n di vi d u al.  T h e  t e st  b att er y  i n cl u d e s:  ( P h a s e  I 
o nl y) . 
o M o ntr e al C o g niti v e A s s e s s m e nt ( M o C A)  
o R e p e at a bl e B att er y f or t h e A s s e s s m e nt of N e ur o p s y c h ol o gi c al St at u s ( R B A N S)  
o Tr ail  M a ki n g T e st P art s A a n d B  
Pri or t o h o s pit al di s c h ar g e, r e s e ar c h st aff s h o ul d al s o r e vi e w t h e f oll o w -u p r e q uir e m e nt s wit h 
t h e s u bj e ct t o h el p e n s ur e t h at t h e p ati e nt r et ur n s t o t h e cli ni c f or t h e o n e -m o nt h f oll o w -u p 
vi sit. T el e p h o n e n u m b er s s h o ul d b e o bt ai n e d fr o m t h e p ati e nt t o e n s ur e t h e a bilit y t o c o nt a ct 
hi m or h er at  t h e  r e q uir e d  ti m e. T h e s e p h o n e  n u m b er s  s h o ul d  i n cl u d e  all h o m e  n u m b er s, 
w or k n u m b er s a n d pri m ar y p h y si ci a n n u m b er s. A p h o n e n u m b er of a r el ati v e or fri e n d s h o ul d 
al s o b e r e q u e st e d.   
N ot e: All cli ni c all y si g nifi c a nt a d v er s e e v e nt s  s h o ul d b e c ar ef ull y d o c u m e nt e d b y t h e r e s e ar c h 
st aff  u si n g  t h e a d v er s e  e v e nt  d at a f or m s.  A n y  cli ni c all y -i n di c at e d n e ur oi m a gi n g  s h o ul d b e 
f or w ar d e d t o t h e M RI C or e L a b or at or y.  
7. 6  O n e -m o nt h F oll o w -u p ( Cli ni c Vi sit)  
All s u bj e ct s  will  r et ur n  t o  t h e  cli ni c  at  3 0  d a y s  ( ±  7  d a y s)  p o st -pr o c e d ur e  f or  a  cli ni c al 
e v al u ati o n.  
T h e 3 0 d a y f oll o w -u p vi sit will c o n si st of t h e f oll o wi n g a s s e s s m e nt s:  
• P h y si c al e x a mi n ati o n  
• D o c u m e nt ati o n  of  a n y  a d v er s e  e v e nt s/  s eri o u s  a d v er s e  e v e nt s  o c c urri n g  si n c e  t h e 
pr e vi o u s e v al u ati o n  
• C urr e n t  c o n c o mit a nt  m e di c ati o n  d o c u m e nt ati o n,  i n cl u di n g  a nti pl at el et  a n d 
a nti c o a g ul a nt t h er a p y  
• NI H Str o k e S c al e ( NI H S S):  N e ur ol o gi c st at u s e v al u ati o n u si n g t h e NI H str o k e s c al e 
m u st b e p erf or m e d b y a n e ur ol o gi st or a cli ni c al d e si g n e e (e. g.  n e ur ol o g y f ell o w) . 
• M o difi e d  R a n ki n  S c al e  ( m R S) m u st  b e  p erf or m e d  b y a n e ur ol o gi st  or a  cli ni c al  
d e si g n e e ( e. g.  n e ur ol o g y f ell o w).  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
65 
 • A full neurological evaluation should be performed by a neurologist in all patients in 
whom a stroke or TIA is suspected on the basis of the NIHSS,  mRS, or other signs or 
symptoms.  
• A neuropsychological  test battery (§16.7), to be administered by a qualified individual. 
The test battery includes:  (Phase I only)  
o Montreal Cognitive Assessment (MoCA)  
o Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)  
o Trail Making Test Parts A and B  
• The Short Form 36 Health Survey (SF -36) (Phase I only)  
Prior to concluding the visit, research staff should also review the follow -up requirements with 
the subject to help ensure that the patient can be contacted by telephone at the three- month 
follow -up time point .  
Note: All clinically significant adverse events  should be carefully documented by the research 
staff using the adverse event data forms. Any clinically -indicated neuroimaging should be 
forwarded to the  MRI Core Laboratory.  
7.7 Three -month Follow -up  
7.7.1  Phase I:  
All subjects in Phase I were expected to return to the clinic at 90 days (± 14 days) post -
procedure for a clinical evaluation.  
The 90 day follow -up visit consis ted of the following assessments:  
• Physical examination including ischemic / anginal status (CCS or silent ischemia), heart rate, and blood pressure  
• Frailty assessment with the Clinical Frailty Scale  
• Documentation of any adverse events/ serious adverse events occurring since the previous evaluation  
• Current concomitant medication documentation, including antiplatelet and anticoagulant therapy  
• NIH Stroke Scale (NIHSS): Neurologic status evaluation using the NIH stroke scale must be performed by a neurologist or a clinical designee ( e.g. neurology fellow).  
• Modified Rankin Scale (mRS) must be performed by a neurologist or a clinical  
designee ( e.g. neurology fellow).  
• A full neurological evaluation should be performed by a neurologist in all patients in whom a stroke or TIA is suspected on the basis of the NIHSS, mRS, or other signs or symptoms.  
• A neuropsychological test battery (§16.7), to be administered by a qualified individual. The test battery includes:  
o Montreal Cognitive Assess ment (MoCA)  
o Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)  
o Trail Making Test Parts A and B  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
66 
 • The Short Form 36 Health Survey (SF -36) 
Note: All clinically significant adverse events should be carefully documented by the research 
staff using the adverse event data forms. Any clinically -indicated neuroimaging should be 
forwarded to the MRI Core Laboratory.  
7.7.2  Phase II:  
In Phase II, a telephone contact at 90 days (± 14 days) post -procedure will establish : 
• Mortal ity 
• Stroke  
If death or stro ke is reported, source documentation will be requested from treating facility  
to enable CEC adjudication of cause of death (cardiovascular [subclassified and neurologic -event related]  or non- cardiovascular ) and stroke classification according to the 
protocol -specified definitions.  
8.0 Device Accountability  
The Site Principal Investigator is responsible for device accountability at his/her trial site and 
must maintain associated trial records according to 21 CFR Part 812.140  (§15.5.2) . The 
investigator may assign the responsibility for device accountability to an appropriate study staff member, but remain s the final responsible person.  
The investigator will maintain device use/disposition records that document device delivery 
to the trial site, the inventory at the site, administration to each patient as well as any device that was  opened but not used . These records must include dates, quantities, batch/serial 
numbers, expiration dates, and the unique code numbers assigned to the trial patients. The investigator must maintain records that adequately document which device was used (or 
exposed to the circulation) of each subject  and any device malfunctions.  
At the trial closeout visit, the Investigator must return to the Sponsor any unused devices and a copy of the completed device inventory. The Investigator’s copy of the device reconciliation records must document all device usage (including devices that were opened but not used) 
and any unused devices that have been returned to the sponsor.  
9.0 Adverse Events , Serious Adverse Events, and End -points 
Potentially Meeting End- point Criteria  
In this study, patients should be encouraged to report adverse events (AEs) spontaneously or in response to general, non- directed questioning. Any time during the study, the patient 
may volunteer information that resembles an adverse event (AE). If it is determined that a clinically significant AE has occurred, the investigator should obtain all the information 
required to complete the AE CRFs.  Non-clinically -significant adverse events will not be 
required post discharge from the initial study procedure.  
9.1 Adverse Events (AE)  
An adverse event  is any untoward medical occurrence, unintended disease or injury or any 
untoward clinical signs (including an abnormal laboratory finding) in subjects, users or other 
persons , whether or not related to the study  device.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
67 
 NOTE : This definition includes events related to the study  device or to the procedures 
involved, but does not imply that there is a relationship between the adverse event and the 
study device.  
Pre-Existing Conditions:  
Pre-existing medical conditions or a repeat of symptoms reported prior to the TAVR 
procedure will not be recorded as an AE. Pre-existing conditions that worsen during a study 
are to be considered adverse events. For users or other persons , this classification is 
restricted to events related to the study device. 
9.2 Serious Adverse Events (SAE)  
A serious adverse event  is an adverse event that:  
1. Led to a death  
2. Led to a serious deterioration in the health of the subject that : 
a. Resulted in a life- threatening illness or injury  
b. Resulted in a permanent impairment of a body structure or a body function  
c. Required in- patient hospitalization or prolongation of existing hospitalization 
d. Resulted in medical or  surgical intervention to prevent life-threatening illness or 
injury or permanent impairment to body structure or a body function.  
3. Led to fetal distress, fetal death or a congenital abnormality or birth defect.  
9.3 Adverse Device Effect (ADE)  
An a dverse device effect is an adverse event related to the use of a medical device. This 
includes:  
• Any adverse event resulting from insufficiencies or inadequacies in the Instructions for 
Use, the deployment, the implantation, the installation, the operation, or any 
malfu nction of the medical device 
• Any event that is a result of a use error or intentional misuse  
9.4 Serious Adverse Device Effect (SADE)  
A serious adverse device e ffect is an adverse device effect that has resulted in any of the 
consequences characteristic of a s erious adverse event.  
9.5 Unanticipated Adverse Device Effect (UADE)  
An u nanticipated adverse device e ffect is any serious adverse effect on the health or safety 
or any life- threatening problem or death caused by, or associated with, a device, if that effect,  
problem, or death was not previously identified in nature, severity or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that  relates to the rights, safety 
or welfare of subjects.  
NOTE: An a nticipated serious adverse device e ffect (ASADE) is a serious adverse device 
effect which by its nature, incidence, severity, or outcome has been identified in the 
investigational plan or application (including a supplementary plan or application).   
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
68 
 9.6 Device Deficiencies , Malfunctions, and Use Error 
Investigators are instructed to report all possible device deficiencies , malfunctions , misuse or 
use error observed during the course of the trial. These incidents will be documented in the 
case report form provided as follows:  
• Device deficiency : Inadequacy of a medical device related to its identity, quality, 
durability, reliability, safety or performance. NOTE: Device deficiencies include 
malfunctio n, use error, and inadequate labeling. They may or may not affect device 
performance or lead to an adverse event.  
• Device malfunction: Failure of an investigational medical device to perform in 
accordance with its intended purpose when used in accordance wi th the Instructions 
for Use or protocol. NOTE: A device malfunction occurs when the device is used in compliance with the Instructions for Use, but does not perform as described in the Instructions for Use.  
• Use error:  Act or omission of an act that results  in a different medical device response 
than intended by the manufacturer or expected by the user. NOTE 1: Use error includes slips, lapses and mistakes. NOTE 2: An unexpected physiological response of the patient does not itself constitute a use error.  
• Device misuse: Any use of the investigational device by an investigator that is 
contradictory to the application described in the Instructions for Use will be categorized as device misuse. This is a form of Use Error.  
9.7 End-points Potentially Meeting End-point  Criteria  
Investigators are instructed to report all cardiovascular events and all adverse events potentially meeting end- point criteria. These events  will be documented in the case report 
form as SAEs and be assessed by the medical monitor. Events classified as potential end-
points will then be sent to CEC adjudication ( §11.2).  
9.8 Documentation 
Adverse events must be listed on the appropriate CRF. All AEs will be characterized by the following criteria:  
• Intensity or Severity  
• Relatedness  
• Outcome  
• Treatment or Action Taken  
9.8.1  Intensity or Severity  
The following categories of the intensity of an adverse event are to be used:  
Mild Awareness of a sign or symptom that does not interfere with the 
patient’s usual activity or is transient, re solved without treatment 
and with no sequelae.  
Moderate  Interferes with the patient’s usual activity and/or requires 
symptomatic treatment.  
Severe Symptom(s) causing severe discomfort and significant impact of 
the patient’s usual activity and requires tr eatment.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
69 
 9.8.2  Relatedness  
The investigator will use the following definitions to assess the relationship to the device:  
Not related  
 The cause of the AE is known and the event is not related to 
any aspect of study participation.  
Unlikely to be 
related  There is little or no temporal relationship to the study device and/or a more likely alternative etiology exists.  
Possibly 
related  There is a reasonable possibility that the event may have been caused by study participation.  
The AE has a timely relationship  to the study procedure(s); 
however, follows no known pattern of response , and an 
alternative cause seems more likely or there is significant uncertainty about the cause of the event.  
Probably 
related  It is likely that the event was caused by study participation.  
The AE has a timely relationship  to the study procedure(s) 
and follows a known pattern of response ; a potential 
alternative cause, however, may explain the event.  
Related  A related  event has a strong temporal relationship and an 
alternative cause is  unlikely.  
 
If the relationship between any adverse event and the use of the investigational medical 
device is considered to be possibly or probably related, that event will be classified as an ADE or SADE.  
 
9.8.3  Outcome  
The clinical outcome of the AE or SAE will be characterized as follows:  
Death  The SAE CRF must be completed for this outcome  
Recovered without 
sequelae  The patient returned to baseline status  
Ongoing Patient did not recover and symptoms continue;  
Recovered with 
sequelae  The patient has recov ered but with clinical sequelae 
from the event  
Unknown  The patient outcome is unknown 
 
 
9.8.4  Treatment or Action Taken  
The treatment or action taken after the occurrence of an AE or SAE will be reported as:  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
70 
 Interventional 
Treatment  Surgical, percutaneous or o ther procedure  
Medical Treatment  Medication dose reduction/interruption or 
discontinuation, or medication initiated for event  
None  No action is taken  
9.9 Reporting  
9.9.1  General Adverse Event Reporting Procedures  
Investigators are required to keep records on “all relevant observations, including records 
concerning adverse device effects (whether anticipated or unanticipated)” according to 21 
CFR 812.140. Adverse event collection will occur from the point of study enrollment to study closure. All new or worsening (from baseline) clinically significant adverse events will be 
captured on the AE CRF through the 90-day follow -up telephone visit . Non-clinically -
significant adverse events will not be required post discharge from the initial study procedure.  
It is the res ponsibility of the Investigator to assess the subject for adverse events  and, if it is 
determined that a clinically significant AE has occurred, to capture the required adverse event 
information on the AE CRF. Independent monitoring will be conducted (§ 14.1) to review 
source documentation and verify the complete and accurate capturing of adverse events.  
The general procedure for investigators reporting any adverse event is as follows:  
• If an adverse event occurs, complete all sections of the Adverse Ev ent CRF  
• Each unique event/diagnosis must be documented separately  
• Documented pre- existing conditions are not considered to be reportable AEs unless 
there is a change in the nature or severity of the condition  
• The AE CRF must be reviewed by the investigator  
For adverse events not meeting the criteria for an SAE or (potential) UADE, the sponsor recommends that the Investigator notify the sponsor within 10 working days of first learning of the AE using the electronic data capture (EDC) CRF. If necessary, the Investigator may be requested to provide de-identified copies of source documentation (e.g., physician/nurse 
notes or summaries) regarding the event.  
The Investigator must also notify the responsible IRB /EC regarding new and significant safety 
information a nd any event s identified by Keystone Heart Ltd. that require expedited FDA or 
other regulatory authority reporting as serious, unexpected, and related to the investigational 
device. It is the responsibility of the investigator to ensure site- specific IRB/E C reporting 
requirement are met.  
The sponsor is responsible for reporting SAEs and device deficiencies to regulatory authorities in line with applicable regulatory requirements and for reviewing the risk analysis, determining the need for corrective or preventative action, and informing investigators and 
regulatory authorities accordingly.  
9.9.2  Serious Adverse Events 
Keystone Heart Ltd. recommends that the Investigator notify the sponsor within 3 working days of first learning of any SAE using the EDC CRF. All cardiovascular events and all 
adverse events potentially meeting endpoint criteria will be considered an SAE (even if they do not result in death or prolong the hospitalization) and should be reported as well (see also section 11.2). If necessary, the Investigator may be requested to provide copies of de-
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
71 
 identified source documentation (e.g., physician/nurse notes or summaries) regarding the 
event. The sponsor will conduct an evaluation of the event and, if it is determined by the 
sponsor to be a UADE, it will be reported as described in the following section.  
At EU sites  (phase I) , Serious Adverse Device Effects ( SADEs ) must be reported to genae, 
N.V. within 48 hours of knowledge if required by local or national regulations . Contact details 
are as follows:  
genae, N.V. 
Justitiestraat 6B  
2018 Antwerp, Belgium  
Tel: +32 3 290 0306  
Fax: +32 3 290 0307  
It is the responsibility of each Investigator to report all serious a dverse events and/or serious 
adverse device effects and device deficiencies that could have led to a serious adverse 
device effect to the IRB/EC , according to national regulations and IRB/EC  requirements. If 
required by national regulations, the Investigator may also be required to report SAEs to the regulatory authority.  
European investigators  (phas e I) who become aware of an event must report the event to 
genae  and to the Sponsor . While there is no legal requirement within the Medical Device 
Directives obliging users to have an active role in the medical devices vigilance system, user involvement is  critical to successful post market surveillance by 1.) Ensuring that suspected 
incidents are communicated to manufacturers, and 2.) Making the proper implementation of field safety corrective actions possible.  
9.9.3  Unanticipated Adverse Device Effects  
Investi gators must report any (potential) unanticipated adverse device effects to the sponsor 
and their IRB as soon as possible but no later than within 5 working days after the investigator 
first learns of the event [21 CFR 812.150]. UADEs should be reported imm ediatel y via 
telephone (contact details follow) as well as on the eCRF.  
Sponsor contact  (US):  
M. Pauliina Margolis, MD, PhD  
Chief Medical Officer  
Tel: 305.972.8447  
email: pauliina.margolis@keystoneheart.com
  
 Sponsor contact (OUS):  
Ron Nitzan, PhD  
Vice President, Regulatory and Quality Affairs  
Tel: +972 4 615 8005  
Fax: +972 4 615 8099  
email: ron.nitzan@keystoneheart.com
  
Investigators should consider  the device labeling and the listing of expected adverse events 
(§9.10) in determining whether an event may qualify as “unanticipated. ” 
If an event is determined by Keystone Heart Ltd. to be a UADE, the sponsor will report  the 
event to the FDA, relevant competent authorities and the European Databank on Medical Devices (Eudamed) if necessary (in accordance with MEDDEV 2.12- 1), and to all 
investigators to enable reporting to their respective IRB/EC. The sponsor will provide this 
notification within 10 days after first receiving notice of the effect [21 CFR 812.150].  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
72 
 If the sponsor and the DSM B deter mine that the event presents an unreasonable risk  to the 
participating subjects, the sponsor must terminate all investigations or parts of investigations 
presenting the risk in the clinical trial not more than 5 working days after making that 
determination, and not more than 15 working days after the sponsor first received notice of the effect [21 CFR 812.26]. Follow -up visits for enrolled subjects will continue according to 
the schedule of assessments.  
9.10 Expected Adverse Events 
As with any endovascular intervention, TAVI involves some risks and possible complications . 
The following anticipated events have been identified as possible complications of TAVI  
procedures:  
• Acute cardiovas cular surgery (need for)  
• Acute coronary artery occlusion  
• Acute myocardial infarction  
• Acute neurological events such as stroke, transient ischemic attack (TIA), and encephalopathy  
• Allergic reaction to contrast, antiplatelet therapy or device component materials  
• Angina pectoris  
• Anesthesia r eactions  
• Aneurysm or pseudo aneurysm  
• Arteriovenous fistula  
• Ascending or descending aorta trauma  
• Atrial or ventricular arrhythmias or fibrillation  or sustained heart palpitations requiring 
therapy  
• Bleeding complications such as hematoma and hemorrhage 
• Blood loss requiring transfusion  
• Bowel ischemia  
• Coronary artery or other vascular injury, dissection, or perforation (which may require 
repair)   
• Embolism (air, tissue, device, or t hrombus)  
• Fever  
• Femoral nerve damage 
• Hemodynamic changes  
• Hypertension or hypotension  (sustained requiring therapy)  
• Infection , including endocarditis and septicemia 
• Pain (at the femoral puncture site, abdominal, back, or other)  
• Percutaneous coronary intervention (need for)  
• Peripheral ischemia, peripheral nerve damage 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
73 
 • Pulmonary edema  
• Pyrogenic reaction  
• Renal complications, injury,  or failure  
• Unstable angina  
• Vascular complications which may require vessel repair  
• Vessel spasm  (sustained, not responding to ther apy) 
In addition to the risks listed above, the potential risks specifically associated with the 
TriGuard HDH or TriGUARD 3 procedure include, but may not be limited to, the following:  
• Dissection of the innominate artery by improper manipulations, disruption or migration  
of the TriGuard HDH CEPD filter  due to passage of other instrumentation, e.g.: 
balloon, stent, catheter, wire  
• Blue toe syndrome or blue discoloration of a toe  
• Femoral bleeding at the access site  
• Local trauma to the aortic wall due to device migration  
10.0 Risk/Benefit Analysis  
10.1 Potential Risks and Discomforts  
Enrollment in the trial involves exposure to some risks. Most  risks of trial participation 
are not materially different than those encountered by an individual undergoing TAVI 
outside the context of the trial (§9.10 ). However, the use of the TriGuard HDH or 
TriGUARD 3 embolic protection device s may involve exposure to additional  risks (§ 9.10) 
as well as other potential  risks of an unknown nature.  
10.2 Methods to Minimize Risks  
The clinical investigation plan is specifically designed to manage and minimize risks through careful subject selection, thorough training of investigators, adherence to pre- determined 
time points to assess subject clinical status, and regular clinical monitoring visits by Sponsor -
appointment monitoring personnel. A dedicated contract research organization has been 
included in the study team to ensure high quality follow -up and minimize potential drop out. 
In addition, an independent Data Safety Monitoring Committee will monitor the safety of subjects throughout the trial.  
10.3 Potential Benefits  
The targeted trial population (subjects with severe symptomatic AS meeting indications for TAVI) has been demonstrated to be at risk for stroke and other neurological complications during and after  the procedure. The study intervention has the potential 
to benefit subjects by preventing or reducing cerebral embolization during the TAVI 
procedure, limiting subsequent  cerebral ischemia . Potential risks and benefits will be 
evaluated on an individual basis and discussed with each patient prior to enrollment in the study.
 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
74 
 11.0 Study Committees  
11.1 Patient Review Committee (PRC ) 
The PRC will ensure appropriate and consistent appli cation of selected anatomic eligibility 
criteria to all potentially eligible subjects  at all study sites. The PRC will consist of at least one 
imaging specialist , two interventional cardiologists,  and a Sponsor representative (non- voting 
role).  
Following initial pre-screening for study eligibility by the research team and documentation of 
informed consent,  the following information will be submitted to the PRC for review  for each 
potentially eligible subject : 
• A completed Screening Worksheet  
• The results of  independent core laboratory analysis of CT imaging (standard and 
contrast -enhanced angiography preferred) of the left heart, aorta, great vessels, and 
peripheral access vessels  performed up to 1 year prior to procedure .  
The PRC will meet regularly during the enrollment phase to determine whether potential 
candidates meet selected applicable anatomic eligibility criteria ( §6.1.2.1.15 , §6.1.2.1.16 , 
§6.1.2.1.17 , §6.1.2.1.18, § 6.1.2.1.19). PRC responsibilities, membership, meeting 
frequencies, and procedures will be outlined in the PRC charter prior to the onset of the trial.  
11.2 Clinical Events Committee (CEC)  
The CEC  will be responsible for adjudicating all site -reported cardiovascular events and all 
adverse events potentially meeting endpoint criteria, in an ongoing fashion during the trial. In 
order to fully capture all endpoints,  events  potentially  meeting end -point criteria will be 
considered an SAE  (even if they do not result in death or prolong the hospitalization)  and 
sent to the medical monitor for further assessment. Events appropriately  classified 
as potential endpoints by the medical monitor  will be sent to CEC for  adjudication.  
Events potentially meeting end- point criteria and therefore defined as SAE for this 
purpose include:  
• Death  
• Stroke/TIA or any  other Neurological Dysfunction (NeuroARC definitions)  
• MI or Coronary artery obstruction requiring intervention 
• Bleeding (including  life-threatening or disabling bleeding, Major and Minor  bleeding)  
• Acute kidney injury (stage 2 or 3 or requiring dialysis)  
• Major vascular complications  
• Valve -related dysfunction requiring repeat procedure  
The CEC will include at least  one interventional cardiologist with relevant clinical experience 
and one neurologist with experience in clinical trials involving stroke who are otherwise 
independent of the Sponsor or the conduct of the study. Members will not have scientific, 
financial  or other conflicts of interest related to Keystone Heart Ltd. or the Investigators. The 
CEC will operate and conduct all meetings and event reviews independent of the Sponsor unless specific expert knowledge regarding the characteristics or function of the study device is requested by the CEC from the Sponsor.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
75 
 The CEC will meet regularly throughout the study to adjudicate events in an ongoing and 
timely fashion. The adjudication process, event definitions and required source document materials for each types of event will be pre- specified in the CEC Charter  prior to the onset 
of the trial . The adjudication process will include CEC member review of copies of all relevant 
medical records and imaging studies associated with an event reporting. All adjudicatio n 
decisions will be made by the CEC in an independent fashion based upon review of all available medical evidence associated with an event.  
11.3 Data  and Safety Monitoring Board  (DSM B) 
The Data Safety Monitoring Committee ( DSM B) is responsible for the oversight  and safety 
monitoring of the study. The DSM B advises the Sponsor regarding the continuing safety of 
the trial subjects and those yet to be recruited to the trial, as well as the continuing validity and scientific merit of the trial. The DSM B will be composed of members are leading experts 
in cardiovascular medicine, vascular neurology  (with experience in clinical trials involving 
stroke) , and biostatistics who are not participating in the trial and have no affiliation with the 
sponsor.  
During the enrollment phase of the trial, the DSM B will review accumulating safety data to 
monitor for the incidence of serious adverse events that would warrant modification or termination of the trial  according to a pre- specified safety monitoring plan. Any DSM B 
recommendat ions for study modification or termination prompted by concerns regarding 
subject safety or issues relating to data monitoring or quality control will be submitted in writing to the Sponsor for consideration and final decision. However, if the DSM B at any time 
determines that a potential serious risk exists to subjects in this trial, the DSM B chairman will 
immediately notify the Sponsor.  
The DSM B will meet at regular intervals to review the safety data. DSM B responsibilities, 
membership, meeting frequencies , and procedures will be outlined in the DSM B charter  prior 
to the onset of the trial . The circumstances under which the DSMB may request unblinding 
to treatment allocation will also be outlined in the charter.   
12.0 Statistical Considerations and Analysis Plan 
12.1 General Analysis Definitions  
Analysis will be conducted using SAS (version 9. 3 or greater), unless otherwise noted. 
Descriptive s tatistics for continuous variables will include mean, median, standard deviation, 
quartiles, minimum, maximum, and sample size for each treatment group. Binary variables will be summarized using frequencies, percentages, and sampl e size for each treatment 
group. For time -to-event data, Kaplan- Meier estimates at the indicated time points will be 
displayed graphically. Further clarifications regarding endpoint criteria assessment and 
analysis between subjects will be provided in the Statistical Analysis Plan ( SAP). 
12.1.1  Adaptive Design  
Once at least 50%  of the initial randomized Phase II cohort has been enrolled and has 
reached the 30 day primary efficacy endpoint  evaluation time point , the independent 
unblinded statistician will perform a conditional power analysis. If the trial, based on the results at that point is either  ≤40% powered to achieve success in meeting the primary 
efficacy endpoint or is ≥80% powered to achieve the primary efficacy endpoint no sample 
size reestimation will be required. If the conditional power of the study is >40% but <80% the 
independent unblinded statistician will recommend a sample size reestimation, subject to approval by the Sponsor. If this analysis determines that more than 225 randomized subjects 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
76 
 will be required to ensure adequate study power, enrollment may continue until the required 
number of subjects have been enrolled, or until the total subject limit for the study has been reached (whichever occurs first).  
Promising zone computation 
After the trial has enrolled 50% of the originally planned sample size of the initial randomized 
cohort  (112 patients), an independent statistician will estimate all 4 levels of the Finkelstein-
Schoenfeld hierarchy for device and control, and use these estimates to re- calculate the trial’s 
power given the originally planned 225 Phase II patients.   
If the trial power is between >40% and <80%, the trial will be considered promising and the trial will readjust the sample size to attain 80% power. If on the other hand the power falls to 
≤ 40% or ≥ 80%, the sample size will not be adjusted.  
Conditional power computation 
The conditional power will estimate all four Finkelstein- Schoenfeld levels and use these 
estimates to simulate future enrolled patients. The power simulation will follow ex actly the 
same algorithm as used to power the original Phase II study with updated estimates of effect size. 
Alpha spending and controlling type I error  
Since the study leadership and sponsor do not conduct any formal statistical hypothesis  test, 
this design will not incur any alpha penalty or affect the overall type I error. As detailed by Mehta and Pocock
11 and based on the work of Chen10 as long as the sample size 
reestimation occurs only when the conditional power falls in the promising zone, no additional alpha spend is required and the overall type I error is preserved.   
 
12.2 Sample Size Calculation   
12.2.1  Hypothes es 
12.2.1.1.1  Primary Safety Hypothesis  (Phase I and Phase II reported 
individually)  
The primary safety hypothesis is that the rate of the primary safety endpoint (a composite of 
death, stroke, life- threatening of disabling bleeding, AKI [Stage 2 OR 3], coronary artery 
obstruction requiring intervention, major vascular complication, and valve- related dysfunc tion 
requiring repeat procedure) in the group undergoing TAVI with either protection device 
system ( Intervention Groups) at 30 days will be less  in each device group (TriGuard HDH 
and TriGUARD 3) compared separately to a performance goal (PG) of 34.4%.  
Specifically, the primary safety analysis will assess if the Intervention group’s safety event 
rate is significantly less than the PG of 34.4% using a one- sample z -test of proportions.  The 
formal null and alternative hypotheses to be tested are:  
 H0: π ≥ 0.344  
 H1: π < 0.344  
where π is the true safety event rate for the Intervention arm.   
The primary hypothesis test will be carried out by comparing the upper bound of the one -
sided 95% confidence interval of the primary safety endpoint event rate in the  intervention 
arm to the PG. With the planned evaluable sample size of 179 subjects and a one- sided 
alpha of 0.05, the critical value for rejection of the null hypothesis is 28.5%:  if the primary 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
77 
 safety endpoint occurs in 28.5% or less of intervention group subjects, the performance goal 
will be met.  
After accounting for a potential 5% loss to clinical follow -up at 30 days (including subjects 
who do not meet As Treated population criteria), the total required intervention group sample 
size is 190 subjects  in each Phase. For Phase II 150 subjects randomized to the TriGUARD 
3 and the 40-50 roll -ins will constitute the primary safety population.  
Trial success depends on both primary endpoints being met in their primary analysis populations; i.e., the primary sa fety endpoint must be met in the primary (AT) population and 
the primary efficacy endpoint must be met in the primary (eITT) population in order for the trial to be declared a success.  Because both primary endpoints (safety and efficacy) must be 
met (i.e., both H
0 must be rejected) for the trial to be declared a success , no adjustment to 
alpha for multiple endpoints is required for the two primary study endpoints.  
12.2.1.1.2  Primary Efficacy Hypothesis  
The primary hypothesis is that TAVI with the TriGUARD 3 system is superior to standard 
(unprotected) TAVI for the primary hierarchical composite efficacy endpoint of all -cause 
mortality or any stroke at 30 days (Tier 1), NIHSS worsening from baseline assessed at 2-5 
days post -procedure (Tier 2), freedom from any cerebral  ischemic lesions detected by 
diffusion -weighted magnetic resonance imaging (DW -MRI) 2 to 5 days post -procedure (Tier 
3), and total volume of post -procedure cerebral ischemic lesions detected by DW -MRI (Tier 
4).  
Specifically, the primary efficacy hypothes es are:  
H0: The hierarchical composite of death/stroke, NIHSS worsening, freedom from 
any lesions detected by DW -MRI, and larger total lesion volumes is not different 
between Intervention and Control groups  
H1:  The hierarchical composite of death/stroke, NIHSS worsening, freedom from 
any lesions detected by DW -MRI, and larger  total lesion volumes is lower  in the 
Intervention group than in the Control group  
The null hypothesis will be tested at the final analysis at a one-sided 0. 025 level of 
significance . The null hypothesis will be tested using the chi-square test according to the 
method described in Finkelstein- Schoenfeld2 and Pocock77. 
12.2.1.1.3  Hypothesis -driven Secondary Endpoints  
In order to control alpha at 0.02 5 level overall, the secondary endpoints will be tested if and 
only if the primary study endpoints are met. Secondary testing will be conducted sequentially 
beginning with all stroke,  followed by NIHSS worsening, followed by the composite of all -
cause mortality and all stroke, followed by CNS Infarction , followed by total volume of cerebral 
ischemic lesions.  
• All stro ke [evaluated at 7 days  in the eITT analysis population]  
The hypothesis is that the event rate for  all stroke in the Intervention Group at 7 days will be 
lower than the Control Group at 7 days.  
The formal null and alternative hypotheses to be tested are:  
 H0: πSTRK -I = πSTRK -C 
 H1: πSTRK -I < πSTRK -C 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
78 
 where πSTRK -I is the true rate of all stroke  in the Intervention arm and πSTRK -C is the true rate 
of all stroke in the Control arm.  
The null hypothesis will be tested at a one-sided 0.0 25 level of significance  using  a two -
sample z -test of proportions . 
• NIHSS worsening, defined as an NIHSS score increase from 
baseline [evaluated at 2-5 days post-procedure in the efficacy 
Intention to Treat (eITT) analysis population]  
The hypothesis is that the rate of the patients with worsening NIHSS score in the Intervention 
Group at post-procedure (2-5 days post -procedure)  will be lower than the Control Group at 
post-procedure  (2-5 days post -procedure) .  
The formal null and alternative hypotheses to be tested are:  
 H0: πNIHSS -I = πNIHSS -C 
 H1: πNIHSS -I < πNIHSS -C 
where πNIHSS -I is the true rate of worsening NIHSS scores in the Intervention arm and πNIHSS -
C is the true rate of worsening NIHSS scores in the Control arm.  
The null hypothesis will be tested at a one-sided 0.0 25 level of significance  using a two -
sample z -test of proportions . 
• Composite of all -cause mortality and all stroke [evaluated at 7 
days  in the eITT analysis population]  
The hypothesis is that the event rate for  the composite of all -cause mortality and all stroke in 
the Intervention Group at 7 days will be lower than  the Control Group at 7 days.  
The formal null and alternative hypotheses to be tested are:  
 H0: πCOMP -I = πCOMP -C 
 H1: πCOMP -I < πCOMP -C 
where πCOMP -I is the true rate of the composite of all -cause death and all stroke  in the 
Intervention arm and πCOMP -C is the true rate of the composite of all -cause death and all stroke 
in the Control arm.  
The null hypothesis will be tested at a one-sided 0.0 25 level of significance  using a two -
sample z -test of proportions . 
• CNS infarction  (NeuroARC defined) [evaluated at 30 days in the 
eITT analysis population]  
The hypothesis is that the event rate for  CNS infarction  in the Intervention Group at 30 days 
will be lower than the Control Group at 30 days.  
The formal null and alternative hypotheses to be tested are:  
 H0: πCNS -I = πCNS -C 
 H1: πCNS -I < πCNS -C 
where πCNS -I is the true rate of CNS infarction  in the Intervention arm and πCNS -C is the true 
rate of CNS infarction  in the Control arm.  
The null hypothesis will be tested at a one-sided 0.0 25 level of significance  using a two -
sample z -test of proportions . 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
79 
 • Total volume of cerebral ischemic lesions  detected by DW-MRI, 
[evaluated 2 to 5 days post -procedure in the efficacy Intention to 
Treat (eITT) analysis population]  
The hypothesis is that the total volume of cerebral i schemic lesions in the Intervention Group 
will be lower than the Control Group.  
The formal null and alternative hypotheses to be tested are:  
 H0: πTLV-I = πTLV-C 
 H1: πTLV-I < πTLV-C 
where πTLV-I is the true total volume of cerebral ischemic lesions in the Intervention arm and 
πTLV-C is the true total volume of cerebral ischemic lesions  in the Control arm.  
The null hypothesis will be tested at a one-sided 0.02 5 level of significance using the two-
sample z -test. 
12.2.2  Expected Control Primary Safety Endpoint Event Rate  
An expected event rate for the control group was determined based on published data from 
subjects undergoing unprotected TAVI.  
A search of  bibliographic scientific databases (PubMed and EMBASE) was undertaken to 
identify studies reporting VARC combined safety outcomes using the following search parameters:  
• Language = English, species = humans  
• Publication date January 2011 (publication of original VARC definitions) to present  
• Keywords included: Valve Academic Research Consortium or VARC; aortic valve; and percutaneous, transcatheter, transluminal, transarterial, transfemoral, or transapical  
Results were evaluated according to the following selection criteria:  
• Peer -reviewed publications only. Abstracts, case reports, conference presentations, 
editorials, and expert opinions were excluded.  
• Reported using VARC or VARC -2 definitions (explicitly mentioned in text), and 
reported VARC combined safety  endpoint or the VARC -2 early safety endpoint at 30 
days  
• N≥20 (studies reporting outcomes in fewer than 20 TAVI subjects were excluded)  
• Patients with severe AS undergoing TAVI with Medtronic or Edwards valves. Studies reporting outcomes exclusively in valv e-in valve or subjects undergoing TAVI via any 
approach other than transfemoral or transapical (e.g., transaxillary, transsubclavian, direct aortic) were excluded. When larger cohorts included these subjects, the results in these subjects were excluded when data allowed; otherwise they were included.  
• Publications with overlapping data were identified where possible, and the most recent procedural timeframe (or largest N) was used and the other(s) discarded.  
Additional relevant studies were identified through a manual search of secondary sources, including the bibliographies of initially identified articles and review articles and commentaries.  
Although the primary safety endpoint is the VARC -2
1 early safety endpoint, which differs from 
the original VARC definition78, studies reporting either composite endpoint were collected and 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
80 
 evaluated to inform determination of the PG. Based on differences between the definitions 
(see Table 9 below), we would expect the VARC -2 event rate to be slightly higher based on 
the addition of all stroke and Stage 2 acute kidney injury; however, mor e published data 
according to the earlier VARC definitions is likely available.  
 
Table 9. Comparison of VARC and VARC- 2 Early Safety Endpoint Components  
VARC78 
Combi ned Safety Endpoint (at 30 days)  VARC -21 
Early Safety (at 30 days)  
• All-cause mortality  
• Major stroke  
• Life-threatening (or disabling) bleeding 
• Acute kidney injury  – Stage 3 
(including renal replacement therapy)  
• Coronary artery obstruction requiring 
intervention 
• Major vascular complication 
• Repeat procedure for valve- related 
dysfunction (surgical or interventional 
therapy)  
• Peri-procedural MI  • All-cause mortality  
• All s troke (disabling and non- disabling)  
• Life-threatening bleeding 
• Acute kidney injury – Stage 2 or 3 
(including renal replacement therapy)  
• Coronary artery obstruction requiring 
intervention 
• Major vascular complication 
• Valve -related dysfunction requiring repeat  
procedure (BAV, TAVI, or SAVR)  
Note : Bold text indicates differences between the two definitions. This table represents an overall 
comparison; details of individual component definitions have also changed between consensus documents.  
The literature search and sift identified a total of 19 studies reporting the original VARC 
combined safety endpoint and 6 studies reporting the VARC -2 early safety endpoint (Table 
10 below).  
Table 10. Published Combined Safety Event Rates at 30 days after Unprotected TAVI  
Study  N Event Rate (%)  
VARC 1 Combined Safety    
Abdel -Wahab 201279 70 13.0 
Buchanan 201180 305 38.2 
D’Ascenzo 201381 377 28.9 
Dubois 201382 73 29.0 
van der Boon 201483 882 26.6 
Eltchaninoff 201284 190 16.3 
Gurvitch 201185 310 18.4 
Hammerer 201286 50 18.0 
Hayashida 201287 260 17.3 
van der Boon 201388 298 23.5 
Scherner 201289 150 28.0 
Seiffert 201390 326 21.2 
Stahli 201191 130 20.8 
Ussia 201292 181 25.8 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
81 
 Wenaweser 201193 256 29.3 
Yamamoto 201394 415 16.4 
Abramowitz 201495 249 6.8 
Greif 201496 461 12.6 
Sabate 201397 1416  14.0 
Simple mean  337 23.8 
Weighted mean  -- 20.4 
VARC 2  Early Safety    
D’Onofrio 201398 774 21.7 
Tarantini 201399 250 21.2 
Chopard 2014100 3928  40.4 
Conrad i 2013101 100 19.0 
Magri 2013102 330 30.9 
Seco 2014103 32 21.9 
Simple mean  902 25.9 
Weighted mean  -- 35.8 
The above studies represent the best estimation of the expected event rate in the population 
of subjects with severe AS undergoing TAVI via the transfemoral or transapical route with 
Edwards or Med tronic valve systems. The average event rate in studies reporting outcomes 
according to the VARC -2 definition (the primary safety endpoint for the REFLECT Trial) was 
25.9%;  among studies reporting the slightly more circumscribed VARC 1 definition, the 
average event rate was 23.8%.  Therefore, the expected event rate of the primary safety 
endpoint in the Control group was estimated at 25%.   
12.2.3  Expected Primary Efficacy Endpoint Event Rate  
Occurr ence of the components of the primary hierarchical composite efficacy endpoint was 
estimated based on published literature and  special consideration of  data from the DEFLECT 
III randomized controlled trial of the TriGuard device:  
For T ier 1 of the hierarc hy, a n expected event rate of all -cause mortality or stroke (disabling 
and non- disabling) at 30 days was estimated based on published data from randomized 
controlled trials of subjects undergoing unprotected TAVI (Table 11).  
Table 11. Composite of all -cause mortality and any stroke (30 days) in unprotected TAVI 
RCTs  
Trial  N Composite  Component  
Death + 
All Stroke  Death + 
Disabling 
Stroke Death   All 
Stroke All stroke 
or TIA  Disabling 
/ Major 
Stroke Non-
disabling 
/ Minor 
Stroke TIA 
PARTNER 1A 
(High Risk)4* 348 7.8% (27)  6.9% (24)  3.4% (12)  4.6% (16)  5.5%(19)  3.8% (13)  0.9% (3)  0.9% (3)  
PARTNER 1B 
(Inoperable)5 179 10.1% (18)  8.4% (15)  5.0% (9)  6.7% (12)  6.7% (1 2) 5.0% (9)  1.7% (3)  0% (0)  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
82 
 In addition,  we took into account randomized control trials of subjects randomized to TAVI 
with vs. without protection device (table 11a).  
 
   Table 11a. Rates of death and Stroke at 30 days in RCTs of protection devices.  
Trial*  N Death at 30 days  Stroke at 30 days  
Device  Control  Device  Control  
DEFLECT III8 2015  85 2.17%  5.13%  4.35%  5.13%  
EMBOL -X72 2015  30 0% 0% -- -- 
MISTRAL -C73 2016  65 3.12%  9.09%  0% 6.06%  
CLEAN TAVI74 2016  100 0% 2% 8% 8% 
SENTINEL9 2017  363 1.28%  1.8%  5.63%  9.09%  
Simple mean   1.32%  3.6%  3.6%  5.66%  
Weighted mean   1.33%  3.21%  5.09%  7.25%  
Meta -analytic mean*   1.6%  3.83%  5.09%  7.26%  
* Embol -X excluded  
A recent ly published letter104 presented a meta- analysis of the above trials for the primary 
end point of death and stroke at longest follow -up available, showed rates  of 6% vs 10% for 
device vs. control respectively.  
Based on the above, and considering SENTINEL being the most recent trial (with up to 9% 
stroke rate and 1.8% death rate in the controls), we conservatively estimate an ~11% rate of 
all-cause mortality or stroke at 30 days in subjects undergoing unprotected TAVI  and a 50% 
reduction yielding a ~6% assumed event rate in the protected group.  CoreValve 
High Risk6* 390 6.9% (27)  5.9% (23)  3.3% (13)  4.9% (19)  5.9% (23)  3.9% (15)  1.0% (4)  0.8% (3)  
CoreValve 
Extreme 
Risk7* 489 11.5% (56)  9.8% (48)  8.4% (41)  4.0% (19)  4.5% (22)  2.3% (11)  1.9% (9)  0.6% (3)  
Simple average  9.1%  
Weighted average  9.1%  
Meta -analytic 
average 8.8%  
NOTE: Italics indicates that the event rate is not directly reported, but the given percentage represents a best estimate based on 
component event rates; for the composite of death and all stroke, it is assumed that no subject with a non-disabling stroke also 
experienced a death or disabling stroke within the 30-day timeframe (with the exception of CoreValve Extreme, in which data 
indicates that 1 subject experienced both a major and a minor stroke).  
*Percentages given are Kaplan Meier estimates, and therefore do not equal the number of subjects experiencing an event divided by the total number of subjects  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
83 
 The remaining component event rates  (Tiers 2 -4) are estimat ed based on data from the 
above mentioned trials , which employed identical NIHSS assessments and DW -MRI analysis 
methodology . 
We conservatively expect 9% of controls and 6% of device group patients to have any NIHSS 
worsening  (table 6b).  
Among subjects who survived free of stroke to 30 days, and who did not experience NIHSS 
worsening at the post -procedure (2-5 days post -procedure)  assessment (Tier 3 of the 
hierarchy),  we expect 11% of controls and 2 7% of device group patients to be free of any 
lesions on MRI. These assumptions are based on the above trials and more specifically on the published results of DEFLECT III
8 (Per Treatment) which used a similar device with full 
cerebral protection (as opposed to SENTINEL) and the same MRI assessment  modality as 
planned in this trial (see also table 6a). 
Among patients surviving without stroke at 30 days, and who did not experience NIHSS worsening, and who had MRI lesions on DW-MRI (final 4th Tier) we expect  the rates of  lesion 
volumes  categorized by size in pre-specified set ranges of >0-50 mm
3, >50-150 mm3 and 
above 150 mm3 to be 7%, 33%, and 48% in the controls, respectively, and 19%, 7.5% and 
46% in the device arm, respect ively. Expected rates were adapted from DEFLECT III  (Per 
Treatment) , the only published study thus far to incorporate such volume subdivisions .8 
All tiers and their  respective assumed rates are presented in table 11b.  
 
 Table 11b . Assumed event rates  
  Assumed 
Control Rates  Assumed 
TriGUARD 3 Rates  
Death or Stroke  11% 6% 
Worsening NIHSS  9% 6% 
Freedom from MRI Findings  
(Lesion Volume 0 mm3) 11% 27% 
Lesion Volume  (mm3)   
>0-50 7% 19% 
>50-150 33% 7.5%  
> 150  48% 46% 
15% Missing in MRI Follow -up and 5% missing for all other parameters  
Type I Error = 5%    
 
The primary analysis population for the primary endpoint is the efficacy Intention to Treat 
(eITT) population (§12.3.1), which excludes subjects with conversion to surgery  or prolonged 
cardiac arrest  prior to the post -procedure DW-MRI. Selection of this population as the primary 
analysis population for the efficacy endpoint ensures that, should a small number of subjects 
experience an  adverse endpoint event  due to circumstances unrelated to procedural  
neuroprotection, the study will remain powered to detect a clinically -meaningful treatment 
effect , particularly  regarding the volume of  subclinical cerebral ischemic lesions on DW -MRI.   
12.2.4  Sample Size Estimation  
12.2.4.1.1  Primary Safety Endpoint  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
84 
 The primary safety endpoint is combined safety (VARC -2 defined as a composite of death, 
stroke, life -threatening or disabling bleeding, acute kidney injury [Stage 2 or 3], coronary 
artery obstruction requiring intervention, major vascular complication, and valve- related 
dysfunction requiring repeat procedure), evaluated at 30 days.  
Based on published literature of patients undergoing unprotected TAVI (§12.2.2), establishing 
the expected Control event rate of 25%, and a 37.5% relative margin (absolute delta 9.4%) , 
a Performance Goal (PG) has been has been set at 34.4% (25% + 9.4%). The primary safety analysis will assess if the Intervention group’s safety event rate is significan tly less than the 
PG of 34.4%.  
A sample size of 179 evaluable subjects in the intervention group will provide 85% power to 
determine whether the intervention group meets the PG at the one- sided alpha=0.05 level 
when using a one-sample z -test of proportions. After accounting for a potential 5% loss to 
clinical follow -up or dropout from the primary analysis population (As Treated) at 30 days, the 
total required sample size is 190 subjects in each intervention group. Therefore, the initial 
randomized sample size of 190 subjects in each  intervention group in each phase will have 
sufficient power to determine whether the intervention meets the safety PG.  For Phase II 150 
subjects randomized to the TriGUARD 3 and 40- 5 0 roll -ins will con stitute the primary safety 
population.  
12.2.4.1.2  Primary Efficacy Endpoint  
Sample size for assessing superiority of Intervention over Control with respect to the 
hierarchical composite primary efficacy endpoint was estimated using the following assumptions:  
• All-caus e mortality or any stroke at 30 days will occur in ~11% of Control subjects 
and ~6% of Intervention subjects  (5% absolute reduction, ~45% relative reduction)  
• Among subjects without all -cause mortality or any stroke to 30 days, NIHSS 
worsening  2-5 days  post-procedure will occur in 9% of Control subjects and 6% of 
Intervention subjects ( 3% absolute reduction, 33.3%  relative reduction)   
• Among subjects without all -cause mortality or any stroke to 30 days and without 
NIHSS worsening 2-5 days post-procedure , MRI findings will occur in 89% of Control 
subjects and in 7 3% of intervention subjects (16% absolute reduction, 17.9% relative 
reduction) . 
• Among subjects without all -cause mortality or any stroke to 30 days, without NIHSS 
worsening 2-5 days post procedure, but with MRI findings, lesion volumes can be 
divided into 3 out of  4 subsets - 0 mm
3, >0-50 mm3, >50 -150 mm3 and >150 mm3 . 
For these volume subsets, we expect rates of 11%, 7%, 33% and 48%, respectively, in the control group and 27%, 19%, 7.5% , and  46%, respectively, in the intervention 
group. 
• For sample size calculations a relative reduction of 30% is expected in each lesion volume subset, based on the comparison of total lesion volumes between device and control groups in DEFLECT I, MISTRAL C
73 SENTINEL9 and CLEAN -TAVI74.  
• The smallest detectable difference in MRI is a single voxel. In addition, inter -rater 
mean differences between two independent observers was 15% or ~5 voxels  (40.5 
mm3) in the KSH Methodology/Reproducibility Study  (data on file) . Accordingly, a 
meaningful difference to declare a win/lose between MRI lesion volumes  was set at 
a 15% relative difference or a 50 mm3 absolute difference.   
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
85 
 • Loss to post -procedure DW -MRI follow -up is expected to occur in 15% of all subje cts 
(due to contraindications to post -procedure DW -MRI [e.g., pacemaker implantation] 
or subject non- compliance)  
• Loss to follow -up for all other reasons is expected to be 5%.  
• Overall α (one- sided) =0.025; (see §12.4.2) 
To deter mine the required sample size, calculations were performed by simulating 5000 
samples on SAS software postulating the above parameters; mortality and stroke rates and 
proportions of patients with NIHSS worsening, any  MRI lesions and volumes divided to 
subs ets were simulated by a random binary function. 
An evaluable sample size of 225 subjects (2:1 randomization with 150 in the Intervention 
group and 75 new  Control subjects ) is sufficient to demonstrate superiority of the Intervention 
group to the Control group for the primary efficacy endpoint  when pair-wise comparisons are 
made between subjects using the Finkelstein -Schoenfeld method,2 and outcomes between 
treatment groups are compared by the chi-square test.  
Therefore, the initial randomized cohort sample size of 225 subjects ( 150 in the Intervention 
group and 75 new control subjects ) will have >80% power to demonstrate superiority of the 
Intervention group for the primary efficacy endpoint  (one sided α=0.025). Notably, in several 
simulations, considering different distributions for lesion volume and different distributions for 
death/ stroke, the study power remained greater than 80%.  
Adding  the 63 control  subjects already enrolled in REFLECT Phase I for a total of 138 control 
subjects would increase the power to at least 92% to demonstrate superiority of the primary 
efficacy endpoint. 5% loss to follow  up is included.  
12.3 Analysis  Populations  
12.3.1  Efficacy Intention to Treat (eITT) Analysis Population 
The efficacy Intention to Treat (eITT) analysis population is defined as : 
• Subjects who are enrolled in the trial and randomized to a treatment group, regardless of treatment actually received AND  
• Who do not have  conversion to surgery or prolonged cardiac arrest (>3 minutes) pri or 
to the post -procedure DW -MRI 
The eITT population of evaluable (i.e., not Roll -In) subjects will be used for the primary 
analysis of the primary efficacy endpoint, the primary analysis of the secondary hypothesis -
driven endpoints,  and the primary analysis of all secondary neurologic efficacy endpoints.  
12.3.2  Intention to Treat Analysis Population  
The Intention To Treat (ITT) analysis population is defined as all subjects enrolled in the study, by assigned treatment, regardless of the treatment actually received.  
The ITT population of evaluable (i.e., not Roll -In) subjects will be used for the primary analysis 
of secondary performance endpoints and Other Measures. The ITT population will also be 
used for a secondary analysis of the primary  and secondary  efficacy endpoint s and the 
primary and secondary safety endpoints.  
12.3.3  As Treated Analysis Population 
The As Treated (AT)  analysis population is defined by the treatment actually received, rather 
than the treatment assigned. In the AT population,  subjects  in whom vascular access in the 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
86 
 contralateral femoral artery has been established for the intended deployment of the TriGuard 
HDH or TriGUARD 3 device will be analyzed as part of the Intervention group, and subject s 
in whom the TAVI procedure is initiated (but no vascular access for intended deployment of 
the TriGuard HDH or TriGUARD 3 is established) w ill be analyzed as part of the C ontrol 
group.  
The AT population will be used for the primary analysis of all primary and secondary safety 
endpoints.  The AT population will also be used as the secondary analysis population for the 
secondary performance endpoints and Other Measures.  
12.3.4  Per Treatment Population 
The Per Treatment (PT) analysis population is defined as subjects in the Intervention group in whom device positioning is maintained until final procedure with complete cerebral coverage, and all Control group subjects.  
The PT population will be used for an additional analysis of the primary and secondary 
efficacy en dpoint s and other measures . 
12.3.5  Roll-In Patient Population 
The Roll- In (RI) patient population is defined as all subjects who undergo TAVI with the 
TriGuard HDH or TriGUARD 3 prior to enrollment of the first evaluable subject at each 
investigational site. Each investigational site without prior experience with the TriGuard 
device (minimum of 2 prior cases) will enroll a minimum of  2 RI subjects. RI subjects will not 
be randomized to a treatment arm, but will undergo TAVI with the embolic protection device 
and will undergo all protocol -specified follow -ups.  
For the purposes of analysis, a subject is considered enrolled in the Roll -In phase of the study 
when:  
• The patient has been judged to meet all inclusion and no exclusion criteria, and has signed a Patient Inf ormed Consent form  
• The TriGuard HDH of TriGUARD 3  device has been introduced into the patient’s 
bloodstream  
The RI patient population will be used for a separate analysis of all primary and secondary 
endpoints and Other Measures. Additional analyses will evaluate primary and secondary 
endpoints in the pooled population of RI Subjects plus Evaluable Subjects.   
12.4 Method of Analysis and Reporting   
12.4.1  Baseline Characteristics  
The following data will be summarized using descriptive statistics and presented by treat ment 
group for eITT (Roll- In subjects are excluded), ITT (Roll- In subjects are excluded), AT (Roll-
In subjects are excluded) , PT (Roll- In subjects are excluded), and Roll -In analysis sets. 
Descriptive s tatistics for continuous variables will include mean, median, standard deviation, 
minimum, maximum, and sample size for each treatment group. Binary variables will be summarized using frequencies, percentages, and sample size for each treatment group.  
• Baseline demographics  
• Baseline comorbidities, risk factors and medical history  
• Cardiac risk factors, angina status and cardiac history  
• Procedural characteristics  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
87 
 • Device details  
12.4.2  Primary Safety Endpoint  
The primary safety hypothesis is that the rate of the Combined Safety Endpoint (defined 
according to VARC 2 as the composite of death, stroke, life- threatening or disabling bleeding, 
AKI [Stage 2/3], coronary artery obstruction requiring intervention, major vascular complication, and valve- related dysfunction requiring repeat procedure) at 30 days in the 
group undergoing TAVI with the TriGuard HDH or TriGUARD 3  system (Intervention group) 
is significantly less than the Performance Goal (PG). The following analysis will be carried out in the AT (primary analysis population) and ITT populations  including Roll- ins. 
The primary safety analysis will assess if the Intervention group’s safety endpoint rate is significantly less than 34.4% using a one- sample z -test of proportions. Specifically, the null 
and alternative hypotheses to be tested are:  
H
0: π ≥ 0.344  
H1: π < 0.344 
where π is the true, unknown, safety event rate for the Intervention arm.    
The number and percentage of patients in each group experiencing the safety endpoint rate will be presented for each treatment; in addition, one-sided 95% confidence intervals  of the 
percentage will be presented, based on the normal approximation to the binomial distribution. For the intervention group, the above null hypothesis will be carried out at a one- sided 0.05 
level of significance using the one- sample z -test of proport ions. Only AT and ITT patients 
who experienced a safety endpoint or had at least 23 days (30 days minus the allowable 7 day visit window) of follow -up will be included in the analyses.  
As a secondary analysis, to account for any missing data in the primary  endpoint (caused by 
not experiencing the safety endpoint AND prematurely withdrawing from the study before 23 
days of follow -up), a tipping point analysis will be conducted.  Here the above safety null 
hypothesis will be repeatedly tested, first assuming 0 patients with missing data failed (i.e., 
experienced the safety event), then assuming 1 patient with missing data experienced the 
safety event, then assuming 2 patients with missing data experienced the safety event, etc.  
Of interest is the “tipping” point, i.e., the number of Intervention missing data subjects who 
must be imputed as failures in order for the safety null hypothesis to no longer be rejected.  
In addition, in the final analysis, assessments of study -center and of region effect on the 
primary safety endpoint will be carried out on the interventional group within the AT population 
using logistic regressions. A 0.15 level of significance will be used to assess the significance of each of the study center and region effects on the safety  endpoint.  A non- significant result 
for each of study center s and regions will support the pooling of patients across study centers 
and across regions for the primary safety analysis. A significant result will require further inspection of the by -center and by -regio n results to assess  if poolability is appropriate.  Note 
that centers with less than 5 subjects will be pooled with other centers by closest geographic region; this pooling will be carried out prior to the unblinding.  
In addition, a logistic regression to assess the consistency of the primary safety endpoint rate across the following categories will also be performed on the interventional arm (separately 
for Phase I and Phase II) within the AT population:  
• Subject gender (male versus female)  
• Valve prosthesis  type (Edwards vs. Medtronic)  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
88 
 • Operative risk (by Society of Thoracic Surgeons [STS] Risk Score)  
• Type and duration of antiplatelet therapy:  
o Pre- and peri -procedural therapy:  
 Protocol -recommended antiplatelet therapy vs. other  
o Maintenance therapy:   
 Dual antiplatelet therapy (DAPT) to 90 days vs.  
 Monotherapy (aspirin or clopidogrel) to 90 days vs.  
 Warfarin with antiplatelet therapy to 90 days vs.  
 Other  
As above, a 0.15 level of significance will be used to assess the significance of the difference 
of the pr imary safety endpoint rate across the subgroups of each factor.  
12.4.3  Primary Efficacy Endpoint  
The primary hypothesis is that TAVI with the TriGuard HDH or TriGUARD 3 system is superior 
to standard (unprotected) TAVI for the primary hierarchical composite efficacy endpoint of all -
cause mortality or any stroke at 30 days (Tier 1), followed by NIHSS worsening (increase 
from baseline) 2-5 days post-procedure (Tier 2), followed by any ischemic cerebral findings 
on DW -MRI (T ier 3), followed by total volume of post -procedure cerebral ischemic lesions 
detected by DW -MRI divided into preset subdivisions  (Tier 4). Poolability of  the Phase I and 
Phase II control subject s will be assessed at the time of the primary analysis and the results 
will determine the control population used for the primary analysis of the primary efficacy 
endpoint as detailed in the SAP . 
The analytic approach is based on the statistical method described by Finkelstein and Schoenfeld.
2 A similar approach was used in PARTNER Trial (Cohort B) where the co-
primary end point was hierarchical composite of the time to death from any cause or the time to the first occurrence of repeat hospitalization (after the index procedure) due to valve-related or procedure related clinical deterioration.
105 In addition, this approach was further 
explored and recommended for cardiovascular trials by Pocock et al.77 
In brief, we propose the following analysis methodology:  
Each subject in the intervention group is compared with each and every subject  from the 
control group based on the following prespecified hierarchy:  
• All-cause mortality or any stroke (disabling or non- disabling) [evaluated at 30 days]  
o If both had a death/ stroke a time to event analysis by days will determine a win 
o If both patients had a stroke at the same day the comparison moves to the next 
tier 
• NIHSS worsening (increase from baseline)  [evaluated at post -procedure (2 to 5 days post -
procedure) ]  
• Freedom from any cerebral ischemic lesions detected by diffusion- weighted magnetic 
resonance imaging (DW -MRI) 2 to 5 days post-procedure  
• Total volume of cerebral ischemic lesions detected by diffusion- weighted magnetic 
resonance imaging (DW -MRI) 2 to 5 days post -procedure  
For example:  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
89 
 • If Subject A has stroke and Subject B survives free of stroke or death to 30 days, 
Subject B wins (score +1) and Subject A loses (score -1). 
• If Subject A and Subject B both have death/ stroke,  time to event by day will determine 
a win . 
• If both had a stroke on same day, the comparison moves on to the next  tier. 
• Assuming neither experiences a stroke or death before 30 days, if Subject A 
experiences NIHSS worsening , and Subject B does not experience NIHSS  
worsening , Subject A loses (score -1) and Subject B wins (score +1). In case both 
have NIHSS worsening the patient with the lesser worsening wins.  
• Assuming neither subject experiences a stroke or death before 30 days or NIHSS worsening from baseline, if Subject A has no cerebral ischemic lesion s on DW -MRI 
and Subject B has a cerebral ischemic lesion on DW -MRI, Subject A wins (score +1) 
and Subject B loses (Score -1).  
• Assuming neither subject experiences a stroke or death before 30 days , NIHSS 
worsening from baseline or freedom from  DW-MRI cerebral ischemic lesions , if 
Subject A has a total cerebral ischemic lesion volume of 50 mm
3 and Subject B has 
a total cerebral ischemic lesion volume of 100 mm3, Subject A wins (score +1) and 
Subject B loses (Score -1).  
An illustration of this algorithm is provided in Figure 4 below.  
  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
90 
 Figure 4.  Algorithm of a ssigning scores by the Finkelstein and Schoenfeld method ( Note: 
each patient from the intervention group is compared with each and every patient from the 
control group) 
 
  Subject A  Subject B  
Subject A: death or stroke  
Subject B: no death or stroke   Subject A: no death 
or stroke  
Subject B: no death 
or stroke  Subject A: stroke on same 
day  
Subject B: stroke on same day 
 
 Subject A: death or 
stroke on same day  
Subject B:  death or stroke on same day
 
Subject A gets -1 
Subject B gets +1  Subject A gets 0  
Subject B gets 0  
(Equilibrium)  Subject A gets 0  
Subject B gets 0  
(Equilibrium)  
Subject A: NIHSS worsening  
Subject B: no NIHSS worsening
 Subject A: no 
worsening  
Subject B: no 
worsening  Subject A: no worsening  
Subject B:  NIHSS 
worsening  
 Subject A: NIHSS 
worsening  
Subject B: NIHSS 
worsening  
Subject A gets -1 
Subject B gets +1  Subject A gets 0  
Subject B gets 0  
Compare:  
Freedom from any new lesions  Subject A gets +1  
Subject B gets -1 
Subject A: New lesion  
Subject  B: no lesions  Subject A: MRI lesions  
Subject B: MRI lesions  Subject A: no lesions  
Subject B: New lesion  Subject A: no lesions  
Subject B: no lesions  
Subject A gets -1 
Subject B gets +1  Subject A gets 0  
Subject B gets 0  Subject A gets +1  
Subject B gets -1 Compare:  
 Death or stroke 
Compare:  
Total lesion volume  
Subject A volume  
>  
Subject B volume  One or both values 
is missing.  Subject A volume  
<  
Subject B volume  Subject A volume  
= 
Subject B volume  
Subject A gets -1 
Subject B gets +1  Subject A gets 0  
Subject B gets 0  Subject A – no 
score assigned  
Subject B – no 
score assigned  Subject A gets +1  
Subject B gets -1 Compare:  
   NIHSS worsening  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
91 
 After all between- subjec t comparisons have been performed, scores are summed to obtain 
a cumulative score for each subject, and outcomes between treatment groups are then 
compared by chi-square test.  
This analytic approach does not result in a natural point -estimate (e.g., propo rtion, mean, 
median, time- to-event); however, Pocock et al . provided a computational framework for the 
test statistic called “win ratio". In brief , it is calculated as a proportion of "wins" for each group 
out of the total num ber of the pairwise comparisons.  
No imputation of missing DW-MRI data will be performed for the primary analysis. However, 
in order to assess the sensitivity of results to missing DW -MRI data, multiple imputations with 
the linear regression approach will be used as the secondary sensit ivity analysis.  This 
assessment is necessary because the rate of permanent pacemaker implantation (causing loss to DW -MRI follow- up) may vary according to patient clinical characteristics and 
prosthesis type.
106 Specifically, missing  total volume of cerebral ischemic lesions on post -
procedure diffusion- weighted MRI will be imputed via multiple imputation linear regression 
(10 imputed data sets will be created). The covariates used for the imputation model will be treatment group, age at time of enrollment, body mass index, race, smoking status, creatinine level, hyperlipidemia, hypertension, aortic arch disease burden, porcelain aorta, aortic valve area at baseline, procedure time, country, valve type, balloon post dilatation, arch type, and level of calcification.  This creation of the 10 datasets will be carried out using PROC MI in 
SAS.  For each data set, the above- mentioned chi-square test will be carried out o n the 
primary endpoint and one overall chi-square  result will be generated from the 10 datasets. 
For each patient with missing TLV, the crux of multiple imputation is to estimate TLV from patients with non- missing TLV who have similar baseline characteristics as the patient with 
missing TLV. Thus, in essence, TLV for high risk patients with missing TLV due to pacemaker will theoretically be estimated from patients with similar high risk profiles who do not have pacemakers.  
The assumptions for powering the primary efficacy endpoint are based on neurologic, and imaging data from a limited number of subjects in the above mentioned RCTs  (§12.2.2) . In 
Phase I d ue to uncertainty regarding the primary efficacy endpoint, an unblinded interim 
analysis was planned to be conducted to re- evaluate the sample size required to demonstrate 
superiority of the Intervention group to the Control group.  The unblinded interim analysis was 
planned to  be conducted when 90 subjects total who meet the eITT population definition have 
completed the 30- day follow -up visit . This interim analysis was to  be inspected by an 
independent data safety and monitoring Board ( DSMB ) and the unblinded results will not be 
made privy to the sponsor, investigator, or any REFLECT team member, even in the event of a DSMB recommendation of an increase in sample size (i.e., the sponsor will not be made 
privy to the reason for any DSMB  recommendation of an increase in sample size).  If the 
interim analysis would have determined that more than 285 randomized subjects will be 
required to ensure adequate study power, enrollment would have continued (contingent on 
DSMB recommendation and prior FDA approval, and at the Sponsor’s discretion) until the 
required number of subjects  would  have been enrolled, or until the total subject limit for the 
study has been reached (whichever occurs first).  
Specifically,  at the interim analysis  in Phase I , the trial sample size was to  be re -calculated, 
if necessary, to ensure 80% conditional power to demonstrate superiority (overall 2- sided 
α=0.05) of the Intervention group to the control group for the primary efficacy endpoint, conditioned on the interim unblinded results and loss to DW -MRI follow -up, according to the 
eITT population definition (there will be no imputation of missing data in this interim analysis; i.e., missing data will be excluded; also, sample size can only be increased at this interim 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
92 
 stage; it will not be decreased beyond what is currently planned). The conditional power and 
sample size re- calculation for the final analysis were to be ascertained by computer 
simulations and by established methodology outlined in Chen, DeMets and Lan.10 i.e., at the 
interim stage, we were to use Monte Carlo simulations to assess the conditional power of 
achieving a significant Mann- Whitney  test by the end of the study, conditioned on the 
distribution of the observed interim data. If the conditional power is 50% - 80% (the “promising 
zone” according to Chen, DeMets and Lan), we were to use simulations to ascertain the 
increase in sample size required to yield 80% conditional power for the Mann -Whitney  test. 
If the conditional power was determined to be <50% or >80%, the study was to  proceed as 
is without a sample size adjustment  (i.e., only the initial randomized cohort of 225 subjects 
were to be enrolled) . The above- mentioned computer simulations were t o be carried out 
assuming the distribution of TLV data follows a negative binomial distribution within each 
treatment group. The intent of this analysis was to ensure adequate power to detect a 
clinically meaningful treatment effect  at the end of the study  by providing the option to 
increase the sample size if necessary.  
There was no intention to stop the study for overwhelming efficacy at the interim analysis. 
However, as a precautionary measure and to be conservative (due to the presence of an 
unblinded interim analysis), the O’Brien Fleming alpha spending method was to  be used to 
calculate an alpha penalty for the final analysis regardless of whether a sample size increase is needed (final analysis two- sided alpha = 0.049).  
NOTE: A revised adaptive design has been developed for Phase II of the study to inform a 
potential sample size increase based on interim conditional power; for details, please refer to §12.1.1 . 
In the final analysis, assessment of treatment -by-study -center and treatment -by-region on 
the primary efficacy endpoint will be carried out on the eITT population  using quantile 
regression.  Total score obtained for each subject using the proposed approach (Finkelstein 
and Schoenfeld) will be the model dependent variable. The following two models will be built: 1.) Model inclusive of treatment, study center, and treatment -by-study center interaction, and 
2.) Treatment region ( US versus OUS , Phase I only), and treatment -by-region interaction. A 
0.15 level of significance will be used to assess the significance of each of the study center 
and region effects on the efficacy endpoint. A non- significant result for each of study center 
and region will support the pooling of patients across study centers and across regions for the primary efficacy analysis. A significant result will require further inspection of the by -center 
and by -region results to assess  if poolability is appropriate.  Note that centers with less than 
5 subjects will be pooled with other centers by closest geographic region; this pooling will be carried out prior to the unblinding.  
Additionally, an assessment of treatment -by-study -center and treatment -by-region on each 
component of the primary efficacy endpoint will be carried out on the eITT population using 
analysis of variance on the cube root  transformation for total lesion volume data and logistic 
regression for death/stroke and NIHSS worsening, with effects for 1.) Treatment, study 
center, and treatment -by-study center interaction, and 2.) Treatment, region ( US versus OUS , 
Phase I only ), and treatment -by-region interaction. As above, a  0.15 level of significance will 
be used to assess the significance of the interaction; a non-significant interaction or an 
interaction that is significant but only quantitative (and not qualitative) in nature will support the pooling of patients across study centers and across regions for the primary analysis ; and 
centers with less than 5 subjects will be pooled with other centers by closest geographic region, with pooling  carried out prior to the unblinding.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
93 
 In addition, the above analysis will be repeated in the eITT population (separately in Phase I 
and Phase II analysis sets) to assess the consistency of treatment effects on each component 
of the primary efficacy endpoint across the following variables:  
• Subject gender (male versus female)  
• Valve prosthesis type (Edwards vs. Medtronic)  
• Operative risk (by Society of Thoracic Surgeons [STS] Risk Score)  
• Type and duration of antiplatelet therapy : 
o Pre- and peri -procedural therapy:  
 Protocol -recommended antiplatelet therapy vs. other  
o Maintenance therapy:   
 Dual antiplatelet therapy (DAPT) to 90 days vs.  
 Monotherapy (aspirin or clopidogrel) to 90 days vs.  
 Warfarin with antiplatelet therapy to 90 days vs.  
 Other  
As above, analysis of variance on the cube root transformation for total lesion volume data 
and logistic regression for death/stroke and NIHSS worsening will be used, and a 0.15 level of significance will be used to assess the significance of the interaction.  
If the primary efficacy endpoint is met in the primary (eITT) analysis population, sequential 
testing of the primary efficacy hypothesis will be conducted in the ITT analysis population of evaluable subjects (Roll -In patients are excluded.) As a secondary analysis, the prim ary 
efficacy endpoint and its components will be evaluated in the ITT analysis population of 
evaluable subjects (Roll -In patients are excluded). As an additional analysis, the primary 
efficacy endpoint will be evaluated in the PT population of subjects  with available data.  
An additional analysis of the primary  efficacy endpoint will also be performed in the primary 
eITT analysis population with adjustment for pre- existing cerebral lesion volumes.  The 
adjustment will be performed using a quantile regression with the resultant score being the 
dependent variable and group and the pre-existing cerebral lesion volumes  will be 
independent. Speci fically, the PROC QUANTREG procedure will be used to model the 
median of the score with QUANTILE=0.5 option.  
12.4.4  Hypothesis -driven Secondary Endpoints  
For the following secondary endpoints, a test for superiority of each intervention group to the control group will be performed. To address the issue of multiple tests among these secondary endpoints, sequential testing is planned. Secondary endpoints will be formally tested if and only if the primary study hypotheses are confirmed. The secondary endpoints will be tested individually, in the order in which they are listed as follows:  
• All stroke [evaluated at 7 days in the eITT population]  
• NIHSS worsening, defined as any NIHSS score increase from baseline [evaluated at 
2 to 5 days post -procedure in the efficacy Intention to Treat (eITT) analysis population]. 
A sensitivity analysis will further compare >2 points NIHSS worsening [evaluated at 2-
5 days post -procedure in the efficacy Intention to Treat (eITT) analysis population]  
R E F L E C T – U S I D E Tri al [ CI P -0 9 ( v 1 3. 0)]             K e y st o n e H e art Lt d.  
9 4  
 • C o m p o sit e of all -c a u s e m ort alit y a n d all str o k e [ e v al u at e d at 7 d a y s i n t h e eI T T 
p o p ul ati o n]  
• C N S  I nf ar cti o n  ( N e ur o A R C  d efi n e d)  [ e v al u at e d  at  3 0  d a y s  i n  t h e  eI T T  a n al y si s 
p o p ul ati o n]  
• T ot al v ol u m e of c er e br al i s c h e mi c l e si o n s  d et e ct e d b y D W -M RI, [ e v al u at e d 2 t o 5 
d a y s p o st -pr o c e d ur e i n t h e effi c a c y I nt e nti o n t o Tr e at ( eI T T) a n al y si s p o p ul ati o n ]  
T h e  a b o v e  e n d p oi nt s  will  b e  t e st e d  b y  t hi s  pr e -s p e cifi e d  s e q u e n c e,  u nt il  t h e  fir st  n o n -
si g nifi c a nt diff er e n c e i s f o u n d b et w e e n t h e t w o tr e at m e nt gr o u p s. Aft er t h at, ot h er tr e at m e nt 
c o m p ari s o n s will b e e x a mi n e d i n a n e x pl or at or y m a n n er.  
1 2. 4. 5  E x pl or at or y S e c o n d ar y E n d p oi nt s  
1 2. 4. 5. 1. 1  S e c o n d ar y S af et y E n d p oi nt s  
All s e c o n d ar y s af et y e n d p oi nt s , i n cl u di n g t h e c o m p o n e nt s of t h e pri m ar y s af et y e n d p oi nt  will 
b e r e p ort e d b y tr e at m e nt gr o u p i n t h e AT p o p ul ati o n of e v al u a bl e s u bj e ct s u si n g a p pr o pri at e 
d e s cri pti v e st ati sti c s  ( s a m pl e si z e, m e a n, st a n d ar d d e vi ati o n, m e di a n, mi ni m u m, m a xi m u m 
f or  c o nti n u o u s  c h ar a ct eri sti c s;  c o u nt s  a n d  p er c e nt a g e s  of  p ati e nt s  f or  di c h ot o m o u s 
c h ar a ct eri sti c s) . N o f or m al h y p ot h e si s t e sti n g will b e p erf or m e d, a n d t h er e i s n o pl a n t o a dj u st 
al p h a t o a c c o u nt f or m ulti pl e t e sti n g of e x pl or at or y s e c o n d ar y e n d p oi nt s . 
T h e A T a n al y si s will b e c o n si d er e d pri m ar y. A s a s e c o n d ar y a n al y si s, all s e c o n d ar y s af et y 
a n d p erf or m a n c e e n d p oi nt s will b e e v al u at e d i n t h e I T T p o p ul ati o n of e v al u a bl e s u bj e ct s.  
F or  s af et y  e n d p oi nt s  o c c urri n g  i n  t h e  I nt er v e nti o n  a n d  R oll -I n  gr o u p s,  r el ati o n s hi p  t o  t h e 
in v e sti g ati o n al d e vi c e/i n v e sti g ati o n al pr o c e d ur e ( a s d et er mi n e d b y a n i n d e p e n d e nt Cli ni c al 
E v e nt s C o m mitt e e [ § 1 1. 1 ]) will al s o b e r e p ort e d.  
1 2. 4. 5. 1. 2  S e c o n d ar y Effi c a c y E n d p oi nt s  
• I m a gi n g Effi c a c y E n d p oi nt s  
All  s e c o n d ar y i m a gi n g effi c a c y  e n d p oi nt s  will  b e  r e p ort e d  b y  tr e at m e nt  gr o u p  i n  t h e eI T T  
P o p ul ati o n of s u bj e ct s wit h a v ail a bl e d at a  u si n g d e s cri pti v e st ati sti c s. N o f or m al h y p ot h e si s 
t e sti n g will b e p erf or m e d, a n d t h er e i s n o pl a n t o a dj u st al p h a t o a c c o u nt f or m ulti pl e t e sti n g 
of  e x pl or at or y  s e c o n d ar y  e n d p oi nt s . St ati sti c s  f or  c o nti n u o u s  v ari a bl e s  will  i n cl u d e  m e a n, 
m e di a n, st a n d ar d d e vi ati o n, mi ni m u m, m a xi m u m, a n d s a m pl e si z e f or e a c h tr e at m e nt gr o u p. 
Bi n ar y  v ari a bl e s  will  b e  s u m m ari z e d  u si n g  fr e q u e n ci e s,  p er c e nt a g e s,  a n d s a m pl e  si z e  f or 
e a c h tr e at m e nt gr o u p . 
T h e eI T T  a n al y si s will b e c o n si d er e d pri m ar y. A s a s e c o n d ar y a n al y si s, all s e c o n d ar y i m a gi n g 
effi c a c y e n d p oi nt s will b e e v al u at e d i n t h e I T T p o p ul ati o n of e v al u a bl e s u bj e ct s. A n a d diti o n al 
a n al y si s will al s o b e p erf or m e d i n t h e P T p o p ul ati o n.   
A n  a d diti o n al  a n al y si s  of  s e c o n d ar y  i m a gi n g  effi c a c y  e n d p oi nt s wit h  a dj u st m e nt  f or  pr e -
e xi sti n g c er e br al l e si o n v ol u m e wil l al s o b e p erf or m e d i n t h e pri m ar y eI T T a n al y si s p o p ul ati o n.  
T h e s e  e n d p oi nt s  i n cl u d e  pr e s e n c e  of  c er e br al  i s c h e mi c  l e si o n s  ( § ), nu m b er  of  c er e br al 
i s c h e mi c  l e si o n s  ( § ), per -p ati e nt  a v er a g e  si n gl e  c er e br al  i s c h e mi c  l e si o n  v ol u m e  ( § ), 
si n gl e c er e br al i s c h e mi c l e si o n v ol u m e ( § ), a n d tot a l v ol u m e of c er e br al i s c h e mi c l e si o n s  
( § ), w hi c h  v ar y  b y  t h eir  di stri b uti o n  fr o m  bi n ar y  ( a s  i n  " pr e s e n c e  of  c er e br al  i s c h e mi c 
l e si o n s" ) t o P oi s s o n, or p o s si bl y n e g ati v e bi n o mi al i n ot h er s. T h e c h oi c e of a s p e cifi c m o d el 
u s e d f or a dj u st m e nt will t h er ef or e d e p e n d o n t h e a ct u al di stri b uti o n of t h e d e p e n d e nt v ari a bl e  
(l o gi sti c,  l o g -li n e ar, P oi s s o n, n e g ati v e bi n o mi al or q u a ntil e) . T h e m o d el s will i n cl u d e t h e st u d y 
gr o u p a n d pr e -e xi sti n g c er e br al l e si o n v ol u m e a s i n d e p e n d e nt v ari a bl e s. 
R E F L E C T – U S I D E Tri al [ CI P -0 9 ( v 1 3. 0)]             K e y st o n e H e art Lt d.  
9 5  
 • N e ur ol o gi c Effi c a c y E n d p oi nt s  
All s e c o n d ar y n e ur ol o gi c effi c a c y e n d p oi nt s will b e r e p ort e d b y tr e at m e nt gr o u p i n t h e eI T T 
P o p ul ati o n of e v al u a bl e s u bj e ct s ( R oll -I n s u bj e ct s ar e e x cl u d e d) u si n g d e s cri pti v e st ati sti c s. 
N o f or m al h y p ot h e si s t e sti n g will b e p erf or m e d, a n d t h er e i s n o pl a n t o a dj u st al p h a t o a c c o u nt 
f or m ulti pl e t e sti n g of e x pl or at or y s e c o n d ar y e n d p oi nt s. St ati sti c s f or c o nti n u o u s v ari a bl e s will 
i n cl u d e m e a n, m e di a n, q u artil e s, st a n d ar d d e vi ati o n, mi ni m u m, m a xi m u m, a n d s a m pl e si z e 
f or  e a c h  tr e at m e nt  gr o u p.  Bi n ar y  v ari a bl e s  will  b e  s u m m ari z e d  u si n g  fr e q u e n ci e s, 
p er c e nt a g e s, a n d s a m pl e si z e f or e a c h tr e at m e nt gr o u p . 
T h e a n al y si s of t h e eI T T p o p ul ati o n will b e c o n si d er e d pri m ar y. A s a s e c o n d ar y a n al y si s, all 
s e c o n d ar y n e ur ol o gi c a n d c o g niti v e effi c a c y e n d p oi nt s will b e e v al u at e d i n t h e I T T p o p ul ati o n 
of e v al u a bl e s u bj e ct s. A n a d diti o n al a n al y si s will al s o b e p erf or m e d i n t h e P T p o p ul ati o n.  
A n  a d diti o n al  a n al y si s  of  s e c o n d ar y  n e ur ol o gi c  a n d  c o g niti v e  effi c a c y  e n d p oi nt s wit h 
a dj u st m e nt f or pr e -e xi s ti n g c er e br al l e si o n v ol u m e will al s o b e p erf or m e d i n t h e pri m ar y eI T T 
a n al y si s  p o p ul ati o n.  A s  i n  s e c o n d ar y  i m a gi n g  effi c a c y  e n d p oi nt s,  t h e  di stri b uti o n  of  t h e 
n e ur ol o gi c e n d p oi nt s (i n cl u di n g NI H S S w or s e ni n g  [ § ], a n d n e w n e ur ol o gi c i m p air m e nt  [ § ]) 
v ari e s. T h e m o d el s, t h er ef or e, will b e c h o s e n b a s e d o n t h e a ct u al di stri b uti o n of d e p e n d e nt 
v ari a bl e (l o gi sti c,  l o g -li n e ar, p oi s s o n, n e g ati v e bi n o mi al or q u a ntil e), wit h st u d y gr o u p v a ri a bl e 
a n d c er e br al l e si o n v ol u m e a s i n d e p e n d e nt v ari a bl e.  
1 2. 4. 5. 1. 3  S e c o n d ar y P erf or m a n c e E n d p oi nt s  
All  s e c o n d ar y  p erf or m a n c e  e n d p oi nt s  will  b e  r e p ort e d  b y  tr e at m e nt  gr o u p  i n  t h e  I T T 
p o p ul ati o n  of  e v al u a bl e  s u bj e ct s  ( RI  s u bj e ct s  ar e  e x cl u d e d)  u si n g  a p pr o pri at e  d e s c ri pti v e 
st ati sti c s  ( s a m pl e  si z e,  m e a n,  st a n d ar d  d e vi ati o n,  m e di a n,  mi ni m u m,  m a xi m u m  f or 
c o nti n u o u s  c h ar a ct eri sti c s;  c o u nt s  a n d  p er c e nt a g e s  of  p ati e nt s  f or  di c h ot o m o u s 
c h ar a ct eri sti c s). N o f or m al h y p ot h e si s t e sti n g will b e p erf or m e d, a n d t h er e i s n o pl a n t o  a dj u st 
al p h a t o a c c o u nt f or m ulti pl e t e sti n g of e x pl or at or y s e c o n d ar y e n d p oi nt s . 
T h e I T T a n al y si s will b e c o n si d er e d pri m ar y. A s a s e c o n d ar y a n al y si s, all s e c o n d ar y s af et y 
a n d p erf or m a n c e e n d p oi nt s will b e e v al u at e d i n t h e A T p o p ul ati o n of e v al u a bl e s u bj e ct s.  
1 2. 4. 6  Ot h er M e a s ur e s  
Ot h er  M e a s ur e s  will  b e  r e p ort e d  b y  tr e at m e nt  gr o u p  i n  t h e  I T T  p o p ul ati o n  of  e v al u a bl e 
s u bj e ct s ( RI  s u bj e ct s ar e e x cl u d e d) u si n g d e s cri pti v e st ati sti c s. N o f or m al h y p ot h e si s t e sti n g 
will b e p erf or m e d.  
T h e I T T a n al y si s will b e c o n si d er e d  pri m ar y. A s a s e c o n d ar y a n al y si s, Ot h er M e a s ur e s will 
b e e v al u at e d i n t h e A T  p o p ul ati o n of e v al u a bl e s u bj e ct s. A n a d diti o n al a n al y si s will al s o b e 
p erf or m e d i n t h e P T p o p ul ati o n.  
1 2. 4. 7  S u b gr o u p A n al y s e s  
S u b gr o u p  a n al y s e s  will  b e  p erf or m e d  f or  all  pri m ar y  a n d  s e c o n d ar y  e n d p oi nt s  i n  t h eir 
r e s p e cti v e  pri m ar y  a n al y si s  p o p ul ati o n s  f or  t h e  f oll o wi n g  s u b gr o u p s,  a n d  r e s ult s  will  b e 
r e p ort e d b y tr e at m e nt gr o u p u si n g d e s cri pti v e st ati sti c s : 
• S u bj e ct s wit h p ar o x y s m al or p er si st e nt atri al fi brill ati o n ( A F) at b a s eli n e  
• S u bj e c t s b y v al v e pr o st h e si s t y p e ( E d w ar d s v s. M e dtr o ni c)  
1 2. 4. 8  R oll -I n P o p ul ati o n A n al y si s  
T h e P h a s e II R oll -I n p o p ul ati o n will b e p o ol e d wit h t h e P h a s e II i nt er v e nti o n gr o u p f or t h e 
pri m ar y a n al y si s of t h e pri m ar y s af et y e n d p oi nt.  T h e R oll -I n p ati e nt p o p ul ati o n wil l al s o b e 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
96 
 used for a separate analysis of all primary and secondary endpoints and other measures . 
Additional analyses will evaluate primary and secondary endpoints in the pooled population 
of Roll- In Subjects plus Evaluable Subjects.  The results of all analyses will be reported using 
descriptive statistics.  
12.4.9  Additional Analyses  
The following data will be summarized using descriptive statistics presented by treatment group:  
• Subject enrollment and data compliance by site and visit (data compliance at each visit is percent of patients whose data forms have been collected and entered divided 
by the percent of patients whose forms should have been collected and entered)  (ITT, 
eITT, PT, and AT populations)  
• Frequency (number and percent of patients) with each type of concomitant medication  
(AT population)  
• Frequency (number and percent of patients) with each site- reported Treatment 
Emergent AE overall and by MedDRA system organ class and preferred term (a treatment emergent AE is an AE that started or worsened during  or after  the index 
procedure)  (AT population)  
• Frequency (number and percent of patients) with each site- reported Treatment 
Emergent Serious AE overall and by MedDRA system organ class and preferred term  
(AT population)  
• Frequency (number and percent of patients) with each site- reported Treatment 
Emergent AE or SAE, by CEC -adjudicated relationship to the investigational device or 
procedure (AT population)  
• Protocol deviations (number and percentage of patients with each deviation type)  (ITT 
population)  
• Kaplan- Meier plots for MACCE and TAVI early safety through 30 days (AT Population; 
patients without an event will be censored at 30 days or day of withdrawal, whichever is earlier)  
• Detailed listings on primary and secondary endpoints, site- reported AE as well as  
protocol deviations  
13.0 Publication Policy  
The Sponsor  and the Principal Investigators  are committed to the publication and widespread 
dissemination of the results of the study in the scientific community.  This study represents a joint effort between the Spo nsor and the Principal Investigator s; as such, the parties agree 
that the recommendation of any party concerning manuscript or text shall be taken into consideration in the preparation of final scientific documents for publication or presentation.  
All par ties agree that the Investigator s will prepare  publications and/ or presentations. The 
number of authors will be determined according to the rules of the addressed scientific journal and by decision of the investigators. Abstracts and articles shall be submitted to the Sponsor in advance of their publication. An agreement on the final form of abstracts and articles shall be obtained within an appropriate time frame of 60 days. In the event that diverging opinions 
on presentation of the data cannot be reconci led, the executive operation committee 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
97 
 consisting of one representative of the trial management team, the Sponsor and the Principal 
Investigator s (or designated substitutes) will make a final decision.  
Any and all information supplied or obtained during this study by or on behalf of any party 
involved in the study (in whatever form) shall be treated as confidential, shall not be disclosed to any third party unless with the prior written consent of the Sponsor in each case. Any documents, papers, drawings or other materials which are released or created by any party involved in this study are and shall remain at all times the property of the Sponsor excluding publications which are approved in writing by the Sponsor. Such materials shall not be reproduced in any form without the prior written consent of the Sponsor and must be returned 
to the Sponsor immediately upon request, or upon completion of the evaluation of such materials, whichever is the earlier.  
All clinical data or any other information gathered during or after this Study related to the Study, people involved, or materials involved will be considered confidential. Confidential 
information will remain confidential for a period of 36 months following the study completion.  
14.0 Data Collection and Monitori ng 
14.1 Data Collection and Monitoring  
All required data for this study will be collected on standardized Case Report Forms (CRFs) using an electronic data capture system (EDC).  The investigator (or designated hospital staff) 
will assure primary data collection based on source- documented hospital chart reviews.  
Independent monitoring will be performed to ensure that the investigator and his/her study 
team conduct the clinical investigation in accordance with contract specifications, this 
protocol, the Declaration of Helsinki, ICH- GCP, ISO 14155 , 21 CFR Part 812, and other  
applicable FDA and local  regulations, and to ensure adequate protection of the rights and 
safety of subjects and the quality and integrity of the resulting data.  Submitted t rial data will 
be verified against patient charts and other sources containing original records of patient 
data. Source document verification will occur in accordance with the pre-specified  Monitoring 
Plan.  
Progress of the trial will be monitored by:  
• On-site review, as deemed  appropriate by the sponsor  
• Telephone communications between site personnel (e.g., Site Investigator, Trial Coordinator) and trial monitors  
• Review of CRFs and associated clinical records  
• Review of regulatory documents  
Responsible entities for monitoring in the US and EU respectively are listed in § 3.0.   
If a monitor becomes aware that an Investigator is not complying with the requirements mentioned above, the sponsor will be notified by the monitor. The sponsor will evaluate t he 
non-compliance and if necessary, immediately either secure compliance or discontinue 
shipments of the investigational device to the Investigator and terminate the Investigator’s participation in continued enrolment in the investigation. The Investigator  will be required to 
return all unused devices to the sponsor.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
98 
 14.2 Source Documentation and Verification 
Auditors, monitors, IRBs/ECs , the study sponsor, and the FDA and other regulatory 
authorities will have access to the medical records related to this study. Original or certified 
copies of all relevant clinical findings, observations, and other activities throughout the clinical 
investigation must be recorded and maintained in the medical  file of each enrolled patient (no 
source documentation will be recorded directly on the CRF ). At a minimum, the following 
must be included in each patient’s file:  
• Sufficient medical history and current physical condition, including any medication(s) the patient is taking at the time of the procedure to assess the patient’s eligibility;  
• The medical file should reveal the patient’s participation in this study, including documentation of written informed consent;  
• Dated report of the investigational procedure including medication, material usage, and complications, if applicable; 
• Dated reports of the discharge and follow -up assessments;  
• Dated results of required laboratory tests;  
• Any adverse event(s), the resultant action or treatment, and outcome, if applicable; and 
• In the case of withdrawal of patient consent, the reason and patient status at time of 
withdrawal.  
The investigator will permit stu dy-related monitoring, audits, IRB/EC  review , and FDA and 
other applicable regulatory authority inspections by allowing direct access to the source data.  
In case of electronic source data,  periodic access will be allowed for full safety review. The 
review will be specific to study subjects and the records that would contain potential safety data. D ated print -outs are acceptable for preliminary review of safety information. Print -outs 
will not be limited to cardiac data only, but should include all available data related to the 
identified patient(s).  
14.3 Record Retention  
Sponsor and investigator will maintain records related to this study for 7 years (or longer 
according to local requirements) af ter the end of this study.  
15.0 Ethical and Regulatory Considerations 
15.1 Applicable Regulations  
This trial will be conducted in compliance with the protocol, the sponsor’s standard operating 
procedures and/or guidelines, FDA regulations, local regulations where ap plicable, ICH GCP 
guidelines,  the Declaration of Helsinki, Annex X of the European Medical Devices Directive, 
and EN/ISO 14155:2011.  
15.2 Institu tional Review Board / Medical Ethics  Committee 
This trial will be conducted in accordance with 21 CFR 56 Institutional Review Boards. The 
investigator will assure that an appropriately constituted Institutional Review Board (IRB)  or 
Ethics Committee  (EC) complies with the requirements of the International Conference on 
Harmonization Guideline. Prior to initiation of the  study, the investigator will forward copies 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
99 
 of the protocol, Investigators Brochure, informed consent form and all other appendices t o be 
used for the study to the IRB/EC  for its review and approval. A copy of the written IRB/EC  
approval must be provided to the Sponsor (or designee) and should include the following:  
• A statement of IRB/EC  approval for the proposed study at the institution;  
• The date the study was approved and the duration of approval (if applicable);  
• Identification of the approved documents including version dates and/or other 
references. At a minimum, the following documents should be listed:  
o Study protocol  
o Patient information and consent form  
o Any additional written information to be provided to the patient  
• A listing of any conditions attached to the approval (if applicable);  
• Identification of the approved primary investigator;  
• The signature of the IRB/EC chairperson;  
• Acknowledgement of the sub- Investigators.  
Any amendments to the protocol, as well as possible associated information and cons ent 
form changes, will be submitted to the IRB/EC  and written approval obtained prior to 
implementation. Substantive changes will be submitted to the FDA for approval prior to 
implementation, and the FDA will be notified of any changes not requiring approv al according 
to applicable guidelines . 
15.3 Regulatory Approval  
The Sponsor is responsible for notifying the study to the FDA and any other relevant 
authorities  (as applicable)  according to regulatory requirements. Investigators may not 
commence enrollment of subjects until they have met any local IRB/EC  and hospital 
management requirements and have received confirmation from the Sponsor that the appropriate regulatory approvals have been obtained.  
15.4 Trial Registration  
This trial meets the definition of an “applicable clinical trial” according to Section 801 of the Food and Drug Administration Amendments Act. The Sponsor affirms that it will serve as the Responsible Party and fulfill all requirements regarding trial registration, the provision of clinical trial inf ormation, and results reporting through the ClinicalTrials.gov registry data 
bank.  
Clinical trial information will be submitted no more than 21 days after the first subject is enrolled in the trial, and results information will be submitted no later than  1 year after 
completion of the trial or no later than 30 days after the device is approved, licensed, or 
cleared by the FDA.  
15.5 Records and Reports  
15.5.1  Responsibilities of the Sponsor  
The Sponsor must maintain the following records:  
• All essential correspondence related to the clinical trial  
• Signed Investigator Agreement  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
100 
 • Curriculum vitae  for each Investigator  
• Records of device shipment and disposition (shipping receipts, material destruct 
records, etc.)  
• Adverse event information  
• Complaint documentation  
• All data forms  prepared and signed by the Investigators and received source 
documentation and core lab reports  
• Clinical Investigation Plan (CIP) and any amendments  
• Investigators Brochure / Report of Prior Investigations  
• Site monitoring reports  
• Financial disclosure i nformation  
The Sponsor is responsible for the preparation of, the accuracy of the data contained in, and the review and submission of the reports listed in Table 1 2.  
Table 1 2. Sponsor Reporting Responsibilities  
Report  Submit To  Description  
(confirmed) UA DE IRB/EC, Investigators, 
FDA, Other 
Regulatory (as 
applicable)  Sponsor will report on any confirmed UADE 
within 10 working days of notice receipt [21 CFR 812.150]  
Withdrawal of IRB/EC approval  IRB/EC, Investigators, 
FDA, Other Regulatory (as 
applicable)  Notification, when appropriate, will be made 
with 5 working days of notice receipt.  
Withdrawal of FDA/other 
regulatory approval  IRB/EC, Investigators  Notification, when appropriate, will be made 
with 5 working days of notice receipt.  
Current investigator  list FDA Sponsor will submit a list of the names and 
addresses of all investigators at 6 month 
intervals, beginning 6 months after FDA IDE 
approval.  
Progress report  IRB/EC, Investigators, 
FDA Annual  
Recall and device disposition  IRB/EC, Investigators, 
FDA Notification and explanation will be made 
within 30 days of the Sponsor’s request that 
an Investigator return, repair, or otherwise 
dispose of any devices.  
Final Report  IRB/EC, Investigators, 
FDA, Notified Bodies 
and Other Regulatory 
(as applicable)  Notification will be made within 30 working 
days of trial completion or termination. A final report will be submitted within 6 months of trial 
completion or termination.  
Failure to obtain Informed 
Consent  FDA Notification will be made within 5 working days 
after Sponsor’s receipt of notification that 
Informed Consent was not obtained.  
Emergency deviation from Clinical 
Investigation Plan (CIP)  FDA Notification will be made within 5 working days 
after Sponsor’s receipt of notification that an emergency deviation from the CIP was made to protect the life or physical well -being of a 
subject.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
101 
 15.5.2  Responsibilities of the Investigator  
Each Site Investigator is responsible for the preparation, review, signature, and retention of 
the records below:  
• All essential correspondence related to the clinical trial  
• Device use/disposition records  
• Records of each subject’s case history and exposure to the device. Case histories include the CRFs and supporting data (source documentation).  
• Signed Investigator Agreement  
• Curriculum vit ae  
• Clinical Investigation Plan (CIP) and any amendments  
The investigator is responsible for the preparation, review, signature, and submission of the reports listed in Table 13 . These are also subject to inspection by regulatory authorities and 
must be retained as specified in the CIP.  The investigator may delegate responsibility for 
record maintenance to a member of his/her study team, but remains the ultimate responsible person.  
Table 1 3. Investigator Reporting Responsibilities  
Report  Submit To  Descripti on 
(potential) UADE  Sponsor, IRB/EC  Submit immediately via EDC CRF and via 
telephone. UADE must be submitted as soon 
as possible, but no later than 5 working days 
after first learning of the event.  
SAE Sponsor  Submit within 3 working days of first learni ng 
of the event  (via EDC CRF) . 
SADE Sponsor  Within 48 hours  (if required by local or national 
regulations ; otherwise , report as SAE)  
Withdrawal of IRB/EC approval  Sponsor  Submit within 5 working days.  
Failure to obtain Informed 
Consent  Sponsor, IRB/EC  Submit within 5 working days of subject 
exposure to device.  
Emergency deviation from CIP  Sponsor, IRB/EC  Submit within 5 working days.  
Planned deviation from CIP  Sponsor, IRB/EC, 
FDA If the deviation affects the scientific soundness 
of the trial or the rights, safety, or welfare or the subject, and is not an emergency, prior approval must be obtained from the Sponsor, 
the IRB/EC, and the FDA.  
Other deviation from CIP  Sponsor  Uncontrollable deviations (e.g., loss to follow -
up) or deviations that do not aff ect the 
scientific soundness of the trial or the rights, safety, or welfare of the subject, and that are not an emergency, should be submitted as 
identified by the site or the Sponsor (or 
designee).  
15.6 Protocol Amendments  
Any protocol amendments will be approved by the Sponsor, the Principal Investigator, the 
IRB/EC  and any necessary regulatory body before it can be implemented.  Substantive 
changes will be submitted to the FDA for approval prior to implementation, and the FDA will 
be notified of any changes not requiring approval according to applicable guidelines.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
102 
 15.7 Informed Consent  
The background of the proposed study and the benefits and risks of the procedures and study 
must be explained to the patient  in accordance with 21 CFR Part 50. The patient must sign 
the consent form prior to enrollment. This form or a modification based on local IRB/EC  
recommendations must be presented to and signed by all enrolled patients and signed by the principal investigator, sub- investigator or designated research staff in accordance with 
approving IRB/EC  guidelines.  
Prior to obtaining informed consent, information should be given in a language and at a level of complexity understandable to the subject in both oral and written form  by the investigator 
or assigned designee. Patients should not be coerced, persuaded, or unduly influenced to 
participate or remain in the trial. A subject or his/her legal representative must be given ample 
time and opportunity to inquire about details of the trial and all questions about the trial sh ould 
be answered to the satisfaction of the subject or the representative.  
Prior to participation in the trial, the written informed consent form should be signed and personally dated by the subject or his/her legal representative, and by the person who conducted the informed consent discussion (investigator or designee).  If the subject or his/her 
legal representative is unable to read the consent form, a witness should be present during the entire informed consent discussion. After the informed consent form is read to the subject and signed by the subject or his/her legal representative, the witness should also sign the consent form, attesting that informed consent was freely given by the subject or hi s/her legal 
representative. For non -English speaking subjects, the written informed consent should be 
translated into the subject’s native language, or a short form (including the elements of informed consent translated into the subject’s native language) should be used. The informed 
consent process should be documented in each subject’s medical record.   
The subject or his/her legal representative must receive a copy of the signed and dated informed consent form.  
The Investigator shall inform the subject of any new significant findings occurring during the clinical investigation, including the need for additional medical care that may be required, that 
may be relevant to the subject and his/her willingness to continue participation in the study. The consent form should be updated or amended whenever such new inf ormation becomes 
available and updated consent shall be recorded.  
15.8 Termination of the Study  
Keystone Heart Ltd. reserves the right to terminate the study but intends only to exercise this 
right for valid scientific or administrative reasons and reasons related to protection of patients. Possible reasons for early trial termination include:  
• Unanticipated Adverse Device Effects (UADEs) present an unreasonable risk to patients  
• Recommendation from the DSM B 
If the trial is terminated early, the Sponsor will provide a written statement to the Investigators to enable notification of the IRBs/ECs. The Sponsor will also inform the FDA and the relevant Competent Authority (where required). In the case of early termination of trial enrollment, follow -up visits will cont inue for all enrolled subjects.  
The S ponsor may terminate an investigator’s or site’s participation in the study if there is 
evidence of an investigator’s failure to maintain adequate clinical standards or evidence of an investigator or staff’s failure to comply with the protocol. Should investigator or site 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
103 
 participation be considered for termination, the Sponsor (or designee) will ensure appropriate 
follow -up for any subjects enrolled, including transferal  to the supervision of an approved 
investigator and approval of transfer of subject oversight and follow -up by the appropriate 
IRB/EC . Notification of study site suspension or termination will occur no later than five (5) 
working days after the Sponsor makes the determination. A suspended or terminated st udy 
site may not be reinitiated without approval of the reviewing  IRB/EC. The investigator should 
notify the IRB/EC in writing as soon as possible but no later than within 10 days if the 
premature termination is related to safety or compliance issues. The same procedure will be applied to the Competent Authority where required.  
15.9 Auditing 
As a quality assurance measure, the site may be audited during the course of the ongoing clinical trial as well as following completion of the trial. The purpose of an audit  is to provide 
an independent evaluation separate from routine monitoring or quality cont rol functions of 
trial conduct and protocol and GCP compliance. The audit may be conducted by Keystone 
Heart Ltd personnel (or designee), the FDA, or another regulatory body. Please notify the 
Sponsor if the FDA or another regulatory body requests an audit. The site investigator and/or institution shall permit Keystone Heart Ltd. and regulatory bodies direct access to source data and documents.  
15.10  Patient Privacy  
Keystone Heart Ltd affirms and upholds the principle of patient confidentiality.  Throughout 
this study, all data forwarded to Keystone Heart Ltd. or its designee wil l only be identified by 
a study -specific subject identification number. “Protected Health Informati on” will be 
maintained in compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) , and all personal data of EU individuals will be protected in compliance with the EU -
US Privacy Shield Principles (12.7.2016) . 
The investigator agrees that representatives of Keystone Heart Ltd ., the contract research 
organizations and regulatory authorities may inspect included patients’ records to verify trial data, provide the data are treated as confidential and that the subject’s privacy is  guaranteed.  
 
 
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
10416.0 Appendices  
16.1 Appendix I: Definitions  
Acute cardiovascular 
surgery  An immediate transfer from the cath eterization  lab to the 
operative room during the initial treatment phase due to the 
need for emergency coronary artery bypass graft surgery , 
cardiac valve surgery, or other vascular surgical 
intervention.   
Access r elated  Any adverse clinical consequence possibly associated with 
any of the access sites used during the procedure.  
Access s ite Any location (arterial or venous) traversed by a g uide-wire, 
a catheter or a sheath, including the left ventricular (LV) 
apex and the aorta.  
Acute Kidney Injury 
(AKI) , 
[AKIN classification ] Change in serum creatinine (up to 7 days) compared with 
baseline:35 
•Stage 1:
oIncrease  in serum creatinine to 150– 199%
(1.5–1.99 × increase compared with
baseline) OR increase of ≥0.3 mg/dL (≥26.4mmol/L) OR
oUrine output <0.5 ml/kg per hour for >6 but<12 hours
•Stage 2:
oIncrease in serum creatinine to 200– 299%
(2.0–2.99 × increase compared  with
baseline) OR
oUrine output <0.5 ml/kg per hour for >12 but<24 hours
•Stage 3:
oIncrease in serum creatinine to ≥300% (>3 ×increase compared with baseline) OR serumcreatinine of ≥4.0 mg/dL (≥354 mmol/L) withan acute increase of at least 0.5 mg/dL (44mmol/L) OR
oUrine output <0.3 ml/kg per hour for ≥24hours OR
oAnuria for >12 hours
o[Patients receiving renal replacement therapyare considered to meet Stage 3 criteriairrespective of other criteria]
Adverse Event (AE)  An adverse event is any untoward medical occurrence, 
unintended disease or injury or any untoward clinical signs 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
105 
 (including an abnormal laboratory finding) in subjects, users 
or other persons whether or not related to the investigational 
medical device.   
NOTE : This definition includes ev ents related to the 
investigational medical device or to the procedures involved 
but does not imply that there is a relationship between the 
adverse event and the device under investigation.  
Pre-Existing Conditions:  
Pre-existing medical conditions or a repeat of symptoms 
reported prior to the TAVR procedure will not be recorded 
as an AE. Pre-existing conditions that worsen during a study 
are to be considered adverse events. For users or other 
persons this classification is restricted to events related to 
the investigational medical device.  
Adverse Device Effect 
(ADE)  An adverse device effect is an adverse event related to the 
use of a medical device. This includes:  
• Any adverse event resulting from insufficiencies or 
inadequacies in the instructions for use , the 
deployment, the implantation, the installation, the 
operation, or any malfunction of the medical device 
• Any event that is a result of a use error or intentional 
misuse 
Anticipated Serious 
Adverse Device Effect 
(ASADE)  An anticipated s erious adverse device e ffect is a serious 
adverse device e ffect which by its nature, incidence, 
severity, or outcome has been identified in the 
investigational plan or application (including a 
supplementary plan or application).  
As Treated (AT) 
Population The AT popula tion is defined by the treatment actually 
received, regardless of the assigned treatment. In the AT 
population,  all subjects  in whom vascular access in the 
contralateral femoral artery has been established for the 
intended deployment of the TriGuard HDH or TriGUARD 3 
device will be assigned to the intervention group, and 
subjects in whom the TAVI procedure is initiated (but no vascular access for intended deployment of the TriGuard 
HDH or TriGUARD 3 is established) will be assigned to the 
control group.  
Bleeding  Life-threatening or disabling bleeding :35   
• Fatal bleeding (BARC type 5) OR 
• Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with 
compartment syndrome (BARC type 3b and 3c) OR 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
106 
 • Bleeding causing hypovolemic shock or severe 
hypotension requiring vasopressors or surgery 
(BARC type 3b) OR 
• Overt source of bleeding with drop in hemoglobin of 
≥5 g/dL or whole blood or packed red blood cells 
(RBCs) transfusion ≥4 units [Given that one unit of 
packed RBC typically will raise hemoglobin 
concentration by 1 g/dL, an estimated decrease in 
hemoglobin will be calculated] (BARC type 3b)  
Major bleeding (BARC type 3a) : 
• Overt bleeding either associated with a drop in the 
hemoglobin level of at least 3.0 g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC, or causing hospitalization or permanent injury, or requiring surgery AND  
• Does not meet criteria of life- threatening or disabling 
bleeding  
Minor bleeding (BARC type 2 or 3a, depending on the 
severity) : 
• Any bleeding worthy of clinical mention (e.g., access site hematoma) that does not qualify as  life-
threatening, disabling, or major  
Cardiac tamponade  Evidence of a new pericardial effusion associated with 
hemodynamic instability and clearly related to the TAVI procedure
35 
CCS (Canadian 
Cardiovascular Society) classification  Class I:  Ordinary physical activity, such as walking and 
climbing stairs, does not cause angina. Angina with 
strenuous, rapid, or prolonged exertion at work or 
recreation.  
Class II: Slight limitation of ordinary activity. Walking or 
climbing stairs rapidly, walking up hill, walking or 
stair climbing after meals, in cold, in wind, or when 
under emotional stress or during the first few hours 
after awakening may cause pain. Walking more 
than two blocks on the level and climbing more 
than one flight of stairs at a normal pace and in 
normal conditions.  
Class III: Marked limitation of ordinary physical activity. 
Walking one -two blocks on a level and climbing 
one flight of stairs at normal pace results in angina.  
Class IV: Inability to carry on any physical activity without 
discomfort. Anginal syndrome may be present at 
rest. 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
107 
 Child -Pugh score  A scoring s ystem used to assess the prognosis of chronic 
liver disease.107 Scoring and interpretation as below:  
Scoring  
Measure  1 point  2 points  3 points  
Total bilirubin, μmol/l (mg/dl)  <34 (<2)  34-50 (2 -3) >50 (>3)  
Serum albumin, g/dl  >3.5 2.8-3.5 <2.8 
PT INR  <1.7 1.71-2.30 > 2.30  
Ascites  None  Mild Moderate  to Severe  
Hepatic encephalopathy  None  Grade I -II (or suppressed 
with medication)  Grade III -IV (or 
refractory)  
Interpretation  
Points  Class  One year survival  Two year survival  
5-6 A 100%  85% 
7-9 B 81% 57% 
10-15 C 45% 35% 
 
Clinical Frailty Scale  A me asure of frailty based on clinical judgement, scored 
according to the following categories108: 
1. Very Fit  – People who are robust, active, energetic, and 
motivated. These people commonly exercise regularly . 
They are among the fittest for their age.  
2. Well – People who have no active disease symptoms but 
are less f it than Category 1. Often, they exercise or are very 
active occasionally, e.g., seasonally.  
3. Managing Well  – People whose medical problems are 
well controlled, but are not regulatory active beyond routine 
walking.  
4. Vulnerable  – While not dependent on o thers for daily 
help, often symptoms limit activities. A common complaint is 
being “slowed up,” and/or being tired during the day.  
5. Mildly Frail – These people often have more evident 
slowing, and need help in high order independent activities 
of daily living (finances, transportation, heavy housework, 
medications). Typically, mild frailty progressively impairs 
shopping and walking outside alone, meal preparation, and 
housework.  
6. Moderately Frail  – People need help with all outside 
activities and with  keeping house. Inside, they often have 
problems with stairs and need help with bathing, and might 
need minimal assistance (cuing, standby) with dressing.  
7. Severely Frail  – Completely dependent for personal care, 
from whatever cause (physical or cognitive). Even so, they 
seem stable and not at high risk of dying (within ~6 months).  
8. Very Severely Frail  – Completely dependent, 
approaching the end of life. Typically, they could not recover 
even from a minor illness.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
108 
 9. Terminally Ill  – Approaching the end of life. The category 
applies to people with a life expectancy < 6 months, who are 
not otherwise evidently frail.  
Based on the above categories, subjects also will be 
classified as Not Frail (Category 1- 3), Mildly Frail (Category 
4-5), and Moderately -to-Severely Frail (Category 6- 9). 
CNS hemorrhage  NeuroARC defined3 as a ny brain, spinal cord, or ret inal 
hemorrhage on the basis of imaging or pathology, not 
caused by trauma  (includes  symptomatic intracerebral 
hemorrhage [Type 1.b] , symptomatic subarachnoid 
hemorrhage [Type 1.c], and covert CNS hemorrhage [Type 
2.b]) 
CNS infarction  NeuroARC defined3 as a ny brain, spinal cord, or retinal 
infarction on the basis of imaging, pathology, or clinical 
sympt oms persisting for ≥24 h (includes ischemic stroke 
[Type 1.a], ischemic stroke with hemorrhagic conversion 
[Type 1.a.H], stroke not otherwise specified [Type 1.d], 
symptomatic hypoxic -ischemic injury  [Type 1.e ], covert CNS 
infarction [Type 2.a], and covert CNS infarction wit h 
hemorrhagic conversion [Type 2.a.H ]) 
Cockcroft -Gault formula  A proxy for Glomerular Filtration Rate in which creatinine 
clearance is estimated from age, weight, and serum 
creatinine by the formula:  
 
in which weight is recorded in kg and creatinine in m g/dL, 
and which is valid for male patients. If the patient is female, 
the result should be multiplied by 0.85.  
Combined safety 
endpoint  Equivalent to the VARC -2 definition  of “early safety (at 30 
days)”,1 defined as the composite of:  
• All-cause mortality  
• All stroke (disabling and non- disabling)  
• Life-threatening bleeding  
• Acute kidney injury – Stage 2 or 3 (including renal 
replacement therapy)  
• Coronary artery obstruction requiring intervention  
• Major vascular complication  
• Valve -related dysfunction requiring repeat procedure 
(BAV, TAVI, or SAVR)  
Covert CNS i njury  Acutely asymptomatic brain or spinal cord injury detected 
by neuroimaging (NeuroARC Type 2), including3: 
Type 2.a Covert CNS infarction  

REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
109 
 Brain, spinal cord, or retinal cell death attributable to focal 
or multifocal ischemia, on the basis of neuroimaging or 
pathological evidence of CNS infarction, wi thout a history 
of acute neurological symptoms consistent with the lesion 
location  
Subtype 2.a.H Covert CNS infarction with hemorrhagic 
conversion 
Covert CNS infarction includes hemorrhagic conversions . These should be subclassified as Class A 
or B when CNS infarction is the primary mechanism and neuroimaging or pathology confirms a hemorrhagic conversion.  
Class A (Petechial hemorrhage): Petechiae or 
confluent petechiae within the infarction or its margins, but without a space- occupying effect  
Class B (Conf luent hemorrhage): Confluent 
hemorrhage or hematoma originating from within the infarcted area with space- occupying effect   
Type 2.b Covert CNS hemorrhage  
Neuroimaging or pathological evidence of CNS hemorrhage within the brain parenchyma, subarachnoid space, ventricular system, spinal cord, or retina on 
neuroimaging that is not caused by trauma, without a history of acute neurological symptoms consistent with the bleeding location  
Device deployment time  Time elapsed between insertion of the TriGuard HDH  or 
TriGUARD 3 device into the groin access point  and 
successful device deployment  
Device deficiency  Inadequacy of a medical device related to its identity, 
quality, durability, reliability, safety or performance.  
NOTE: Device deficiencies include malfunct ion, use error, 
and inadequate labeling. They may or may not affect device 
performance or lead to an adverse event.  
Device interference  Interaction of the TriGuard device with the TAVI system 
leading to:  
o Inability to advance or manipulate the TAVI deliver y 
system or valve prosthesis, OR  
o Inability to deploy the TAVI valve prosthesis, OR  
o Inability to retrieve the valve prosthesis or delivery 
system  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
110 
 Device malfunction  Failure of an investigational medical device to perform in 
accordance with its intended pu rpose when used in 
accordance with the Instructions for Use or protocol.  
NOTE: A device malfunction occurs when the device is used 
in compliance with the Instructions for Use, but does not 
perform as described in the Instructions for Use.  
Device misuse  Any use of the investigational device by an investigator that 
is contradictory to the application described in the 
Instructions for Use will be categorized as device misuse. 
This is a form of Use Error.  
Device positioning  Ability to position the TriGuard HD H or TriGUARD  3 device 
in the aortic arch to cover all major cerebral arteries, with 
proper positioning maintained (verified by fluoroscopy ) until 
the following time points:  
o Final deployment of the first prosthetic valve 
o Final procedure (after any additional post -dilatation 
or additional valve implantations have been 
completed, and the TAVR delivery system has been 
removed)  
Extent of cerebral artery coverage will be reported as:  
o Complete (coverage of all 3 cerebral artery branches)  
o Partial (coverage of 1- 2 cerebral artery branches)  
o None  
Note:  Maintenance of device positioning to each time point 
and extent of cerebral coverage will be evaluated separately 
by the Angiographic Core Laboratory.  
Efficacy Intention to Treat 
(eITT) population The eITT analysis p opulation is defined as:  
• Subjects who are enrolled in the trial and 
randomized to a treatment group, regardless of 
treatment actually received AND  
• Who do not have conversion to surgery or prolonged 
cardiac arrest (>3 minutes) prior to the post -
procedure D W-MRI 
Encephalopathy  Altered mental state (e.g., seizures, delirium, confusion, 
hallucinations, dementia, coma, psychiatric episode, etc.)  
Evaluable  Evaluable subjects are those who are enrolled in the 
randomized portion of the trial (i.e., not Roll -In subjects)  
General safety  Defined as the composite of the following adverse events 
(each VARC -2 defined):  
• All-cause mortality  
• All stroke (disabling and non- disabling)  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
111 
 • Acute kidney injury  – Stage 3 (including renal 
replacement therapy)  
Hepatic failure  Child -Pugh Class C (see definition for classification scoring)  
In-hospital procedural 
safety  The composite of the following Major Adverse 
Cardiovascular and Cerebrovascular events (MACCE):  
• All-cause mortality  
• All stroke (disabling and non- disabling)  
• Life threatening (or disabling) bleeding  
• Acute kidney injury – Stage 2 or 3 (including renal 
replacement therapy)  
• Major vascular complications  
Intention to treat (ITT)  The principle of including outcomes of all subjects in the 
analysis who are randomized into the s tudy, regardless of 
the treatment actually received.  The ITT analysis population 
is defined as all subjects enrolled in the study, by assigned 
treatment, regardless of the treatment actually received.  
Intracranial hemorrhage  Collection of blood between th e brain and skull. 
Subcategorized as epidural, subdural, and subarachnoid 
bleeds.  
Modification of Diet in 
Renal Disease (MDRD)  A proxy for Glomerular Filtration Rate in which creatinine 
clearance is estimated from age, serum creatinine , gender 
and race by the formula:  
 GFR (mL/min/1.73 m2) = 175 × (Scr) -1.154 × (Age) -0.203 
× (0.742 if female) × (1.212 if African American)  
Modified RANKIN Score (mRS) 
 
 A commonly used scale for measuring stroke functional 
outcome.109 See § 16.5 for the standardized interview.  The 
scale runs from 0 to 6.  The scores and descriptions are:   
0. No symptoms at all  
1. No significant disability despite symptoms; able to 
carry out all usual duties and activities  
2. Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 
3. Moderate disability; requiring some help, but able to walk without assistance 
4. Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance  
5. Severe disability; bedridden, incontinent and requiring constant nursing care and attention  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
112 
 6. Dead  
Montreal Cognitive 
Assessment (MoCA) worsening  A MoCA score  decrease  of 3 or more points from baseline 
to follow -up. 
Mortality  All-cause mortality
35 
Cardiovascular mortality  
Any of the following criteria:  
• Death due to proximate cardiac cause (e.g. myocardial infarction, cardiac tamponade, worsening heart failure)  
• Death caused by non- coronary vascular conditions 
such as neurological events, pulmonary  embolism, ruptured aortic aneurysm, dissecting aneurysm, or 
other vascular disease  
• All procedure- related deaths, including those related 
to a complication of the procedure or treatment for a complication of the procedure  
• All valve -related deaths including structural or 
nonstructural valve dysfunction or other valve -
related adverse events  
• Sudden or unwitnessed death  
• Death of unknown cause 
Non-cardiovascular mortality  
Any death in which the primary cause of death is clearly 
related to another condition (e.g. trauma, cancer, suicide)  
Myocardial infarction (MI)  Peri-procedural MI  (≤72 h after the index procedure):35  
• New ischemic  symptoms (e.g. chest pain or 
shortness of breath), or new ischemic signs (e.g. ventricular arrhythmias, new or worsening heart failure, new ST -segment changes, hemodynamic  
instability, new pathological Q waves in at least two contiguous leads, imaging evidence of new loss of 
viable myocardium or new wall motion abnormality) AND 
• Elevated cardiac biomarkers (preferably CK -MB) 
within 72 h after the index procedure consisting of at least one sample post -procedure with a peak value 
exceeding 15x upper reference limit for troponin or 
5x for CK -MB. If cardiac biomarkers are increased 
at baseline (>99
th percentile), a further increase of at 
least 50% post -procedure is required AND the peak 
value must exceed the previously stated limit.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
113 
 Spontaneous MI  (>72 h after the index procedure). Any one 
of the following criteria:  
• Detection of rise and/or fall of cardiac biomarkers 
(preferably troponin) with at least one value above the 99th percentile URL, together with evidence of myocardial ischemia with at least one of the 
following:  
o Symptoms of ischemia 
o ECG changes indicative of new ischemia 
[new ST -T changes or new left bundle branch 
block (LBBB)]  
o New pathological Q waves in at least two contiguous leads  
o Imaging evidence of new loss of viable myocardium or new wall motion abnormality  
• Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischemia, and accompanied by presumably new ST elevation, or new LBBB, and/or evidence of fresh thrombus by coronary angiography and/or at autopsy, but death occurring before blood samples could be obtained, or at a time before the appearance of cardiac biomarkers in the blood.  
• Pathological findings of an acute myocardial 
infarction.  
National Institute of 
Health Stroke Scale (NIHSS)  A commonly -used scale to assess stroke. See § 16.6 
Neurologic dysfunction 
without CNS injury  Acutely symptomatic (NeuroARC Type 3 ) without CNS 
injury, inclu ding:3 
Type 3.a TIA  
Transient focal neurological signs or symptoms (lasting <24 h) presumed to be due to focal brain, spinal cord, or retinal ischemia, but without evidence of acute infarction by neuroimaging or pathology (or in the absence of imaging)  
Type 3.b Delirium without CNS injury  
Transient nonfocal (global) neurological signs or symptoms (variab le duration) without evidence of cell death by 
neuroimaging or pathology  
Neurological events  See “stroke  (VARC -2 defin ed)”, “Overt CNS Injury”, “Covert 
CNS Injury” , “Neurological dysfunction without CNS injury”, 
“CNS infarction”, and “CNS hemorrhage”  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
114 
 New neurologic 
impairment  NIHSS worsening at post -procedure  (2-5 days post -
procedure)  accompanied by the presence of cerebral 
ischemic lesions.  
NIHSS worsening  An NIHSS score increase from baseline to follow -up. 
NYHA (New York Heart 
Association) functional  
capacity  Classified as110:  
Class I.  Patients with cardiac disease but without resulting 
limitation of physical activity. Ordinary physical activity does 
not cause undue fatigue, palpitation, dyspnea, or anginal 
pain. 
Class II.  Patients with cardiac disea se resulting in slight 
limitation of physical activity. They are comfortable at rest. 
Ordinary physical activity results in fatigue, palpitation, 
dyspnea, or anginal pain.  
Class III.  Patients with cardiac disease resulting in marked 
limitation of physical activity. They are comfortable at rest. 
Less than ordinary activity causes fatigue, palpitation, 
dyspnea, or anginal pain. 
Class IV.  Patients with cardiac disease resulting in inability 
to carry on any physical activity without discomfort. 
Symptoms of hear t failure or the anginal syndrome may be 
present even at rest. If any physical activity is undertaken, 
discomfort is increased.  
Overt CNS Injury  Acutely symptomatic brain or spinal cord injury (NeuroARC 
Type 1), including3: 
Type 1.a Ischemic stroke 
Sudden onset of neurological signs or symptoms fitting a 
focal or multifocal vascular territory within the brain, spinal 
cord, or retina, that:  
1) Persist for ≥24 h or until death, with pathology or neuroimaging evidence that demonstrates either:  
a) CNS infarction in the corresponding vascular 
territory (with or without hemorrhage); or 
b) Absence of other apparent causes (including 
hemorrhage), even if no evidence of acute 
ischemia in the corresponding vascular territory is detected  
or 
2) Symptoms lasting <24 h, with pathology or neuroimaging confirmation of CNS infarction in the 
corresponding vascular territory. Note:  When CNS 
infarction location does not mat ch the transient 
symptoms, the event would be classified as covert 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
115 
 CNS infarction (Type 2a) and a TIA (Type 3a), but 
not as an ischemic stroke.  
Signs and symptoms consistent with stroke typically 
include an acute onset of 1 of the following: focal weaknes s and/or numbness; impaired language production 
or comprehension; homonymous hemianopia or quadrantanopsia; diplopia; altitudinal monocular blindness; hemispatial neglect; dysarthria; vertigo; or ataxia.  
Subtype 1.a.H Ischemic stroke with hemorrhagic 
conversion  
Ischemic stroke includes hemorrhagic conversions . 
These should be subclassified as Class A or B when ischemic stroke is the primary mechanism and pathology or neuroimaging confirms a hemorrhagic conversion.  
Class A (Petechial hemorrhage): Petechiae or 
confluent petechiae within the infarction or its margins, but without a space- occupying effect  
Class B (Confluent hemorrhage): Confluent 
hemorrhage or hematoma originating from within the infarcted area with space- occupying effect   
Type 1.b Symptomatic i ntracerebral hemorrhage 
Rapidly developing neurological signs or symptoms (focal or global) caused by an intraparenchymal, intraventricular, spinal cord , or retinal collection of blood, not caused by 
trauma  
Type 1.c Symptomatic subarachnoid hemorrhage 
Rapidly developing neurological signs or symptoms (focal 
or global) and/or headache caused by bleeding into the subarachnoid space, not caused by trauma  
Type 1.d Stroke, not otherwise specified  
An episode of acute focal neurological signs or symptoms and/or headache presumed to be caused by CNS ischemia or CNS hemorrhage, persisting ≥24 h or until death, but without sufficient evidence to be classified as either (i.e., no neuroimaging performed)  
Type 1.e Symptomatic hypoxic -ischemic injury  
Nonfocal (global) neurological signs or symptoms due to 
diffuse brain, spinal cord, or retinal cell death (confirmed by 
pathology or neuroimaging) in a nonvascular distribution, attributable to hypotension and/or hypoxia 
Per Treatment (PT) 
population The PT population is defi ned as subjects in the Intervention 
group in whom device positioning is maintained until final 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
116 
 procedure with complete cerebral coverage, and all Control 
group subjects.  
Procedure success  Technical success in the absence of any investigational 
device- related or investigational procedure- related in-
hospital procedural safety events.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
117 
 Prosthetic Valve 
Dysfunction  Defined according to VARC criteria in the table below:35 
Prosthetic Valve Dysfunction  
Prosthetic aortic valve stenosis*  
 Normal  Mild Stenosis  Moderate/Severe Stenosis  
Quantitative Parameters (Flow -dependent)†  
Peak v elocity  <3 m/s  3-4 m/s  >4 m/s  
Mean gradient  <20 mmHg  20-40 mmHg  >40 mmHg  
Quantitative Parameters (Flow -independent)  
Doppler velocity index‡  >0.35  0.35-0.25 <0.25  
Effective orifice area¶  >1.1 cm2 1.1-0.8 cm2 <0.8 cm2 
Effective orifice area§  >0.9 cm2 0.9-0.6 cm2 <0.6 cm2 
Prosthesis -patient mismatch (PPM)  
 Insignificant  Moderate  Severe  
Indexed effective orifice area**  >0.85 cm2/m2 0.85-0.65 cm2/m2 <0.65 cm2/m2 
Indexed effective orifice area††  >0.70 cm2/m2 0.90-0.60 cm2/m2 <0.60 cm2/m2 
Prosthetic aor tic valve regurgitation  
 Mild Moderate  Severe  
Semi -quantitative Parameters  
Diastolic flow reversal in the descending 
aorta—PW  Absent or brief early 
diastolic  Intermediate  Prominent, holodiastolic  
Circumferential extent of prosthetic valve 
paravalvular  regurgitation (%) ¶¶ <10 10-29 ≥30 
Quantitative Parameters ‡ 
Regurgitant volume (ml/beat)  <30 30-59 ≥60 
Regurgitant fraction (%)  <30 30-49 ≥50 
EROA (cm2)  0.10 0.10-0.29 ≥0.30  
*In conditions of normal or near normal stroke volume (50 –70 mL)  
†These parameters are more affected by flow, including concomitant aortic regurgitation  
‡For LVOT >2.5 cm, significant stenosis criteria is <0.20  
¶Use in setting of BSA ≥1.6 cm2 (note: dependent on the size of the valve and the size of the native annulus)  
§Use in setting of BSA <1.6 cm2 
**Use in setting of BMI <30 kg/cm2 
††Use in setting of BMI ≥30 kg/cm2 
¶¶Not well -validated and may overestimate severity compared to quantitative Doppler  
 
 
Serious Adverse Device 
Effect (SADE)  A serious adverse device effect is an ad verse device effect 
that has resulted in any of the consequences characteristic 
of a serious adverse event.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
118 
 Serious Adverse Event 
(SAE)  A serious adverse event is an adverse event that:  
1. Led to a death  
2. Led to a serious deterioration in the health of the 
subject that:  
a. Resulted in a life- threatening illness or injury  
b. Resulted in a permanent impairment of a body 
structure or a body function  
c. Required in- patient hospitalization or 
prolongation of existing hospitalization  
d. Resulted in medical or surgical intervention to prevent life-
threatening illness or injury or 
permanent impairment to body structure or a 
body function  
3. Led to fetal distress, fetal death or a congenital 
abnormality or birth defect.  
Stroke  (VARC -2 defined)  Diagnostic criteria:  
• Acute episode of a focal or global neurological 
deficit with at least one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, amaurosis fugax, or other neurol ogical signs or symptoms 
consistent with stroke  
• Stroke: duration of a focal or global neurological deficit ≥24 h; OR <24 h if available neuroimaging documents a new hemorrhage or infarct; OR the neurological deficit results in death  
• TIA: duration of a focal or global neurological deficit <24 h, any variable neuroimaging does not demonstrate a new hemorrhage or infarct  
• No other readily identifiable non- stroke cause for the 
clinical presentation (e.g. brain tumor, trauma, infection, hypoglycemia, peripheral l esion, 
pharmacological influences), to be determined by or in conjunction with designated neurologist (Patients with non- focal global encephalopathy will not be 
reported as a stroke without unequivocal evidence of cerebral infarction based upon neuroimaging studies [CT scan or brain MRI]).  
• Confirmation of the diagnosis by at least one of the following:  
o Neurologist or neurosurgical specialist  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
119 
 o Neuroimaging procedure (CT scan or brain 
MRI), but stroke may be diagnosed on clinical 
grounds alone  
Stroke classification:  
• Ischemic – An acute episode of focal cerebral, 
spinal, or retinal dysfunction caused by infarction of 
central nervous system tissue  
• Hemorrhagic – An acute episode of focal or global 
cerebral or spinal dysfunction caused by intraparenchymal, intraventricular, or subarachnoid hemorrhage  
• A stroke may be classified as undetermined if there is insufficient information to allow categorization as ischemic or hemorrhagic  
Stroke definitions (Modified Rankin Scale assessments 
should be made by qualified indivi duals according to a 
certification process):  
• Disabling stroke –  a mRS score of 2 or more at 90 
days and an increase of at least one mRS category from an individual’s pre- stroke baseline  
• Non-disabling stroke – a mRS score of less than 2 
at 90 days or one that does not result in an increase of at least one mRS category from an individual’s pre-stroke baseline  
Successful device 
deployment  Ability to access the aortic arch with the TriGuard HDH  or 
TriGUARD 3 delivery catheter and deploy the device from 
the delivery  catheter into the aortic arch.  
Successful device 
retrieval  Ability to retrieve the TriGuard device and remove the 
TriGuard CEPD . 
TAVI device success  Equivalent to the VARC definition111 of “device success” for 
transcatheter aortic valves.  Defined as:  
• Absence of procedural mortality AND  
• Correct positioning of a single prosthetic heart valve into the proper anatomical location AND  
• Intended performance of the prosthetic heart valve (no 
prosthesis -patient mismatch (VARC -defined) and mean 
aortic valve gradient <20 mm Hg or peak velocity <3 
m/s, AND no moderate or severe prosthetic valve 
regurgitation (V ARC- defined)  
Technical success  Successful TriGuard HDH  or TriGUARD 3 device 
deployment, device positioning, and successful device 
retrieval in the absence of device interference 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
120 
 Total procedural time  Time elapsed between first arterial access and removal  of 
the last catheter from the arterial access sheath  
Unanticipated Adverse 
Device Effect (UADE)  An unanticipated adverse device effect is any serious 
adverse effect on the health or safety or any life- threatening 
problem or death caused by, or associated  with, a device, if 
that effect, problem, or death was not previously identified in 
nature, severity or degree of incidence in the investigational 
plan or application (including a supplementary plan or 
application), or any other unanticipated serious probl em 
associated with a device that relates to the rights, safety or 
welfare of subjects.  
NOTE: An anticipated serious adverse device effect 
(ASADE) is a serious adverse device effect which by its 
nature, incidence, severity, or outcome has been identified 
in the investigational plan or application (including a 
supplementary plan or application).   
Use Error  Act or omission of an act that results in a different medical 
device response than intended by the manufacturer or 
expected by the user.  
NOTE 1: Use err or includes slips, lapses and mistakes.  
NOTE 2: An unexpected physiological response of the 
patient does not itself constitute a use error.  
 
Vascular access site and 
access- related 
complications  Major Vascular Complications :35   
• Any aortic dissection, aortic rupture, annulus rupture, 
left ventricle perforation, or new apical aneurysm/pseudo- aneurysm OR  
• Access sit e or access -related vascular injury 
(dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) leading to death, 
life-threatening or m ajor bleeding, visceral ischemia or 
neurological impairment OR  
• Distal embolization (non- cerebral) from a vascular 
source requiring surgery or resulting in amputation or irreversible end- organ damage OR  
• The use of unplanned endovascular or surgical intervention associated  with death, major bleeding, 
visceral ischemia or neurological impairment OR  
• Any new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR  
• Surgery for access site -related nerve injury OR  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
121 
 • Permanent access site -related nerve injury  
Minor vascular complications : 
• Access site or access- related vascular injury 
(dissection, stenosis, perforation, rupture, arterio-
venous fistula, pseudoaneur ysms, hemat omas, 
percutaneous closure device failure) not leading to 
death, life- threatening or major bleeding, visceral 
ischemia or neurological impairment OR  
• Distal embolization treated with embolectomy and/or thrombectomy and not resulting in amputation or irreversible end- organ damage OR  
• Any unplanned endovascular stenting or unplanned surgical intervention not meeting the criteria for a major vascular complication OR  
• Vascular repair or the need for vascular repair (via surgery, ultrasound- guided compression, tran scatheter 
embolization, or stent -graft)  
 
 
 
 
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
12216.2 Appendix II: Acronyms  
AE  adverse event  
ADE  adverse device effect  
AF atrial fibrillation  
ALT/SGPT  alanine transaminase / serum glutamic pyruvic transaminase  
AKI  acute kidney injury  
AMI  acute myocardial i nfarction  
ANOVA  analysis of variance  
AS aortic stenosis  
ASA  acetylsalicylic acid  
ASADE  anticipated serious adverse device effect  
AST/SGOT Aspartate transaminase / serum glutamic oxaloacetic 
transaminase  
AT As treated  
BARC Bleeding Academic Research Consortium  
BAV balloon aortic valvuloplasty  
BUN  blood urea nitrogen  
CABG coronary artery bypass graft surgery  
CCS Canadian Cardiovascular Society  
CEC clinical events committee  
CEPD  Cerebral Embolic Protection Device 
CI confidence interval  
CIP clinical investigation plan  
CK creatine kinase  
CK-MB creatine kinase- MB fraction  
CNS  central nervous system  
CRF case report form  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
123 
 CT  computed tomography  
DAPT  dual antiplatelet therapy  
DICOM  Digital Imaging and Communications in Medicine  
DSM B data and safety monitoring Board (Interchangeable with 
DSMC)  
DW-MRI  diffusion -weighted magnetic resonance imaging  
EC  Ethics Committee  
ECG  electrocardiogram  
EDC electronic data capture (system)  
EDD/EPD  embolic deflection device/embolic protection dev ice (see also 
CEPD)  
eGFR  estimated Glomerular Filtration Rate  
eITT efficacy Intention to Treat  
EU  European Union  
F french (catheter scale system)  
FDA U.S. Food and Drug Administration  
GCP  good clinical practices  
GI  gastrointestinal  
ICH Internati onal Conference on Harmonization  
INR international normalized ratio  
IQR interquartile range  
IRB  Institutional Review Board 
ISO International Organization for Standardization  
ITT  intention to treat  
IV  intravenous  
LAO  left anterior oblique 
LBBB  left bundle branch block  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
124 
 LV  left ventricle/left ventricular  
MACCE  major adverse cardiovascular and cerebrovascular events  
MDRD  Modification of Diet in Renal Disease  
MI  myocardial infarction  
MoCA  Montreal Cognitive Assessment  
MRI  magnetic resonance  imaging  
mRS  modified Rankin Scale  
NeuroARC  Neurologic Academic Research Consortium  
NIHSS  National Institutes of Health Stroke Scale  
NYHA  New York Heart Association  
OPC  objective performance criterion 
PCI  percutaneous coronary intervention  
PP  per protocol  
PPM  prosthesis -patient mismatch  
PT per treatment  
PTT partial thromboplastin time  
QD  quaque die (daily)  
RBANS  Repeatable Battery for the Assessment of 
Neuropsychological Status  
RBC  red blood cells  
RI roll-in 
SADE  serious adverse device effect  
SAE  serious adverse event  
SAVR  surgical aortic valve replacement  
SD standard deviation  
SF-36 Short Form 36 Health Survey  
SOC  standard of care  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
125 
 STS Society of Thoracic Surgeons  
TAVI  transcatheter aortic valve implantation  
TEE  transesophageal echocardiography  
TIA  transient ischemic attack  
UADE  unanticipated adverse device effect  
URL  upper reference limit  
US United States  
VARC  Valve Academic Research Consortium  
WBC white blood cell  
 
  
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
12616.3 Appendix III: Declaration of Helsinki  
WORLD M EDICAL ASSOCIATION DECLARATION OF HELSINKI  
Ethical Principles for Medical Research Involving Human Subjects  
Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the  
29th WMA General Assembly, Tokyo, Japan, October 1975  
35th WMA General Assembly, Venice, Italy, October 1983  
41st WMA General Assembly, Hong Kong, September 1989  
48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996  
and the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000  
Note of Clarification on Paragraph 29 added by the WMA General Assembly, Washington 2002  
Note of Clarification on Paragraph 30 added by the WMA General Assembly, Tokyo 2004  
A. INTRODUCTION 
1. The World Medical Association has developed the Declaration of Helsinki as a statement of ethical
principles to provide guidance to physicians and other participants in medical research involvinghuman subjects. Medical research involving human subjects includes research on identifiablehuman material or identifiable data.
2. It is the duty of the physician to promote and safeguard the health of the people. The physician'sknowledge and conscience are dedicated to the fulfillment of this duty.
3. The Declaration of Geneva of the World Medical Association binds the physician with t he words,
"The health of my patient will be my first consideration," and the International Code of MedicalEthics declares that, "A physician shall act only in the patient's interest when providing medical carewhich might have the effect of weakening the physical and mental condition of the patient."
4. Medical progress is based on research which ultimately must rest in part on experimentationinvolving human subjects.
5. In medical research on human subjects, considerations related to the well -being of the hum an
subject should take precedence over the interests of science and society.
6. The primary purpose of medical research involving human subjects is to improve prophylactic,
diagnostic and therapeutic procedures and the understanding of the etiology and pathogenesis of
disease. Even the best proven prophylactic, diagnostic, and therapeutic methods must continuouslybe challenged through research for their effectiveness, efficiency, accessibility and quality.
7. In current medical practice and in medical research,  most prophylactic, diagnostic and therapeutic
procedures involve risks and burdens.
8. Medical research is subject to ethical standards that promote respect for all human beings and
protect their health and rights. Some research populations are vulnerable and need special
protection. The particular needs of the economically and medically disadvantaged must berecognized. Special attention is also required for those who cannot give or refuse consent forthemselves, for those who may be subject to giving consent under duress, for those who will notbenefit personally from the research and for those for whom the research is combined with care.
9. Research Investigators should be aware of the ethical, legal and regulatory requirements for
research on human subjects  in their own countries as well as applicable international requirements.
No national ethical, legal or regulatory requirement should be allowed to reduce or eliminate any of
the protections for human subjects set forth in this Declaration.
B. BASIC PRINCIPLE S FOR ALL MEDICAL RESEARCH 
10. It is the duty of the physician in medical research to protect the life, health, privacy, and dignity ofthe human subject.
11. Medical research involving human subjects must conform to generally accepted scientific principles,be based on a thorough knowledge of the scientific literature, other relevant sources of information,
and on adequate laboratory and, where appropriate, animal experimentation.
12. Appropriate caution must be exercised in the conduct of research which may affect the environment,
and the welfare of animals used for research must be respected.
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
127 
 13. The design and performance of each experimental procedure involving human subjects should be 
clearly formulated in an experimental protocol. This protocol should be submitted for consideration, 
comment, guidance, and where appropriate, approval to a specially appointed ethical review 
committee, which must be independent of the investigator, the sponsor or any other kind of undue influence. This independent committee should be in conformity with the laws and regulations of the country in which the research experiment is performed. The committee has the right to monitor ongoing trials. The researcher has the obligation to provide monitoring information to the committee, especially  any serious adverse events. The researcher should also submit to the committee, for 
review, information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest and incentives for subjects.  
14. The research protocol should always contain a statement of the ethical considerations involved and should indicate that there is compliance with the principles enunciated in this Declaration.  
15. Medical research involving human subjects should be conducted only by scientifically qual ified 
persons and under the supervision of a clinically competent medical person. The responsibility for 
the human subject must always rest with a medically qualified person and never rest on the subject 
of the research, even though the subject has given c onsent.  
16. Every medical research project involving human subjects should be preceded by careful assessment of predictable risks and burdens in comparison with foreseeable benefits to the subject or to others. This does not preclude the participation of healthy volunteers in medical research. The design of all studies should be publicly available.  
17. Physicians should abstain from engaging in research projects involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians should cease any investigation if the risks are found to outweigh the potential benefits or if there is conclusive proof of positive and beneficial results.  
18. Medical research involving human subjects should only be conducted if the importance of the 
objective outweighs the inherent risks and burdens to the subject. This is especially important when 
the human subjects are healthy volunteers.  
19. Medical research is only justified if there is a reasonable likelihood that the populations in which the research is carried out stand to benefit from the results of the research.  
20. The subjects must be volunteers and informed participants in the research project.  
21. The right of research subjects to safeguard their integrity must always be respected. Every 
precaution should be taken to respect the privacy of the subject, the confidentiality of the patient's 
information and to minimize the impact of the study on the subject's physical and mental integrity and on the personality of the subject.  
22. In any research on human beings, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and pot ential risks of the study and the discomfort it may entail. 
The subject should be informed of the right to abstain from participation in the study or to withdraw consent to participate at any time without reprisal. After ensuring that the subject has under stood 
the information, the physician should then obtain the subject's freely -given informed consent, 
preferably in writing. If the consent cannot be obtained in writing, the non- written consent must be 
formally documented and witnessed.  
23. When obtaining informed consent for the research project the physician should be particularly cautious if the subject is in a dependent relationship with the physician or may consent under duress. In that case the informed consent should be obtained by a well -informed physi cian who is 
not engaged in the investigation and who is completely independent of this relationship.  
24. For a research subject who is legally incompetent, physically or mentally incapable of giving consent or is a legally incompetent minor, the investigator must obtain informed consent from the legally 
authorized representative in accordance with applicable law. These groups should not be included 
in research unless the research is necessary to promote the health of the population represented and this research cannot instead be performed on legally competent persons.  
25. When a subject deemed legally incompetent, such as a minor child, is able to give assent to decisions about participation in research, the investigator must obtain that assent in addition to the consent of the legally authorized representative.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
128 
 26. Research on individuals from whom it is not possible to obtain consent, including proxy or advance 
consent, should be done only if the physical/mental condition that prevents obtaining informed 
consent is a necessary characteristic of the research population. The specific reasons for involving 
research subjects with a condition that renders them unable to give informed consent should be stated in the experimental protocol for consideration and approval of the review committee. The 
protocol should state that consent to remain in the research should be obtained as soon as possible from the individual or a legally authorized surrogate.  
27. Both authors and publishers have ethical obligations. In publication of the results of research, the 
investigators are obliged to preserve the accuracy of the results. Negative as well as positive results 
should be published or otherwise publicly available. Sources of funding, institutional affiliations and any possible conflicts of  interest should be declared in the publication. Reports of experimentation 
not in accordance with the principles laid down in this Declaration should not be accepted for publication.  
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE  
a. T he physician may combine medical research with medical care, only to the extent that the research 
is justified by its potential prophylactic, diagnostic or therapeutic value. When medical research is combined with medical care, additional standards apply to protect the patients who are research subjects.  
b. The benefits, risks, burdens and effectiveness of a new method should be tested against those of the best current prophylactic, diagnostic, and therapeutic methods. This does not exclude the use 
of placebo,  or no treatment, in studies where no proven prophylactic, diagnostic or therapeutic 
method exists. See footnote  
c. At the conclusion of the study, every patient entered into the study should be assured of access to 
the best proven prophylactic, diagnostic and therapeutic methods identified by the study. See footnote  
d. The physician should fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study must never interfere with the patient -physi cian 
relationship.  
e. In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic methods do not exist or have been ineffective, the physician, with informed consent from the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic measures, if in the physician's 
judgment it offers hope of saving life, re- establishing health or alleviating suffering. Where possible, 
these measures should be made the object of research, designed to evaluate their safety and 
efficacy. In all cases, new information should be recorded and, where appropriate, published. The other relevant guidelines of this Declaration should be followed.  
Note : Note of clarification on paragraph 29 of the WMA Declaration of Helsinki  
The WMA hereby reaffirms its position that extreme care must be taken in making use of a placebo- controlled 
trial and that in general this methodology should only be used in the absence of existing proven therapy. However, a placebo- controlled trial may be ethically acceptable, even if proven therapy is available, under the 
following circumstances:  
• Where for compelling and scientifically sound methodological reasons its use is necessary to determine the efficacy or safety of a prophylactic, diagnostic or therapeutic method; or  
• Where a prophylactic, diagnostic or therapeutic method is being investigated for a minor condition and 
the patients who receive placebo will not be subject to any additional risk of serious or irreversible harm.  
All other provisions of the Declaration of Helsinki must be adhered to, especially the need for appropriate ethical 
and scientific review.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
12916.4 Appendix IV: References  
1. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott
TG, Cohen DJ, Cutlip  DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, 
Mehran R, Rodes -Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW and Leon MB. 
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve 
Academic Research Consortium -2 consensus document. J Thorac Cardiovasc Surg . 2013;145:6 -
23. 
2. Finkelstein DM and Schoenfeld DA. Combining mortality and longitudinal measures in
clinical trials. Statistics in medicine . 1999;18:1341 -54. 
3. Lansky AJ, Messé SR, Brickman AM, Dwyer MG, van der Worp HB, Lazar RM, Pietras CG,
Abrams KJ, McFadden E, Petersen NH, Browndyke JN, Prendergast B, Ng VG, Cutlip DE, Kapadia 
S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma JJ, Parides MK, Kodali 
S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, 
Holmes D, Kappetein AP, Mack M and Baumbach A. Proposed standardized neurological endpoints 
for cardiovascular clinical trials: an Academic Research Consortium initiative. J Am Coll Cardiol. 
2017;(in press).  
4. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG,
Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D and Pocock SJ. Transcatheter versus Surgical Aortic -Valve Replacement in High- Risk Patients. N Engl J Med. 
2011;364:2187 -98. 
5. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG,
Fontana GP, Makkar RR, Brown DL,  Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, 
Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D and Pocock S. Transcatheter aortic -
valve implantation for aortic stenosis in patients who cannot undergo surgery. New England Journal 
of Medici ne. 2010;363:1597- 607. 
6. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG,
Buchbinder M, Hermiller J, Jr., Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S 
and Oh JK. Transcatheter aortic -valve replacement with a self -expanding prosthesis. N Engl J Med . 
2014;370:1790 -8. 
7. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, Hermiller J,
Jr., Hughes GC, Harrison JK, Coselli J, Diez J, Kafi A, Schreiber T, Gleason TG, Conte J, 
Buchbinder M, Deeb GM, Carabello B, Serruys PW, Chenoweth S and Oh JK. Transcatheter Aortic Valve Replacement Using a Self -Expanding Bioprosthesis in Patients With Severe Aortic Stenosis 
at Extreme Risk for Surgery. J Am Coll Cardiol. 2014;63:1972 -81. 
8. Lansky AJ, Schofer J, Tchetche D, Stella P, Pietras CG, Parise H, Abrams K, Forrest JK,
Cleman M, Reinohl J, Cuisset T, Blackman D, Bolotin G, Spitzer S, Kappert U, Gilard M, Modine T, 
Hildick -Smith D, Haude M, Margolis P, Brickman AM, Voros S and Baumbach A. A prospective 
randomized evaluation of the TriGuard HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J . 2015;36:2070 -2078.  
9. Kapadia SR, Kodali S, Makkar R, Mehran R, Lazar RM, Zivadinov R, Dwyer MG, Jilaihawi H,
Virmani R, Anwaruddin S, Thourani VH, Nazif T, Mangner N, Woitek F, Krishnaswamy A, Mick S, Chakravarty T, Nakamura M, McCabe JM, Satler L, Zajarias A, Szeto WY, Svensson L, Alu MC, 
White RM, Kraemer C, Parhizgar A, Leon MB and Linke A. Protection Against Cerebral Embolism 
During Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology . 
2017;69:367 -377. 
10. Chen YH, DeMets DL and Lan KK. Increasing the sample size when the unblinded interim
result is promising. Stat Med. 2004;23:1023- 38. 
11. Mehta CR and Pocock SJ. Adaptive increase in sample size when interim results are
promising: a practical guide with examples. Stat Med . 2011; 30:3267- 84. 
12. McKhann GM, Grega MA, Borowicz LM, Jr., Baumgartner WA and Selnes OA. Stroke and
encephalopathy after cardiac surgery: an update. Stroke . 2006;37:562 -71. 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
130 
 13. Nuis RJ, Piazza N, Van Mieghem NM, Otten AM, Tzikas A, Schultz CJ, van der Boon R,  van 
Geuns RJ, van Domburg RT, Koudstaal PJ, Kappetein AP, Serruys PW and de Jaegere PP. In-
hospital complications after transcatheter aortic valve implantation revisited according to the valve 
academic research consortium definitions. Catheter Cardiovasc Interv . 2011.  
14. Selim M. Perioperative stroke. N Engl J Med. 2007;356:706 -13. 
15. Fuchs S, Stabile E, Kinnaird TD, Mintz GS, Gruberg L, Canos DA, Pinnow EE, Kornowski R, 
Suddath WO, Satler LF, Pichard AD, Kent KM and Weissman NJ. Stroke complicating 
percutaneous coronary interventions: incidence, predictors, and prognostic implications. Circulation . 
2002;106:86 -91. 
16. Dukkipati S, O'Neill WW, Harjai KJ, Sanders WP, Deo D, Boura JA, Bartholomew BA, 
Yerkey MW, Sadeghi HM and Kahn JK. Characteristics of cerebrovascular accidents after 
percutaneous coronary interventions. J Am Coll Cardiol. 2004;43:1161- 7. 
17. Aggarwal A, Dai D, Rumsfeld JS, Klein LW and Roe MT. Incidence and predictors of stroke 
associated with percutaneous coronary intervention. Am J Cardio l. 2009;104:349- 53. 
18. Segal AZ, Abernethy WB, Palacios IF, BeLue R and Rordorf G. Stroke as a complication of 
cardiac catheterization: risk factors and clinical features. Neurology . 2001;56:975- 7. 
19. Omran H, Schmidt H, Hackenbroch M, Illien S, Bernhardt P, von der Recke G, Fimmers R, 
Flacke S, Layer G, Pohl C, Luderitz B, Schild H and Sommer T. Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, 
randomised study. Lancet . 2003;361:1241- 6. 
20. Rodes -Cabau J, Dumont E, Boone RH, Larose E, Bagur R, Gurvitch R, Bedard F, Doyle D, 
De Larochelliere R, Jayasuria C, Villeneuve J, Marrero A, Cote M, Pibarot P and Webb JG. Cerebral 
embolism following transcatheter aortic valve implantation:  comparison of transfemoral and 
transapical approaches. J Am Coll Cardiol. 2011;57:18- 28. 
21. Stortecky S, Buellesfeld L, Wenaweser P, Heg D, Pilgrim T, Khattab AA, Gloekler S, Huber 
C, Nietlispach F, Meier B, Juni P and Windecker S. Atrial fibrillation and aortic stenosis: impact on 
clinical outcomes among patients undergoing transcatheter aortic valve implantation. Circ 
Cardiovasc Interv . 2013;6:77- 84. 
22. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu 
EM, Miller DC, Her rmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, 
Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC and 
Webb JG. Transcatheter or Surgical Aortic -Valve Replacement in Intermediate- Risk Patients. New 
England Journal of Medicine. 2016;374:1609 -1620.  
23. Eggebrecht H, Schmermund A, Voigtlander T, Kahlert P, Erbel R and Mehta RH. Risk of 
stroke after transcathete r aortic valve implantation (TAVI): a meta- analysis of 10,037 published 
patients. EuroIntervention. 2012;8:129 -38. 
24. Miller DC, Blackstone EH, Mack MJ, Svensson LG, Kodali SK, Kapadia S, Rajeswaran J, 
Anderson WN, Moses JW, Tuzcu EM, Webb JG, Leon MB and Smith CR. Transcatheter (TAVR) 
versus surgical (AVR) aortic valve replacement: Occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg . 
2012;143:832 -843 e13.  
25. Hamon M, Baron JC and Viader F. Periprocedural stroke and cardiac catheterization. 
Circulation . 2008;118:678- 83. 
26. Osranek M, Pilip A, Patel PR, Molisse T, Tunick PA and Kronzon I. Amounts of aortic 
atherosclerosis in patients with aortic stenosis as determined by transesophageal 
echocardiography. Am J Cardiol . 2009;103:713- 7. 
27. Kahlert P, Al -Rashid F, Doettger P, Mori K, Plicht B, Wendt D, Bergmann L, Kottenberg E, 
Schlamann M, Mummel P, Holle D, Thielmann M, Jakob HG, Konorza T, Heusch G, Erbel R and 
Eggebrecht H. Cerebral Embolization During Transcatheter Aortic Valve Implantation: A Transcranial Doppler Study. Circulation . 2012.  
28. Kahlert P, Al -Rashid F, Plicht B, Hildebrandt H, Patsalis P, Chilali K, Wendt D, Thielmann M, 
Bergmann L, Kottenberg E, Schlamann M, Eggebrecht H, Jakob H, Heusch G, Konorza T and Erbel 
R. Incidence, predictors, origin and prevention of early and late neurological events after 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
131 
 transcatheter aortic valve implantation (TAVI): a comprehensive review of current data. Journal of 
thrombosis and thrombolysis . 2013;35:436 -449. 
29. Hauville C, Ben -Dor I, Lindsay J, Pichard AD and Waksman R. Clinical and silent stroke 
following aortic valve surgery and transcatheter aortic valve implantation. Cardiovascular 
revascularization medicine : including molecular interventions . 2012.  
30. Hynes BG and Rodes -Cabau J. Transcatheter aortic valve implantation and cerebrovascular 
events: the current state of the art. Annals of the New York Academy of Sciences . 2012;1254:151 -
63. 
31. Bendszus M and Stoll G. Silent cerebral ischaemia: hidden fingerprints of invasive medical 
procedures. Lancet Neurol . 2006;5:364- 72. 
32. Vermeer SE, Longstreth WT, Jr. and Koudstaal PJ. Silent brain infarcts: a systematic review. 
Lancet Neurol . 2007;6:611- 9. 
33. Mullins ME, Schaefer PW, Sorensen AG, Halpern EF, Ay H, He J, Koroshetz WJ and 
Gonzalez RG. CT and conventional and diffusion -weighted MR imaging in acute stroke: study in 
691 patients at presentation to the emergency department. Radiology . 2002;224:353 -60. 
34. Cooper HA, Thompson EC, Laureno R, Fuisz A, Mark AS, Lin M and Goldstein SA. 
Subclinical brain embolization in left -sided infective endocarditis: results from the evaluation by MRI 
of the brains of patients with left -sided intracardiac solid masses (EMBOLISM) pilot study. 
Circulation . 2009;120:585- 91. 
35. Kappetein AP, Head SJ, Genereux P, Piazza N, Van Mieghem N, Blackstone EH, Brott TG, 
Cohen DJ, Cutlip DE, Van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack M, Mehran R, 
Rodes -Cabau J, Vranckx P, Webb J, Windecker S, Serruys P and  Leon MB. Updated standardized 
endpoint definitions for transcatheter aortic valve replacement: the VARC -2 consensus document. J 
Am Coll Cardiol (In Press) . 2012.  
36. Arnold M, Schulz -Heise S, Achenbach S, Ott S, Dorfler A, Ropers D, Feyrer R, Einhaus F, 
Loders S, Mahmoud F, Roerick O, Daniel WG, Weyand M, Ensminger SM and Ludwig J. Embolic 
cerebral insults after transapical aortic valve implantation detected by magnetic resonance imaging. 
JACC Cardiovasc Interv . 2010;3:1126- 32. 
37. Astarci P, Price J, Glin eur D, D'Hoore W, Kefer J, Elkhoury G, Grandin C and 
Vanoverschelde JL. Cerebral embolization during percutaneous valve implantation does not occur during balloon inflation valvuloplasty: prospective diffusion -weighted brain MRI study. J Heart Valve 
Dis. 2013;22:79- 84. 
38. Fairbairn TA, Mather AN, Bijsterveld P, Worthy G, Currie S, Goddard AJ, Blackman DJ, 
Plein S and Greenwood JP. Diffusion- weighted MRI determined cerebral embolic infarction following 
transcatheter aortic valve implantation: assessment of predictive risk factors and the relationship to subsequent health status. Heart . 2012;98:18 -23. 
39. Ghanem A, Muller A, Sinning JM, Kocurek J, Becker BV, Vogel M, Vasa- Nicotera M, 
Hammerstingl C, Schwab JO, Nahle CP, Thomas D, Wagner M, Grube E, Werner N and Nickenig G. Prognostic value of cerebral injury following transfemoral aortic valve implantation. 
EuroIntervention. 2013;8:1296- 306. 
40. Kahlert P, Knipp SC, Schlamann M, Thielmann M, Al -Rashid F, Weber M, Johansson U, 
Wendt D, Jakob HG, Forsting M, Sack S, Erbel R and Eggebrecht H. Silent and apparent cerebral 
ischemia after percutaneous transfemoral aortic valve implantation: a diffusion- weighted magnetic 
resonance imaging study. Circulation . 2010;121:870- 8. 
41. Knipp SC, Kahlert P, Jokisch D, Schlamann M, Wendt D, Weimar C, Jakob H and Thielmann 
M. Cognitive function after transapical aortic valve implantation: a single- centre study with 3- month 
follow -up. Interact Cardiovasc Thorac Surg. 2013;16:116- 22. 
42. Uddin A, Fairbairn TA, Djoukhader I, Currie S, Steadman CD, Motwani M, Kidambi A, 
Goddard A, Blackman D, McCann GP, Plein S and Greenwood JP. Difference between cerebral embolic events following Transcatheter Aortic Valve Implantation (TAVI) and Surgical Aortic Valve Replacement (SAVR): a Diffusion weighted MRI study. Journal of Cardiovascular Magnetic 
Resonance. 2013;15(Suppl 1). 43. Ghanem A, Muller A, Nahle CP, Kocurek J, Werner N, Hammerstingl C, Schild HH, Schwab 
JO, Mellert F, Fimmers R, Nickenig G and Thomas D. Risk and fate of cerebral emboli sm after 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
132 
 transfemoral aortic valve implantation: a prospective pilot study with diffusion- weighted magnetic 
resonance imaging. J Am Coll Cardiol. 2010;55:1427- 32. 
44. Onsea K, Agostoni P, Samim M, Voskuil M, Kluin J, Budde R, Hendrikse J, Ramjankhan F, 
van Klarenbosch J, Doesburg P, Sieswerda G and Stella P. First -in-man experience with a new 
embolic deflection device in transcatheter aortic valve interventions. EuroIntervention. 2012;8:51 -6. 
45. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ and Breteler MM. Silent brain 
infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215 -22. 
46. Miwa K, Hoshi T, Hougaku H, Tanaka M, Furukado S, Abe Y, Okazaki S, Sakaguchi M, 
Sakoda S and Kitagawa K. Silent cerebral infarction is  associated with incident stroke and TIA 
independent of carotid intima- media thickness. Internal medicine (Tokyo, Japan) . 2010;49:817- 22. 
47. Barber PA, Hach S, Tippett LJ, Ross L, Merry AF and Milsom P. Cerebral ischemic lesions 
on diffusion -weighted imaging are associated with neurocognitive decline after cardiac surgery. 
Stroke . 2008;39:1427 -33. 
48. Knipp SC, Matatko N, Schlamann M, Wilhelm H, Thielmann M, Forsting M, Diener HC and 
Jakob H. Small ischemic brain lesions after cardiac valve replacement detected by diffusion-
weighted magnetic resonance imaging: relation to neurocognitive function. Eur J Cardiothorac Surg. 
2005;28:88 -96. 
49. Stolz E, Gerriets T, Kluge A, Klovekorn WP, Kaps M and Bachmann G. Diffusion- weighted 
magnetic resonance imaging and neurobiochemical markers after aortic valve replacement: 
implications for future neuroprotective trials? Stroke . 2004;35:888 -92. 
50. Astarci P, Glineur D, Kefer J, D'Hoore W, Renkin J, Vanoverschelde JL, El Khoury G and 
Grandin C. Magnetic resonance imaging evaluation of cerebral embolization during percutaneous 
aortic valve implantation: comparison of transfemoral and trans -apical approaches using Edwards 
Sapiens valve. Eur J Cardiothorac Surg. 2011.  
51. Drews T, Pasic M, Buz S, Unbehaun A, Dreysse S, Kukucka M, Mladenow A and Hetzer R. 
Transcranial Doppler Sound Detection of Cerebral Microembolism during Transapical Aortic Valve 
Implantation. Thorac Cardiovasc Surg . 2011;59:237- 42. 
52. Knipp SC. C2 -2 Cerebral ischemia and cognitive functioning after transapi cal minimally 
invasive aortic valve implantation. Paper presented at: European Society for Cardiovascular and Endovascular Surgery (ESCVS) International Congress; 2011; Moscow, Russia.  
53. Russell D. Cerebral microemboli and cognitive impairment. J Neurol Sci. 2002;203- 204:211-
4. 
54. Duffis EJ, Jones D, Tighe D and Moonis M. Neurological complications of coronary 
angiographic procedures. Expert Rev Cardiovasc Ther . 2007;5:1113- 21. 
55. Fearn SJ, Pole R, Wesnes K, Faragher EB, Hooper TL and McCollum CN. Cereb ral injury 
during cardiopulmonary bypass: emboli impair memory. J Thorac Cardiovasc Surg . 2001;121:1150-
60. 
56. Kidwell CS, Alger JR, Di Salle F, Starkman S, Villablanca P, Bentson J and Saver JL. 
Diffusion MRI in patients with transient ischemic attacks. Stroke . 1999;30:1174- 80. 
57. Choi SH, Na DL, Chung CS, Lee KH, Na DG and Adair JC. Diffusion- weighted MRI in 
vascular dementia. Neurology . 2000;54:83 -9. 
58. Cumming TB, Bernhardt J and Linden T. The montreal cognitive assessment: short cognitive 
evaluation in a large stroke trial. Stroke . 2011;42:2642- 4. 
59. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, 
Eberle R and Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. 
Stroke . 1989;20:864 -870. 
60. Tissue Plasminogen Activator for Acute Ischemic Stroke. New England Journal of Medicine. 
1995;333:1581 -1588.  
61. Adams HP, Jr., Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, Woolson RF and 
Hansen MD. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the 
Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology . 1999;53:126- 31. 
62. Chang KC, Tseng MC, Weng HH, Lin YH, Liou CW and Tan TY. Prediction of length of stay 
of first -ever ischemic  stroke. Stroke . 2002;33:2670- 4. 
63. Schlegel D, Kolb SJ, Luciano JM, Tovar JM, Cucchiara BL, Liebeskind DS and Kasner SE. 
Utility of the NIH Stroke Scale as a predictor of hospital disposition. Stroke . 2003;34:134 -7. 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
133 
 64. Siegler JE, Boehme AK, Kumar AD, Gillette MA, Albright KC and Martin- Schild S. What 
Change in the National Institutes of Health Stroke Scale Should Define Neurologic Deterioration in 
Acute Ischemic Stroke? Journal of stroke and cerebrovascular diseases : the official journal of 
National Stroke Association. 2013;22:675 -682. 
65. DeGraba TJ, Hallenbeck JM, Pettigrew KD, Dutka AJ and Kelly BJ. Progression in acute 
stroke: value of the initial NIH stroke scale score on patient stratification in future trials. Stroke . 
1999;30:1208 -12. 
66. Patel SC, Levine SR, Tilley BC and et al. Lack of clinical significance of early ischemic 
changes on computed tomography in acute stroke. Jama . 2001;286:2830 -2838.  
67. Johnston SC, Leira EC, Hansen MD and Adams HP, Jr. Early recovery after cerebral 
ischemia risk of subsequent neurological deterioration. Annals of neurology . 2003;54:439 -44. 
68. Aslanyan S, Weir CJ, Johnston SC and Lees KR. Poststroke neurological improvement 
within 7 days is associated with subsequent deterioration. Stroke . 2004;35:2165- 70. 
69. Kwan J and Hand P. Early neurological deterioration in acute stroke: clinical characteristics 
and impact on outcome. QJM : monthly journal of the Association of Physicians . 2006;99:625 -33. 
70. Roquer J, Rodriguez -Campello A, Gomis M, Jimenez -Conde J, Cuadrado- Godia E, Vivanco 
R, Giralt E, Sepulveda M, Pont -Sunyer C, Cucurella G and Ois A. Acute stroke unit care and early 
neurological deterioration in ischemic stroke. Journal of neurology . 2008;255:1012- 7. 
71. Toyoda K, Fujimoto S, Kamouchi M, Iida M and Okada Y. Acute Blood Pressure Levels and 
Neurological Deterioration in Different Subtypes of Ischemic Stroke. Stroke . 2009;40:2585 -2588.  
72. Wendt D, Kleinbongard P, Knipp S, Al -Rashid F, Gedik N, El Chilali K, Schweter S, 
Schlamann M, Kahlert P, Neuhauser M, Forsting M, Erbel R, Heusch G, Jakob H and Thielmann M. 
Intraaortic Protection From Embolization in Patients Undergoing Transaortic Transcatheter Aortic Valve Implantation. Ann Thorac Surg. 2015;100:686- 91. 
73. Van Mieghem NM, van Gils L, Ahmad H, van Kesteren F, van der Werf HW, Brueren G, 
Storm M, Lenzen M, Daemen J, van den Heuvel AF, Tonino P, Baan J, Koudstaal PJ, Schipper ME, 
van der Lugt A and de Jaegere PP. Filter -based cerebral embolic protection with transcatheter 
aortic valve implantation: the randomised MISTRAL -C trial. EuroIntervention : journal of EuroPCR in 
collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology . 2016;12:499 -507. 
74. Haussig S, Mangner N, Dwyer MG, Lehmkuhl L, Lucke C, Woitek F, Holzhey DM, Mohr FW, 
Gutberlet M, Zivadinov R, Schuler G and Linke A. Effect of a Cerebral Protection Device on Brain 
Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The CLEAN -TAVI Randomized Clinical Trial.  Jama . 2016;316:592 -601. 
75. Lansky AJ. The Keystone Deflector Device: Updates from the DEFLECT I Trial. Paper 
presented at: Transcatheter Cardiovascular Therapeutics; 2013; San Francisco, CA, USA.  
76. Bob-Manuel T, Sharma A, Nanda A, Ardeshna D, Skelton WP and Khouzam RN. A review of 
racial disparities in transcatheter aortic valve replacement (TAVR): accessibility, referrals and implantation. Annals of Translational Medicine. 2018;6. 
77. Pocock SJ, Ariti CA, Collier TJ and Wang D. The win ratio: a new approach to the analysis of 
composite endpoints in clinical trials based on clinical priorities. Eur Heart J . 2012;33:176 -82. 
78. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, 
Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es 
GA, Vranckx P, Webb JG, Windecker S and Serruys PW. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Journal of the American College of Cardiology . 2011;57:253 -69. 
79. Abdel -Wahab M, Mostafa AE, Geist V, Stocker B, Gordian K, Merten C, Richardt D, Toelg R 
and Richardt G. Comparison of outcomes in patients having isolated transcatheter aortic valve 
implantation versus combined with preprocedural percutaneous coronary intervention. Am J Cardiol. 
2012;109:581 -6. 
80. Buchanan GL, Chieffo A, Montorfano M, Maisano F, Latib A, Godino C, Cioni M, Gullace 
MA, Franco A, Gerli C, Alfieri O and Colombo A. The role of sex on VARC outcomes following 
transcatheter aortic valve implantation with both Edwards SAPIEN and Medtronic CoreValve 
ReValving System(R) devices: the Milan registry. EuroIntervention. 2011;7:556- 63. 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
134 
 81. D'Ascenzo F, Gonella A, Moretti C, Omede P, Salizzoni S, La Torre M, Giordana F, Barbanti 
M, Ussia GP, Brambilla N, Bedogni F, Gaita F, Tamburino C and Sheiban I. Gender differences in 
patients undergoing TAVI: a multicentre study. EuroIntervention. 2013;9:367- 72. 
82. Dubois C, Coosemans M, Rega F, Poortmans G, Belmans A, Adriaenssens T, Herregods 
MC, Goetschalckx K, Desmet W, Janssens S, Meyns B and Herijgers P. Prospective evaluation of 
clinical outcomes in all -comer high -risk patients with aortic valve stenosis undergoing medical 
treatment, transcatheter or surgical aortic valve implantation following heart team assessment. 
Interact Cardiovasc Thorac Surg . 2013;17:492 -500. 
83. van der Boon RM, Marcheix B, Tchetche D, Chieffo A, Van Mieghem NM, Dumonteil N, 
Vahdat O, Maisano F, Serruys PW, Kappetein AP, Fajadet J, Colombo A, Carrie D, van Domburg 
RT and de Jaegere PP. Transapical versus transfemoral aortic valve implantation: a multicenter collaborative study. Ann Thorac Surg. 2014;97:22 -8. 
84. Eltchaninoff H, Durand E, Borz B, Godin M, Tron C, Litzler PY, Bessou JP, Bejar K, Fraccaro 
C, Sanchez -Giron C, Dacher JN, Bauer F and Cribier A. Prospective analysis of 30- day safety and 
performance of transfemoral transcatheter aortic valve implantation with Edwards SAPIEN XT versus SAPIEN prostheses. Arch Cardi ovasc Dis. 2012;105:132- 40. 
85. Gurvitch R, Toggweiler S, Willson AB, Wijesinghe N, Cheung A, Wood DA, Ye J and Webb 
JG. Outcomes and complications of transcatheter aortic valve replacement using a balloon expandable valve according to the Valve Academic Research Consortium (VARC) guidelines. 
EuroIntervention. 2011;7:41- 8. 
86. Hammerer M, Schuler J, Altenberger J, Kraus J, Prinz E, Matzinger M, Pichler M and Heigert 
M. Rehospitalization rates after transcatheter aortic valve implantation. Wiener klinische 
Wochenschrift . 2012;124:45- 52. 
87. Hayashida K, Morice MC, Chevalier B, Hovasse T, Romano M, Garot P, Farge A, Donzeau-
Gouge P, Bouvier E, Cormier B and Lefevre T. Sex -related differences in clinical presentation and 
outcome of transcatheter aortic valve implantation for severe aortic stenosis. J Am Coll Cardiol. 
2012;59:566 -71. 
88. van der Boon RM, Nuis RJ, Benitez LM, Van Mieghem NM, Perez S, Cruz L, van Geuns RJ, 
Serruys PW, van Domburg RT, Dager AE and de Jaegere PP. Frequency, determinants and prognosti c implications of infectious complications after transcatheter aortic valve implantation. Am J 
Cardiol . 2013;112:104- 10. 
89. Scherner M, Madershahian N, Rosenkranz S, Slottosch I, Kuhn E, Langebartels G, Deppe 
A, Wippermann J, Choi YH, Strauch JT and Wahlers T. Transapical aortic valve implantation: 
experiences and survival analysis up to three years. J Card Surg . 2012;27:653- 61. 
90. Seiffert M, Schnabel R, Conradi L, Diemert P, Schirmer J, Koschyk D, Linder M, Kersten JF, 
Grosser A, Wilde S, Blankenberg S,  Reichenspurner H, Baldus S and Treede H. Predictors and 
outcomes after transcatheter aortic valve implantation using different approaches according to the valve academic research consortium definitions. Catheter Cardiovasc Interv . 2013;82:640- 52. 
91. Stahli BE, Bunzli R, Grunenfelder J, Buhler I, Felix C, Bettex D, Biaggi P, Tanner FC, 
Nguyen- Kim DL, Plass A, Ge H, Falk V, Luscher TF, Corti R, Maier W and Altwegg LA. 
Transcatheter aortic valve implantation (TAVI) outcome according to standardized endpoint 
definitions by the Valve Academic Research Consortium (VARC). J Invasive Cardiol . 2011;23:307-
12. 
92. Ussia GP, Barbanti M, Petronio AS, Tarantini G, Ettori F, Colombo A, Violini R, Ramondo A, 
Santoro G, Klugmann S, Bedogni F, Maisano F, Marzocchi A, Poli A, De Carlo M, Napodano M, 
Fiorina C, De Marco F, Antoniucci D, de Cillis E, Capodanno D and Tamburino C. Transcatheter 
aortic valve implantation: 3- year outcomes of self -expanding CoreValve prosthesis. Eur Heart J . 
2012.  
93. Wenaweser P, Pilgrim T, Guerios E, Stortecky S, Huber C, Khattab AA, Kadner A, 
Buellesfeld L, Gloekler S, Meier B, Carrel T and Windecker S. Impact of coronary artery disease 
and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis 
undergoing transcatheter aortic valve implantation. EuroIntervention. 2011;7:541- 8. 
94. Yamamoto M, Hayashida K, Mouillet G, Chevalier B, Meguro K, Watanabe Y, Dubois -Rande 
JL, Morice MC, Lefevre T and Teiger E. Renal function- based contrast dosing predicts acute kidney 
injury following transcatheter aortic valve implantation. JACC Cardiovasc Interv . 2013;6:479 -86. 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
135 
 95. Abramowitz Y, Banai S, Katz G, Steinvil A, Arbel Y, Havakuk O, Halkin A, Ben- Gal Y, Keren 
G and Finkelstein A. Comparison of early and late outcomes of TAVI alone compared to TAVI plus 
PCI in aortic stenosis patients with and without coronary artery disease. Catheter Cardiovasc Interv . 
2014;83:649 -54. 
96. Greif M, Lange P, Nabauer M, Schwarz F, Becker C, Schmitz C, Pohl T, D'Anastasi M, 
Boekstegers P, Massberg S and Kupatt C. Transcutaneous aortic valve replacement with the 
Edwards SAPIEN XT and Medtronic CoreValve prosthesis under fluoroscopic guidance and local 
anaesthesia only. Heart . 2014;100:691 -5. 
97. Sabate M, Canovas S, Garcia E, Hernandez Antolin R, Maroto L, Hernandez JM, Alonso 
Briales JH, Munoz Garcia AJ, Gutierrez -Ibanes E and Rodriguez -Roda J. In- hospital and Mid- term 
Predictors of Mortality After Transcatheter Aortic Valve Implantation: Data From the TAVI National 
Registry 2010- 2011. Revista espanola de cardiologia (English ed) . 2013;66:949- 58. 
98. D'Onofrio A, Salizzoni S, Agrifoglio M, Cota L, Luzi G, Tartara PM, Cresce GD, Aiello M, 
Savini C, Cassese M, Cerillo A, Punta G, Cioni M, Gabbieri D, Zanchettin C, Agostinelli A, Mazzaro 
E, Di Gregorio O, Gatti G, Faggian G, Filippini C, Rinaldi M and Gerosa G. Medium term outcomes 
of transapical aortic valve implantation: results from the italian registry of trans -apical aortic valve 
implantation. Ann Thorac Surg. 2013;96:830 -6. 
99. Tarantini G, Gasparetto  V, Napodano M, Frigo AC, Fraccaro C, Buja P, D'Onofrio A, 
D'Amico G, Barioli A, Baritussio A, Facchin M, Dariol G, Isabella G, Gerosa G and Iliceto S. Transcatheter aortic valve implantation and bleeding: Focus on Valve Academic Research 
Consortium -2 clas sification. Int J Cardiol . 2013.  
100. Chopard R, Meneveau N, Chocron S, Gilard M, Laskar M, Eltchaninoff H, Iung B, Leprince 
P, Teiger E, Chevreul K, Prat A, Lievre M, Leguerrier A, Donzeau- Gouge P, Fajadet J and Schiele 
F. Impact of chronic obstructive pulmonary disease on Valve Academic Research Consortium -
defined outcomes after transcatheter aortic valve implantation (from the FRANCE 2 Registry). Am J 
Cardiol . 2014;113:1543- 9. 
101. Conradi L, Seiffert M, Schirmer J, Koschyk D, Blankenberg S, Reichenspurner H, Diemert P 
and Treede H. Transapical transcatheter aortic valve implantation without prior balloon aortic valvuloplasty: feasible and safe. Eur J Cardiothorac Surg . 2013.  
102. Magri CJ, Chieffo A, Durante A, Latib A, Montorfano M, Maisano F, Cioni M, Agricola E, 
Covello RD, Gerli C, Franco A, Spagnolo P, Alfieri O and Colombo A. Impact of mean platelet 
volume on combined safety endpoint and vascular and bleeding complications following 
percutaneous transfemoral transcatheter aortic valve implantation. BioMed research international . 
2013;2013:645265. 
103. Seco M, Martinez G, Bannon PG, Cartwright BL, Adams M, Ng M, Wilson MK and Vallely 
MP. Transapical aortic valve implantation- an Australian experience. Heart Lung Circ . 2014;23:462 -
8. 
104. Giustino G, Sorrentino S, Mehran R, Faggioni M and Dangas G. Cerebral Embolic Protection 
During TAVR: A Clinical Event Meta -Analysis. Journal of the American College of Cardiology . 
2017;69:465 -466. 
105. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, Thourani VH, 
Babaliaros VC, Webb JG, Herrmann HC, Bavaria JE, Kodali S, Brown DL, Bowers B, Dewey TM, 
Svensson LG, Tuzcu M, Moses JW, Williams MR, Siegel RJ, Akin JJ, Anderson WN, Pocock S, 
Smith CR and Leon MB. Transcatheter Aortic -Valve Replacement f or Inoperable Severe Aortic 
Stenosis. New England Journal of Medicine. 2012;366:1696 -1704.  
106. Siontis GC, Juni P, Pilgrim T, Stortecky S, Bullesfeld L, Meier B, Wenaweser P and 
Windecker S. Predictors of permanent pacemaker implantation in patients with severe aortic 
stenosis undergoing TAVR: a meta -analysis. J Am Coll Cardiol. 2014;64:129- 40. 
107. Pugh RN, Murray -Lyon IM, Dawson JL, Pietroni MC and Williams R. Transection of the 
oesophagus for bleeding oesophageal varices. The British journal of surgery . 1973;60:646- 9. 
108. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I and Mitnitski A. A 
global clinical measure of fitness and frailty in elderly people. CMAJ : Canadian Medical Association 
journal = journal de l'Association medicale canadienne. 2005;173:489 -95. 
109. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ and van Gijn J. Interobserver 
agreement for the assessment of handicap in stroke patients. Stroke . 1988;19:604 -7. 
REFLECT – US IDE Trial [CIP -09 (v13.0)]         Keyston e Heart Ltd.  
136 
 110. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for 
diagnosis of diseases of the heart and great vessels.  9th ed. Boston, MA: Little, Brown & Co.; 1994. 
pp. 253 -256. 
111. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott 
TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, 
Mehran R, Rodes -Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW and Leon MB. 
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve 
Academic Research Consortium -2 consensus document. J Am Coll Cardiol. 2012;60:1438 -54. 
 
  
   
   
 
  
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
13716.5 Appendix V: Structured Interview for the Modified Rankin 
Scale  
Modified Rankin Scale  Structured Interview for the  
Modified Rankin Scale  
5=Severe disability : 
bedridden, incontinent, and 
requiring constant nursing 
care and attention  5=Severe disability; someone needs to be available at all times; 
care may be provided by either a trained or untrained caregiver.  
Question: Does the person require constant care? 
4=Modera tely severe 
disability : 
unable to walk without 
assistance, and unable to 
attend to own bodily needs 
without assistance  4=Moderately severe disability; need for assistance with some basic 
activities of daily living (ADL), but not requiring constant care.  
Question: Is assistance essential for eating, using the toilet, daily 
hygiene, or walking?  
3=Moderate disability : 
requiring some help, but 
able to walk without 
assistance 3=Moderate disability; need for assistance with some instrumental 
ADL but not basic AD L.  
Question: Is assistance essential for preparing a simple meal, doing 
household chores, looking after money, shopping, or traveling 
locally?  
2=Slight disability : 
unable to carry out all previous activities but able to look after own affairs 
without ass istance  2=Slight disability; limitations in participation in usual social roles, 
but independent for ADL.  
Questions: Has there been a change in the person’s ability to work 
or look after others if these were roles before stroke? Has there 
been a change in the person’s ability to participate in previous social 
and leisure activities? Has the person had problems with 
relationships or become isolated? 
1=No significant disability 
despite symptoms: 
able to carry out all usual 
duties and activities  1=No signifi cant disability; symptoms present but not other 
limitations.  
Question: Does the person have difficulty reading or writing, 
difficulty speaking or finding the right word, problems with balance 
or coordination, visual problems, numbness (face, arms, legs, 
hands, feet), loss of movement (face, arms, legs, hands, feet), 
difficulty with swallowing, or other symptom resulting from stroke?  
0=No symptoms at all  0=No symptoms at all; no limitations and no symptoms  
Sources : 
Modified Rankin Scale: van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Inter -observer 
agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604- 607. 
Structured Interview: Wilson JRL, Hareendran A, Grant M, Baird T, Schulz UGR, Muir KW, Bone I. Improving 
the assessment of outcomes in stroke: Use of a structured interview to assign grades on the Modified Rankin 
Scale. Stroke. 2002;33:2243 -2246.  
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
13816.6 Appendix V I: NIH Stroke Scale  
Note:  Additional copies of the NIH Stroke Scale are available on the Internet at the following 
web sites:  
•http://www.ninds.nih.gov/disorders/stroke/strokescales.htm
•http://stroke.nih.gov/resources/scale. htm
You may also call the US National Institute of Neurological Disorders and Stroke (NINDS) 
Brain Resources and Information Network at (800) 352-9424 to order hard copies. The NIH 
Stroke Scale is in the Public domain and may be copied and distributed without restriction.  
Patient Identification. ___ ___-___ ___ ___-___ ___ ___ 
     Pt. Date of Birth ___ ___/___ ___/___ ___ 
Hospital ________________________(___ ___-___ ___) 
Date of Exam ___ ___/___ ___/___ ___ 
Interval: [ ] Baseline [ ] 2 hours post treatment    [ ] 24 hours post ons et of symptoms ±20 minutes    [ ] 7-10 days          
[ ] 3 months [ ] Other ________________________________(___ ___) 
Time: ___ ___:___ ___   [ ]am   [ ]pm 
Person Administering Scale _____________________________________  
Administer stroke scale items in the order listed.  Record per formance in each category after each subscale exam.  Do not go 
back and change scores.  Follow directions pr ovided for each exam technique.  Scores should reflect what the patient does, not 
what the clinician thinks the patient can do.  The clinician should record answers while administering the exam and work quickl y. 
Except where indicated, the patient s hould not be coached (i.e., repeated requests to patient to make a special effort). 
Instructions   Scale Definition Score 
1a.  Level of Consciousness: The investigator must choose a 
response if a full evaluation is pr evented by such obstacles as an 
endotracheal tube, language barrier, orotracheal trauma/bandages.  A 
3 is scored only if the patient makes no movement (other than reflexive posturing) in response to  noxious stimulation.  0 =    Alert;  keenly responsive. 
 1 = Not alert; but arousable by minor stimulation to obey, 
answer, or respond. 
 2 = Not alert; requires repeated stimulation to attend, or is 
obtunded and requires strong or painful stimulation to 
make movements (not stereotyped). 
 3 = Responds only with reflex motor or autonomic effects or 
totally  unresponsive, flaccid, and areflexic. ______ 
1b.  LOC Questions:   The patient is asked the month and his/her age. 
The answer must be correct - there is  no partial credit for being close.  
Aphasic and stuporous patients w ho do not comprehend the questions 
will score 2.  Patients unable to speak because of endotracheal intubation, orotracheal trauma, severe dysarthria from any cause, 
language barrier, or any other problem not secondary to aphasia are 
given a 1.  It is important that only the initial answer be graded and that the examiner not "help" the patient  with verbal or non-verbal cues.  0 = Answers both questions correctly. 
 1 = Answers one question correctly. 
 2 = Answers neither question correctly.  ______ 
1c.  LOC Commands:   The patient is asked to open and close the 
eyes and then to grip and release the non-paretic hand.  Substitute another one step command if the hands cannot be used.  Credit is 
given if an unequivocal attempt is made but not completed due to 
weakness.  If the patient does not respond to command, the task should be demonstrated to him or her (pantomime), and the result 
scored (i.e., follows none, one or two commands).  Patients with 
trauma, amputation, or other phy sical impediments should be given 
suitable one-step commands.  Only the first attempt is scored.  0 = Performs  both tasks correctly. 
 1 = Performs  one task correctly. 
 2 = Performs  neither task correctly. ______ 
2. Best Gaze:   Only horizontal eye movements will be tested.
Voluntary or reflexive (oculocephalic) eye movements will be scored, but caloric testing is not done.  If the patient 
has a conjugate 
deviation of the eyes that can be ov ercome by voluntary or reflexive 
activity, the score will be 1.  If a patient has an isolated peripheral 
nerve paresis (CN III, IV or VI), score a 1.  Gaze is testable in all 
aphasic patients.  Patients with ocular trauma, bandages, pre-existing 
blindness, or other disorder of vis ual acuity or fields should be tested 
with reflexive movements, and a choice made by the investigator. 
Establishing eye contact and then mo ving about the patient from side 
to side will occasionally clarify t he presence of a partial gaze palsy.   0 = Normal.  
 1 = Partial gaze palsy; gaze is abnormal in one or both eyes, 
but forced deviation or total gaze paresis is not present. 
 2 = Forced deviation, or total gaze paresis not overcome by the 
oculocephalic maneuver. ______ 
Rev 10/1/2003 
Patient Identification. ___ ___-___ ___ ___-___ ___ ___ 
     Pt. Date of Birth ___ ___/___ ___/___ ___ 
Hospital ________________________(___ ___-___ ___) 
Date of Exam ___ ___/___ ___/___ ___ 
Interval: [ ] Baseline [ ] 2 hours post treatment    [ ] 24 hours post ons et of symptoms ±20 minutes    [ ] 7-10 days          
[ ] 3 months [ ] Other ________________________________(___ ___) 
3. Visual:   Visual fields (upper and lower quadrants) are tested by
confrontation, using finger counting or visual threat, as appropriate. 
Patients may
 be encouraged, but if they look at the side of the 
moving fingers appropriately, this can be scored as normal.  If there is 
unilateral blindness or enucleation, vi sual fields in the remaining eye 
are scored.  Score 1 only if a clear-cut asymmetry, including 
quadrantanopia, is found.  If patient is blind from any cause, score 3. Double simultaneous stimulation is perfo rmed at this point.  If there is 
extinction, patient receives a 1, and the results are used to respond to 
item 11.  0 = No visual loss.  
 1 = Partial hemianopia. 
 2 = Complete hemianopia.  
 3 = Bilateral hemianopia (blind including cortical blindness). ______ 
4. Facial Palsy:   Ask – or use pantomime to encourage – the patient
to show
 teeth or raise eyebrows and close eyes.  Score symmetry of 
grimace in response to noxious st
imuli in the poorly responsive or 
non-comprehending patient.  If faci al trauma/bandages, orotracheal 
tube, tape or other physical barriers obscure the face, these should be removed to the extent possible.  0 = Normal symmetrical movements. 
 1 = Minor paralysis (flattened nasolabial fold, asymmetry on 
smiling). 
 2 = Partial paralysis (total or near-total paralysis of lower 
face). 
 3 = Complete paralysis of one or both sides (absence of 
facial movement in the upper and lower face). ______ 
5. Motor Arm:  The limb is placed in the appropriate position: extendthe arms (palms down) 90 degrees  (if sitting) or 45 degrees (if 
supine). 
 Drift is scored if the arm falls before 10 seconds.  The 
aphasic patient is encouraged us ing urgency in the voice and 
pantomime, but not noxious stimulation.  Each limb is tested in turn, 
beginning with the non-paretic arm.  Only in the case of amputation or 
joint fusion at the shoulder, the exam iner should record the score as 
untestable (UN), and clearly write the explanation for this choice.   0 =  No drift;  limb holds 90 (or 45) degrees for full 10 seconds. 
  1 =  Drift; limb holds 90 (or 45) degrees, but drifts down before 
full 10 seconds; does not hit bed or other support. 
  2 =  Some effort against gravity;  limb cannot get to or 
maintain (if cued) 90 (or 45) degrees, drifts down to bed, 
but has some effort against gravity. 
  3 =  No effort against gravity;  limb falls. 
  4 =  No movement.   UN = Amputation or joint fusion, explain:  _____________________ 
 5a.  Left Arm   
 5b.  Right Arm   ______ 
______ 
6. Motor Leg:   The limb is placed in the appropriate position:  hold
the leg at 30 degrees (always tested supine).  Drift is scored if the leg 
falls before 5 seconds.  The aphas ic patient is encouraged using 
urgency  
in the voice and pantomime, but not noxious stimulation. 
Each limb is tested in turn, beginning with the non-paretic leg.  Only in the case of amputation or joint fusion at the hip, the examiner 
should record the score as untestable (UN), and clearly write the 
explanation for this choice.   0 =  No drift;  leg holds 30-degree position for full 5 seconds. 
  1 =  Drift; leg falls by the end of the 5-second period but does 
not hit bed.    
  2 =  Some effort against gravity;  leg falls to bed by 5 
seconds, but has some effort against gravity. 
  3 =  No effort against gravity; leg falls to bed immediately. 
  4 =  No movement.   UN = Amputation or joint fusion, explain: ________________ 
6a.  Left Leg  
6b.  Right Leg  ______ 
Rev 10/1/2003 
  
  
Patient Identification. ___ ___-___ ___ ___-___ ___ ___ 
 
     Pt. Date of Birth ___ ___/___ ___/___ ___ 
 
Hospital ________________________(___ ___-___ ___) 
 
Date of Exam ___ ___/___ ___/___ ___ 
 
            
Interval: [ ] Baseline [ ] 2 hours post treatment    [ ] 24 hours post ons et of symptoms ±20 minutes    [ ] 7-10 days          
 [ ] 3 months [ ] Other ________________________________(___ ___) 
 
______ 
7.  Limb Ataxia:   This item is aimed at finding evidence of a unilateral 
cerebellar lesion.  Test with eyes open.  In case of visual defect, 
ensure testing is done in intact vis ual field.  The finger-nose-finger 
and heel-shin tests are performed on both sides, and ataxia is scored only if present out of proportion to weakness.  Ataxia is absent in the patient who cannot understand or is paralyzed.  Only in the case of 
amputation or joint fusion, the examiner should record the score as 
untestable (UN), and clearly write the explanation for this choice.  In 
case of blindness, test by having the patient touch nose from 
extended arm position.  0 = Absent. 
 
 1 = Present in one limb.  
  2 = Present in two limbs.  
 
 UN = Amputation or joint fusion, explain:  ________________ 
     ______ 
 
  
 
8.  Sensory:   Sensation or grimace to pinprick when tested, or 
withdrawal from noxious stimulus  in the obtunded or aphasic patient.  
Only sensory loss attributed to st roke is scored as abnormal and the 
examiner should test as many body areas (arms [not hands], legs, 
trunk, face) as needed to accurately check for hemisensory loss.  A 
score of 2, “severe or total s ensory loss,” should only be given when 
a severe or total loss of sensation can be clearly demonstrated.  
Stuporous and aphasic patients will, therefore, probably score 1 or 0. 
The patient with brainstem stroke who has bilateral loss of sensation is scored 2.  If the patient does not respond and is quadriplegic, score 
2.  Patients in a coma (item 1a=3) are automatically given a 2 on this 
item.  0 = Normal;  no sensory loss. 
  1 = Mild-to-moderate sensory loss;  patient feels pinprick is 
less sharp or is dull on the affected side; or there is a 
loss of superficial pain with pi nprick, but patient is aware 
of being touched. 
  2 = Severe to total sensory loss;  patient is not aware of 
being touched in the face, arm, and leg.   
  
 
______ 
9.  Best Language:   A great deal of information about comprehension 
will be obtained during the preceding se ctions of the examination.  
For this scale item, the patient is asked to describe what is happening in the attached picture, to name the items on the attached naming 
sheet and to read from the attached list of sentences.  
Comprehension is judged from responses  here, as well as to all of 
the commands in the preceding general  neurological exam.  If visual 
loss interferes with the tests, ask the patient to identify objects placed in the hand, repeat, and produce speech.  The intubated patient should be asked to write. The patient in a coma (item 1a=3) will 
automatically score 3 on this item.  The examiner must choose a 
score for the patient with stupor or limited cooperation, but a score of 3 should be used only if the patient is mute and follows no one-step 
commands.  0 = No aphasia;  normal. 
 
 1 =  Mild-to-moderate aphasia;  some obvious loss of fluency 
or facility of comprehension, without significant 
limitation on ideas expressed or form of expression.  
Reduction of speech and/or comprehension, however, 
makes conversation about prov ided materials difficult 
or impossible.  For example, in conversation about 
provided materials, examiner  can identify picture or 
naming card content from patient’s response. 
  2 = Severe aphasia;  all communication is through fragmentary 
expression; great need for inference, questioning, and guessing 
by the listener.  Range of information that can be exchanged is 
limited; listener carries burden of communication.  Examiner cannot identify materials prov ided from patient response. 
  3 = Mute, global aphasia;  no usable speech or auditory 
comprehension.  
 
  
 
  
 
 ______ 
10.  Dysarthria:  If patient is thought to be normal, an adequate 
sample of speech must be obtained by asking patient to read or repeat words from the attached list.  If the patient has severe aphasia, the clarity of articulation of spontaneous speech can be 
rated.  Only if the patient is intubated or has other physical barriers to 
producing speech, the examiner should record the score as 
untestable (UN), and clearly write an explanation for this choice.  Do 
not tell the patient why he or she is being tested.  0 = Normal. 
 1 = Mild-to-moderate dysarthria;  patient slurs at least some 
words and, at worst, can be understood with some 
difficulty. 
 2 = Severe dysarthria; patient's speech is so slurred as to be 
unintelligible in the absence of or out of proportion to any dysphasia, or is mute/anarthric. 
UN = Intubated  or other physical barrier, 
explain:_____________________________  
 
 ______ 
 
Rev 10/1/2003 
Patient Identification. ___ ___-___ ___ ___-___ ___ ___ 
     Pt. Date of Birth ___ ___/___ ___/___ ___ 
Hospital ________________________(___ ___-___ ___) 
Date of Exam ___ ___/___ ___/___ ___ 
Interval: [ ] Baseline [ ] 2 hours post treatment    [ ] 24 hours post ons et of symptoms ±20 minutes    [ ] 7-10 days          
[ ] 3 months [ ] Other ________________________________(___ ___) 
11. Extinction and Inattention (formerly Neglect):   Sufficient
information to identify neglect may be obtained during the prior 
testing.  If the patient has a seve re visual loss preventing visual 
double 
simultaneous stimulation, and the cutaneous stimuli are 
normal, the score is normal.  If the patient has aphasia but does appear to attend to both sides, the score is normal.  The presence of 
visual spatial neglect or anosagnosia may also be taken as evidence of abnormality.  Since the abnormality is scored only if present, the 
item is never untestable.    0 = No abnormality. 
 1 = Visual, tactile, auditory, spatial, or personal inattention  
or extinction to bilateral simultaneous stimulation in one 
of the sensory modalities. 
 2 = Profound hemi-inattention or extinction to more than 
one modality; does not recognize own hand or orients 
to only one side of space. ______ 
______ 
______ 
Rev 10/1/2003 
You know how. 
Down to earth. 
I got home from work. 
Near the table in the dining 
room. 
They heard him speak on the 
radio last night. 
MAMA 
TIP – TOP 
FIFTY – FIFTY 
THANKS 
HUCKLEBERRY 
BASEBALL PLAYER  
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
14716.7 Appendix VII: Neuro psychological Test Battery 
Note:  Instructions and score sheet forms for the components of the Neuropsychological 
Test Battery are provided below. Please refer to the Neuropsychological Battery Manual of 
Operations for additional information.  
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is administered as a component of the Neuropsychological Test Battery. The RBANS test is 
copyright NCS Pearson, Inc., and is licensed for use in this trial; authorized copies, alternate versions, and translations will be provided as required. It is provided below for 
informational purposes.  
The Trail  Making Tests Parts A and B are administered as a component of the 
Neuropsychological Test Battery. The test forms are in the public domain and are provided 
below for informational purposes. Administration instructions are licensed for use in this trial  
and will be provided as required, along with additional test forms.  
-
Name------------------ Age ___ Sex ___ Education Level ____ _ 
Examiner __________________ Date ofTesting _____ Ethnicity _____ _ 
--- -- -,- • - - -1 
Immediate · Visuospatial/ 1 l 1 Att t• 1 Delayed . anguage 1 en ron 1 
Memory 1 __ _ _ __ 1 _ Memory , 
Index Score 
Confidence 
Interval __ % 
Percentile 
Percentile Total Scale 
Index Score Rank Index Score 
160 >99.9 160 
155 >99.9 155 
150 >99.9 150 
145 99.9 145 
140 99.6 140 
135 99 135 
130 98 130 
125 95 125 
120 91 120 
115 84 115 
110 75 110 
105 63 105 
100 50 100 
95 37 95 
90 25 90 
85 16 85 
80 9 80 
75 5 75 
70 2 70 
65 65 
60 0.4 60 
55 0.1 55 
50 <0.1 50 
45 <0.1 45 
40 <0.1 40 
Observations: 
PEARSON Copyright© 1998, 2012 NCS Pearson, Inc. All rights reserved. 0 
7 8 9 10 11 12 A 8 C D E Product Number 0158007212 
List Learning 
Trial1 
Say I am going to read you a list of words. I want you to listen carefully and, when I finish, repeat back as 
many words as you can. You don't have to say them in the same order that I do-just repeat back as 
many words as you can remember, in any order. Okay? 
Trials 2-4 
Say I am going to read the list again. When I finish, repeat back as many words as you can, even if you have 
already said them before. Okay? 
Record responses in order. 
Scoring: l point for each word correctly recalled on each trial. 
List 
Market 
Package 
Elbow 
Apple 
Story 
Carpet 
Bubble 
Highway 
Saddle 
Powder 
Number 
Correct Triall Trial2 
+ Trial3 Trial4 
+ + -
Total Triall Total Trial 2 Total Trial 3 Total Trial4 Total Score 
Range=0-40 
PEARSON PsychCorp is an imprint of Pearson Clinical Assessment. 
Pearson Executive Office 5601 Green Valley Drive Bloomington, MN 55437 
800.627.7271 www.PsychCorp.com 
Copyright© 1998, 2012 NCS Pearson, Inc. All rights reserved. 
Warning: No part of this publication may be reproduced or transmitted in any form or by any means, electronic or 
mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing 
from the copyright owner. 
Pearson, the PSI logo, PsychCorp, and RBANS are trademarks in ti"e U.S. and/or other countries of Pearson Education, 
Inc., or its affiliate(s). 
The Line Orientation portion of the RBANS is adapted from "The Judgment of Line Orientation" by Dr. Arthur Benton, 
under license from and reprinted with permission of Psychological Assessment Resources, Inc. 
Printed in the United States of America. 
Story I'V1emory 
Triall 
Say 1 am going to read you a short story. I'd like you to listen carefully and, when I finish, repeat back as much 
of the story as you can remember. Try and use the same wording, if you can. Okay? 
Read the story below, then say Now repeat back as much of that story as you can. 
Trial2 
Say I am going to read that same story again. When I finish, I want you to again repeat back as much of the 
story as you can remember. Try to repeat it as exactly as you can. 
Read the story below, then say Now repeat back as much of that story as you can. 
Scoring: l point for verbatim recall of bold, italic words or alternatives, shown below in color within parentheses. Record intrusions or variations in 
the Responses column. 
Trial1 Trial2 Item Score Story Trial1 Responses Score Trial 2 Responses Score (0-2) (0 or 1) (0 or 1) 
1. On Tuesday, 
2.May 
3. Fourth, 
4. in Cleveland, Ohio, 
5. a3alarm 
6. fire broke out. 
7. Two 
8. hotels 
9. and a restaurant 
10. were destroyed 
11. before the firefighters (firemen) 
12. were able to extinguish it 
(put it out). 
Total Score 
(Trial1 + Trial2) 
Range=0-24 
·-
Figure Copy • Time 4 minutes 
Fold this page back and present the Figure Copy Drawing Page along with stimulus. Ask the examinee to 
make an exact copy of the figure. Tell the examinee that he or she is being timed, but that the score is based only 
on the exactness of his or her copy. 
Scoring: l point for correctness and completeness (drawing), and l point for proper placement. See Appendix lin Stimulus Booklet A for complete 
scoring criteria and scoring examples. 
Item Drawing Placemen Score 
(Oorl) (Oorl) (0, 1, or2) 
l. rectangle 
2. diagonal cross 
3. horizontal line 
4. circle 
5. 3 small circles 
6. square 
7. curving line 
8. outside cross 
9. triangle 
-
10. arrow 
Total Score 
Range=0-20 Figure Copy Criteria 
(Fold back for use.) 
Scoring Criteria 
Drawing: lines are unbroken and straight; angles 90 degrees; top/bottom lines 25% longer than sides 
Placement: not rotated more than 15 degrees 
Drawing: lines are unbroken and straight and should approximately bisect each other 
Placement: ends of lines should meet comers of the rectangle without significant overlap or measurable 
distance between the ends of the lines and the comers 
Drawing: line is unbroken and straight; should not exceed 1/2 the length of the rectangle 
Placement: should bisect left side of the rectangle at approximately a right angle and intersect the 
diagonal cross 
Drawing: round, unbroken and closed; diameter should be approximately 1/4-1/3 height of rectangle 
Placement: placed in appropriate segment; not touching any other part of figure 
Drawing: round, unbroken and closed; equal size; triangular arrangement; not touching each other 
Placement: in appropriate segment; not touching figure; triangle formed not rotated more than 15 degrees 
Drawing: must be closed; 90 degree angles; lines straight and unbroken; height is 1/4-1/3 height of rectangle 
Placement: in appropriate segment; not touching any other part of figure; not rotated more than 15 degrees 
Drawing: 2 curved segments are approximately equal in length and symmetrical; correct direction of curves 
Placement: ends of line touch diagonal; do not touch comer of rectangle or intersection of diagonal lines 
Drawing: vertical line of the outside cross is parallel to side of rectangle; > 1/2 the heifht of rectangle; 
horizontal line crosses vertical at 90 degree angle and is between 20-50% of length o vertical line 
Placement: horizontal line of outside cross touches rectangle higher than 2/3 the height of rectangle, but 
below top; does not penetrate the rectangle 
Drawing: angle formed by 2 sides of triangle is between 60-100 degrees; sides are straight, unbroken 
and meet in a point; distance on vertical side of rectangle subsumed by triangle is approximately 50% of the 
height of vertical side 
Placement: roughly centered on the left vertical side of the rectangle 
Drawing: straight and unbroken; lines forming arrow are approximately equal in length and not more than 
l/3 length of staff 
Placement: must protrude from appropriate comer of rectangle such that staff appears to be continuation 
of diagonal cross 
Figure Copy Dra\\Jing Page 
(Fold back for use.) 
line Orientation • Time Limit: 20 seconds/item 
Present the sample item, and say These two lines down here (indicate) match two of the lines on top. Can you tell 
me the numbers, or point to the lines that they match? Correct any errors and make sure the examinee understands 
the task. Continue with Items 1-10. 
Scoring: l point for each line correctly identified. 
Item Responses Correct Score 
Responses (0, l, or 2) 
6. 1,6 
1. 7. 3,10 
2. 4, 11 8. 5,8 
3. 6,9 9. 1, 3 
10. 11,13 
5. Total Score 
Range=0-20 
Picture Naming Timelimit:20seconds/item 
Ask the examinee to name each picture. Give the semantic cue only if the picture is obviously misperceived. 
Scoring: l point for each item that is correctly named spontaneously or following semantic cue. 
Item Semantic Cue Responses Score 
(0 or l) 
l. chair a piece of furniture 
2. pencil used for writing 
3. well you get water from it 
4. giraffe an animal 
5. sailboat used on the water (if "boat," query "what kind") 
6. cannon a weapon, used in war 
7. pliers a tool 
8. trumpet a musical instrument ("comet" okay) 
9. clothespin used to hold laundry on a line 
10. kite its flown in the air 
Total Score 
Range=0-10 
Semantic Fluency Time Limit: 60 seconds 
Say Now I'd like you to tell me the names of all of the different kinds of fruits and vegetables that 
you can think of. I'll give you one minute to come up with as many as you can. Ready? 
Scoring: l point for each correct response. 
l. 11. 
2. 12. 
3. 13. 
4. 14. 
5. 15. 
6. 16. 
7. 17. 
8. 18. 
9. 19. 
10. 20. 
Digit Span 21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 31. --------
32. --------
33. --------
34. --------
35. --------
36. --------
37. --------
38. --------
39. --------
40. --------
Total Score D 
Range=0-40 
Say I am going to say some numbers, and I want you to repeat them after me. Okay? 
Read the numbers at the rate of 1 per second. Only read the second string in each set if the first string was failed. 
Discontinue after failure of both strings in any set. 
Scoring: 2 points for the first string correct, l point for the second string correct, and 0 points for both strings failed. 
Item First String String Score Second String String Score Item Score 
(0 or 2) (0 or l) (0-2) 
l. 4-9 5-3 
2. 8-3-5 2-4-1 
3. 7-2-4-6 1-6-3-8 
4. 5-3-9-2-4 3-8-4-9-1 
5. 6-4-2-9-3-5 9-1-5-3-7-6 
6. 2-8-5-1-9-3-7 5-3-1-7-4-9-2 
7. 8-3-7-9-5-2-4-1 9-5-1-4-2-7-3-8 
8. 1-5-9-2-3-8-7-4-6 5-1-9-7-6-2-3-6-5 
Total Score 
Range=0-16 
II Coding Time Limit: 90 seconds 
Say Look at these boxes (indicate key). For each one of these marks there is a number that goes with it. Down 
here there are marks, but no numbers. I want you to fill in the number that goes with each mark. 
Demonstrate the first three. Say Now I would like you to fill in the rest of these boxes up to the double lines 
(indicate) for practice. Correct any errors as they are made. Make sure that the examinee understands the task and 
has correctly completed the sample items before you begin timing. 
Say Now 1 would like you to continue to fill in the numbers that match the marks. Go as quickly as you can 
without skipping any. When you reach the end of the line, go on to the next one. Ready? Go ahead. 
Redirect the examinee to the task if he or she becomes distracted. If the examinee is unable to comprehend the 
task, the subtest score is 0. 
Scoring: l point for each item correctly coded within 90 seconds (do not score the sample items). 
Note: Familiarize yourself with these instructions before administering this subtest. 
Total Score 
Range=0-89 
Q ListRecan 
Say Do you remember the list of words that I read to you in the beginning? Tell me as many of those words as 
you can remember now. 
Scoring: l point for each word correctly recalled. 
List Response Score 
(Do not read.) (0 or 1) 
Market 
Package 
Elbow 
Apple 
Story •. 
Carpet 
Bubble 
Highway 
Saddle 
Powder 
Total Score 
Range=0-10 
II!J List Recognition 
Say I'm going to read you some words. Some of these words were on that list, and some of them weren't. I want 
you to tell me which words were on the list. For each word, ask Was on the list? 
Scoring: l point for each word correctly identified. Circle the letter corresponding to examinees response (y =yes, n =no); bold, capitalized (Y, N) 
letter indicates correct response. 
List Circle One List Circle One List Circle One List Circle One 
1. Apple y n 6. sailor y N 11. Bubble y n 16. Saddle y n 
2. honey y N 7. velvet y N 12. prairie y N 17. Powder y n 
3. Market y n 8. Carpet y n 13. Highway y n 18. angel y N 
4. Story y n 9. valley y N 14. oyster y N 19. Package y n 
5. fabric y N 10. Elbow y n 15. student y N 20. meadow y N 
Total Score 
Range=0-20 
m Story Recall 
Say Do you remember that story about a fire that I read to you earlier? Tell me as many details from the 
story as you can remember now. 
Scoring: 1 point for each verbatim recall of bold, italic words or alternatives, shown below in color within parentheses. Record intrusions or variations 
in the Responses column. 
Story (Do not read.) Responses Item Score 
(0 or l) 
1. On Tuesday, 
2. May 
3. Fourth, 
4. in Cleveland, Ohio, 
5. a3alarm 
6. fire broke out. 
7. Two ' 
8. hotels 
9. and a restaurant 
10. were destroyed 
11. before the firefighters (firemen) 
12. were able to extinguish it (put it out). 
Total Score 
Range=0-12 
m Figure Recall 
Say Do you remember that figure that I had you copy? I want you to draw as much of it as you can remember now. 
If you remember a part, but you're not sure where it goes, put it anywhere. Try to draw as much of it as you can. 
Now, present the Figure Recall Drawing Page. 
Scoring: l point for correctness and completeness (drawing), and l point for proper placement. See Appendix lin Stimulus Booklet A for complete 
scoring criteria and scoring examples. 
Item Drawing Placement Score 
(Oar l) (0 or l) (0, 1, or2) 
l. rectangle 
2. diagonal cross 
3. horizontal line 
4. circle 
5. 3 small circles 
6. square 
7. curving line 
8. outside cross 
9. triangle 
10. arrow 
Total Score 
Range=0-20 Figure Recall Criteria 
(Fold back for use.) 
Scoring Criteria 
Drawing: lines are unbroken and straight; angles 90 degrees; top/bottom lines 25% longer than sides 
Placement: not rotated more than 15 degrees 
Drawing: lines are unbroken and straight and should approximately bisect each other 
Placement: ends of lines should meet comers of the rectangle without significant overlap or measurable 
distance between the ends of the lines and the comers 
Drawing: line is unbroken and straight; should not exceed 1/2 the length of the rectangle 
Placement: should bisect left side of the rectangle at approximately a right angle and intersect the diagonal cross 
Drawing: round, unbroken and closed; diameter should be approximately l/4-1/3 height of rectangle 
Placement: placed in appropriate segment; not touching any other part of figure 
Drawing: round, unbroken and closed; equal size; triangular arrangement; not touching each other 
Placement: in appropriate segment; not touching figure; triangle formed not rotated more than 15 degrees 
Drawing: must be closed; 90 degree angles; lines straight and unbroken; height is l/4-1/3 height of rectangle 
Placement: in appropriate segment; not touching any other part of figure; not rotated more than 15 degrees 
Drawing: 2 curved segments are approximately equal in length and symmetrical; correct direction of curves 
Placement: ends of line touch diagonal; do not touch comer of rectangle or intersection of diagonal lines 
Drawing: vertical line of the outside cross is parallel to side of rectangle; > 112 the heifht of rectangle; 
horizontal line crosses vertical at 90 degree angle and is between 20-50% of length o vertical line 
Placement: horizontal line of outside cross touches rectangle higher than 2/3 the height of rectangle, but 
below top; does not penetrate the rectangle 
Drawing: angle formed by 2 sides of triangle is between 60-100 degrees; sides are straight, unbroken 
and meet in a point; distance on vertical side of rectangle subsumed by triangle is approximately 50% of the 
height of vertical side 
Placement: roughly centered on the left vertical side of the rectangle 
Drawing: straight and unbroken; lines forming arrow are approximately equal in length and not more than 
1/3 length of staff 
Placement: must protrude from appropriate comer of rectangle such that staff appears to be continuation 
of diagonal cross 
Figure Recall Drawing Page 
(Fold back for use.) 
Score Conversion Page 
Total 
Score 
I. Immediate Memory 
1. List Learning 
2. Story Memory 
11. (+) 
3. Figure Copy 
1-------1 > 
4. Line Orientation 
Ill. Language 
5. Picture Naming > 6. Semantic Fluency 
IV. Attention (+) 
7. Digit Span > 8. Coding 
·Merri-C:rv- c •· 
' ,::, - " --. .. . -_. ... : ·-· -r·------------ • . I 
I 
9. List Recall 
I I 
1 0. List Recognition D 
I I 
I I 
11. Story Recall 
I I ,. ___________ -4 
I I 
I I 
I I 
I I 12. Figure Recall 
Sum of Total Scores for 101 
Subtests 9 + 11 + 12 = 
Note. Use Appendix 2 in the 
Stimulus Booklet to convert 
Total Scores to Index Scores 
and Sum of Index Scores to 
Total Scale. Subtest scaled 
scores and cumulative per-
centages are also available. (=) 
Sum of Index Scores D 
(light-colored boxes) 
TOTAL SCALE D . - -.. :----, 
. ·' '. . l ' ' 
D 
D 
Supplemental Discrepancy Analysis Page 
Index Differences 
Statistical Frequency of 
Score 1-Score 2 Score 1 Score 2 Difference Significance Difference in 
Standardization --Level Sample 
Immediate Memory-Visuospatiai/Constructional 
Immediate Memory-Attention 
Immediate Memory-Language 
Immediate Memory-Delayed Memory 
Immediate Memory-Total Scale 
Visuospatiai/Constructionai-Attention 
Visuospatiai/Constructionai-Language 
Visuospatiai/Constructionai-Delayed Memory 
Visuospatiai/Constructional- Total Scale 
Attention-Language 
Attention-Delayed Memory 
Attention-Total Scale 
Language-Delayed Memory 
Language-Total Scale 
Delayed Memory-Total Scale 
c -_j 'V + j_ 1- -
1 2 3 4 5 6 7 8 9 
SAMPLE. ________ _ 
- 1-c + _j j_ 'V -1-A + - -
j_ 'V 1--c + _j j_ c + _j -
1-A -'V c _j + j_ - A 1-c - -
+ c 1-_j - 1-+ A c _j j_ + 1- -
c + 1- A - j_ _j c -+ v j_ A ·- -
A -_j 1-+ 'V j_ _j A v j_ c _j -
+ c _j -c + j_ 'V _j A - - -
I
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
16816.8 Appendix VIII : Angiographic Imaging Acquisition Guidelines  
REFLECT TRIAL  
Angiographic Acquisition Guidelines 
 All angiograms should be obtained paying strict attention to the following features:  
1.Acquire  all standard procedural fluoroscopic/ angiograms in DICOM format  at the
highest magnification which will still incorporate the entire segment of the aortic arch
and the ostia of the 3 major cerebral vessel takeoffs (innominate, left carotid and leftsubcla vian).
2.All images should have subject identifiers removed prior to uploading images to theweb-based image transfer system. Imaging studies should be appropriately labeled
with Study Name, site ID, subject ID and date that the imaging study was performed.
3.Submit  the best LAO projection for  assessment of the Aortic Arch and the 3 major
cerebral vessel takeoffs (innominate, left carotid and left subclavian) . If renal
dysfunction or other clinical concerns limit contrast administration, angiogr aphy of the
innominate artery alone is sufficient. All subsequent fluor oscopic/angiographic images
should be taken using the same LAO projection that was used for the initialassessment.
4.Submit  f
luoroscopic images  using the initial arch projection  to document proper dev ice
positioning at the following recommended time points:
•After  deployment of the TriGuard™ HDH or TriGUARD 3, angiography of the
device and the entire arch is strongly recommended and can be done during or
after pigtail placement .
•Tracking of the TAVR del ivery system to the aortic annulus
•Final deployment of the first prosthetic valve
•Removal of the TAVR delivery system  (after any additional post -dilatation or
additional valve implantations have been completed)
•If the position of the TriGuard™ HDH or TriGUARD 3 is perceived to have
changed during the procedure, repeat arch assessment with contrast is stronglyrecommended.
5.Provide a plain, non- contrast image of any device complication  or malfunction
observed during the procedure.
PLEASE TRY TO INCLUDE IN YOUR SUBMISSION:  
1.Cath Lab Procedure Log or Technician’s Worksheet Form (Please keep a copy ofthe original). This may be scanned and emailed to the Angiographic Core Laboratorycontact at the email address below :
Phase I:  Ecaterina Cristea, MD  
Yale Angiographic Core Laboratory  
ecaterina.cristea@yale.edu   
Phase II:  Ivana Jankovic, MD  
CRF Core Lab Operations  
ijankovic@crf.org   
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
1692.Proced
ural films. Angiographic and fluorosc opic imaging studies will be uploaded by
the site to a web- based imaging media transfer system (Intelemage®, LLC,
Cincinna ti, OH USA).
Phase I:  Yale Angiographic Core Lab Contact: 
Ecaterina Cristea, MD  
YALE CARDIOVASCULAR RESEARCH GROUP  
REFLECT TRIAL  
Yale Angiographic Core Laboratory  
Yale University School of Medicine  
135 College Street, Suite 101  
New Haven, CT 06510  
(203) 737- 2275 (Office)  
(203) 737- 7457 (Office Fax)  
ecaterina.cristea@yale.edu   
Phase II:  Cardiovascular Research Foundation Core Lab Contact:  
Ivana Jankovic, MD  
Director, Core Lab Operations  
Cardiovascular Research Foundation  
Clinical Trials Center  
1700 Broadway, 9th Floor  
New York, NY 10019  
Tel: (646) 434- 4388 
Fax: (646) 434- 4711  
ijankovic@crf.org    
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
17016.9 Appendix IX: Magnetic Resonance Imaging Acquisition 
Protocol  
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
18216.10  Appendix X: CT Angiography Imaging Acquisition Guidelines  
CTA Acquisition Guidelines (CIP-09-2 ver  03)   Confidential Page 2 The REFLECT  Trial
Computed Tomography (CT) Angiography  
Acquisition Guidelines  
These acquisition  guidelines are  confidential and proprietary and
meant to accompany the Keystone Heart REFLECT  Clinical
Investigational Plan. Any copying or distribution of this document
outside of the purposes of the REFLECT  Study are prohibited
without the express permission of Keystone Heart Ltd .
CTA Acquisition Guidelines (CIP-09-2 ver  03)   Confidential    Page 3 
 Table of Contents  
1.0 BACKGROUND  4 
2.0 EQUIPMENT  4 
3.0 SCANS  4 
4.0 SCANNING PROCEDURES  4 
4.1 STEP 1: PATIENT PREPARATION  4 
4.2 STEP 2: CHEST TOPOGRAM  5 
4.3 STEP 3: PROSPECTIVE ECG -GATED NON -CONTRAST SCAN OF AOR TIC ROOT  5 
4.4 STEP 4: ECG -GATED CONTRAST ENHAN CED SCAN OF THE AORT IC ROOT AND 
THORACIC AORTA , AND NON -ECG  GATED CONTRAST ENHA NCED SCAN OF 
ABDOMINAL AORTA AND PERIPHERAL VESSELS  5 
4.4.1  EXAMPLE CONTRAST ENHANCED SCAN ACQUISITION PROCEDURE  6 
4.4.2  EXAMPLE POST-PROCESSING PROCEDURE  6 
4.5 STEP 5: SUBMISSION OF CT DATA  6 
 
 
 
 
 
 
 
 
 
  
CTA Acquisition Guidelines (CIP-09-2 ver  03)   Confidential Page 4 1.0 Background
Cardiac Multi -Detector  Computed Tomographic Angiography (Cardiac M DCT Angiography)
is intended to evaluate aortic valve anatomy, aortic root dimensions for prosthetic valve
sizing, and assessment of the aorta  and peripheral vessel s for anatomy and disease burden.
The CT scan results will be used for assessment of the aort ic arch for compliance with
positioning of Keystone Heart TriGuard ™ as well as planning the best fluoroscopy angle for 
the procedure.  Assessment of the ileo -femoral arteries will indicate if the peripheral arteries
anatomy can accommodate the TriGuard  delivery system.
2.0 Equipment 
•Multi -detector CT scanner (64 -slice minimum) with ECG -gating capability.
oThe scans  submitted for analysis of the aortic root should be ECG -gated ; non-
gated scans in areas with cardiac motion lead to measurement inaccuracy  and
therefore incomplete information for device selection .
oAbdominal aorta and p eripheral vessel image acquisition may be non -gated .
•Dual-source scanner pr eferred due to enhanced temporal resolution and reduced
motion artifacts.
3.0 Scans 
1)Chest Topogram .
2)Prospective ECG -gated non -contrast scan of aortic  root and thoracic aorta .
3)Retrospective ECG -gated contrast enhanced scan of the aortic root  and thoracic aorta,
immediately followed by n on ECG -gated contrast enhanced scan of the abdominal
aorta and periphe ral vessels .*
*If CT scanner is incapable of sequential ECG -gated to non -ECG gated scan, the contrast
enhanced CT study can be performed using retrospective ECG -gating in its entirety.
4.0 Scanning Procedures
The optimal scan is similar to a coronary calcium score scan followed by a CT coronary
angiogram  / aortogram . The aim is to first evaluate the degree of calcification in the aortic
valve, and then to obtain adequate contrast in the following region s of interest: endo -luminal
surface for v isualization of left heart, aorta, and peripheral access vessels (i.e., femoral
arteries ). Temporal resolution should be optimized to reduce motion artifact. Spatial
resolution should be as high as possible (goal is smallest isotropic voxel size).
4.1 Step  1: Patient Preparation
•Administer medication per institution standard practice for CT scanning.
•Attach ECG electrodes for gating of scan. Verify quality of ECG tracing on scanner
console.
•Prepare intravenous line for administration of contrast media.
•Assess heart rate variability during breath -hold.
CTA Acquisition Guidelines (CIP-09-2 ver  03)   Confidential Page 5 4.2 Step 2: Chest Topogram
•A chest topogram can be used to plan subsequent imaging.
Figure CTA -1: Example image of chest topogram
4.3 Step 3:  Prospective ECG -gated non -contrast scan of aortic root
The aim of this scan is to quantify the extent of calcium in the aortic valve  and aorta,
equivalent to scans calculating a coronary calcium score  (e.g. Aga tston score) .
1.The submitted scan should cover the area  from the temporal -mandibular -joint (TMJ)
to the diaphragm  to encompass the entire heart, aortic arch and thoracic aorta.
2.Prospective ECG -gating  with sequential slice acquisition is preferred .
3.Scan at p eak voltage of 120kVp with tube current of 14 0-150 mAs tube current .
4.Slice thickness 2.5 -3.0 mm with a pitch of 1 .
4.4 Step 4: ECG -gated contrast enhanced scan of the aortic root  and thoracic
aorta, and non-ECG gated contrast enhanced scan of abdominal aorta and
peripheral vessels
The aim of this scan is to assess the anatomy of the aortic root , aortic arch and cerebral
vessels, thoracic / abdominal aorta, and peripheral vessels  (please refer to Table 1 below for
suggested parameters) .

CTA Acquisition Guidelines (CIP-09-2 ver  03)   Confidential Page 6 1.The optimal scan  would include  the area from the temporal -mandibular -joint (TMJ) to
the mid-thigh , using  dynamic 4D acquisition and retrospective ECG -gating  from the
TMJ to the diaphragm (to evaluate the aortic root, aortic arch, cerebral vessels and
thoracic aorta), followed by a non -ECG -gated scan from the diaphragm to the mid -
thigh (to evaluate the abdomi nal aorta and peripheral vessels). If a sequential ECG -
gated/non -ECG gated study is not available , the entire study could be performed using
retrospective ECG -gating.
2.Detector collimation is 0.4 -0.625mm.
3.Slice thickness is ≤ 0.8mm.
4.Peak voltage of 120kVp w ith tube current from 350 -550 mAs per scanner protocol for
patient body mass index.
4.4.1  Example Contrast Enhanced Scan  Acquisition Procedure
•Prepare iodinated contrast injection apparatus ( suggested  scan parameters are
provided in Table 1).
•Ensure availability of immediate treatments in case of contrast allergy.
•Set up scan parameters.
•Instruct patient to lie still duri ng scan, even if they experience warmth or tingling due
to the injection of contrast.
•Initiate contrast injection.
•When contrast rea ches threshold at bolus -tracking location, instruct patient to hold
breath at end -inspiration, then initiate main scan.
•At completion of scan , verify scan is of adequate quality.
•Record amount of contrast given.
•Record heart rate average and range.
•Record dose -length -product
4.4.2  Example Post -processing  Procedure
•Verify heart rate ECG triggers are at consistent place in cardiac cycle, edit if
necessary. Additional editing/removal of arrhythmias may be performed.
•Reconstruct at multiple phases (20 p referred, increments of 5 -10%), with ≤0.8mm
slice thickness. If the system has the capability, also reconstruct a “best systolic” and
“best diastolic” phase.
4.5 Step 5: Submission of CT data
All available CT data should be sent electronically to the data center (Core Laboratory).
•Data should be stored in DICOM 3.0 format, not DICOMDAT.
•Submitted images must have patient identifiers (protected health information (PHI)
such as name, date of birth, medical record number) removed at time of image
transfer to  the data center.
•Please use the following during anonymization:
CTA Acquisition Guidelines (CIP-09-2 ver  03)   Confidential Page 7 oModality  = CT
o“Body Part Examined” contains the value  = CHEST
o“Protocol Name” contains any of the values  = PWI, Brain, Neuro, Perf,
Low Grade
o“Series Description” contains any of the values  = CHEST TOPOGRAM,
ECG NON CONTRAST AORTIC ROOT, ECG CONTRAST AORTIC ROOT,
ECG CONTRAST THORATIC AORTA, NON ECG CONTRAST ABDOMINAL
AORTA NON ECG CONTRAST PERIPHERAL VESSELS.
•Submitted i maging studies should be labeled as follow s: CCSC TC-SNR
CC- is the region ID which will be assigned in two letter format (US or UK).
SC- is the site ID which will be assigned in two number format (01, 02, etc.).
TC- is the internal ID which will be assigned in two number format (for REFLECT the
number is 09 ).
SNR- is the subject number which will be assigned in three  number format ( 001, 002,
etc.)
•Please provide all the following images if available :
oChest Topogram
oECG -gated non -contrast scan of aortic root and aortic arch
oECG -gated contrast enhanced scan of aortic root and thoracic aorta,
immediately followed by non -ECG -gated contrast scan of abdominal aorta and
peripheral vessels
Instructions for submission of CT imaging data will be reviewed with each site during CT
Protocol Training sessions. Images will be sent via e lectronic transfer  using the transfer
solution.  
Instructions will be provided during site set -up.  Reference the transfer solutions Site User
Guide and/or the  Quick Reference Sheet for specific instructions regarding the electronic
transfer of CT images.
CTA Acquisition Guidelines (CIP-09-2 ver  03)   Confidential Page 8 Table 1. Suggested Scan Parameters  for contrast enhanced scan of aortic root , aorta and
peripheral vessels
Dual -Source CT Single -Source CT
IV injection with iodine
contrast100-120 (320 mg/ml or higher)
Injection Rate 4-5 mL/s
Bolus tracking, delay Delay time calculated using protocol for current scanner
(bolus tracking, etc.) with triggered by contrast
concentration >100 HU in the high descending aorta
ECG Leads Required
ECG -gating Retrospective ECG -gating from TMJ to diaphragm;
then non -ECG -gating from diaphragm to mid -thigh
Scan direction Cranial -caudal
Scan coverage From above the temporal mandibular joint to the mid-thigh
Detector collimation 0.4-0.625 mm
Pitch 0.2-0.43 adapted to the
heart rate0.2 adapted to heart rate
Dose modulation Modulation between 30 % and 80% of the cardiac cycle
Slice thickness 0.8mm
Slice overlap 0.4mm
Reconstruction kernel B25 Smooth++ Medium Smooth
Post-processing Use retrospective ECG gating reconstruction algorithm that
minimizes motion artifact. Reconstruct at multiple phases
(20 preferred, increments of 5 -10%). Reconstructed slice
thickness 0.4 -0.6 mm.
REFLECT – US IDE Trial [CIP -09 (v13.0)]  Keyston e Heart Ltd.  
19016.11  Appendix XI: SF-36 Health Survey  
The Short Form Short Form 36 Health Survey (SF -36v2) is copyright Medical Outcomes Trust  
and Quality  Metric Incorporated, and is licensed for use in this trial; authorized copies, 
alternate versions, and translations will be provided as required. A sample form is provided 
below for informational purposes.  
SF-36v2® Health Survey  1992, 1996, 2000 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved.  
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey  Acute, United States (English))  Your Health and Well -Being  
This survey asks for your views about your health.  This information will help 
keep track of how you feel and how well you are able to do your usual activities. 
Thank you for completing this survey!  
For each of the following questions, please mark an  in the one box that best 
describes your answer.  
1.In gene
ral, would you say your health is:
Excellent  Very good  Good Fair Poor      
   1    2    3    4    5 
2.Compared to one week ago, how would you rate your health in general
now? 
Much better 
now than one 
week ago  Somewhat 
better  
now than one 
week ago  About the 
same as one 
week ago  Somewhat 
worse  
now than one 
week ago  Much worse 
now than one 
week ago  
    
   1    2    3    4    5 
 
SF-36v2® Health Survey  1992, 1996, 2000 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved.  
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey  Acute, United States (English))  3. The following questions are about activities you might do during a typical 
day.  Does your health now limit you  in these activities?  If so, how much?  
 
  Yes,  
limited  
a lot Yes, 
limited  
a little  No, not 
limited  
at all  
      a Vigorous activities , such as running, lifting  
heavy objects, participating in strenuous sports ......................  1 .............  2 .............  3 
 b Moderate activities , such as moving a table, pushing  
a vacuum cleaner, bowling, or playing golf .............................   1 .............   2 .............   3 
 c Lifting or carrying groceries  ....................................................  1 .............  2 .............  3 
 d Climbing several  flights of stairs  .............................................  1 .............  2 .............  3 
 e Climbing one flight of stairs  ....................................................  1 .............  2 .............  3 
 f Bending, kneeling, or stooping ................................................  1 .............  2 .............  3 
 g Walking more than a mile  ........................................................  1 .............  2 .............  3 
 h Walking several hundred yards ...............................................  1 .............  2 .............  3 
 i Walking one hundred yards .....................................................  1 .............  2 .............  3 
 j Bathing or dressing yourself ....................................................  1 .............  2 .............  3 
SF-36v2® Health Survey  1992, 1996, 2000 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved.  
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey  Acute, United States (English))  4.During the past week , how much of the time have you had any of the
following problems with your work or other regular daily activities as a
result of your physical health ?
All of 
the time  Most of 
the time  Some of 
the time  A little of 
the time  None of 
the time      
a Cut down on the amount of  
time you spent on work or 
other activities  ..................................  1 ..............  2 ..............  3 ..............  4 ............. 5
b Accomplished less  than you 
would like ........................................  1 ..............  2 ..............  3 ..............  4 ............. 5
c Were limited in the kind of 
work or other activities  ....................   1 ..............  2 ..............   3 ..............   4 .............  5
d Had difficulty  performing the 
work or other activities (for 
example, it took extra effort) ...........  1 ..............  2 ..............  3 ..............  4 ............. 5
5.During the past week , how much of the time have you had any of the
following problems with your work or other regular daily activities as a
result of any emotional problems  (such as feeling depressed or anxious)?
All of 
the time  Most of 
the time  Some of 
the time  A little of 
the time  None of the time  
    
a Cut down on the amount of  
time you spent on work or 
other activities  ..................................  1 ..............  2 ..............  3 ..............  4 ............. 5
b Accomplished less  than you 
would like ........................................  1 ..............  2 ..............  3 ..............  4 ............. 5
c Did work or other activities 
less carefully than usual  ...................  1 ..............  2 ..............  3 ..............  4 ............. 5
 
SF-36v2® Health Survey  1992, 1996, 2000 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved.  
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey  Acute, United States (English))  6. During the past week , to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, 
neighbors, or groups?  
Not at all Slightly  Moderately  Quite a bit Extremely       
   1    2    3    4    5 
 
 
   
7. How much bodily pain have you had during the past week ? 
None Very mild  Mild  Moderate  Severe  Very severe        
   1    2    3    4    5    6 
  
 
  
8. During the past week , how much did pain  interfere with your normal work 
(including both work outside the home and housework)?  
Not at all A little bit  Moderately  Quite a bit Extremely       
   1    2    3    4    5 
 
SF-36v2® Health Survey  1992, 1996, 2000 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved.  
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey  Acute, United States (English))  9. These questions are about how you feel and how things have been with you 
during the past wee k.  For each question, please give the one answer that 
comes closest to the way you have been feeling.  How much of the time during the past week … 
  
10. During the past week , how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with 
friends, relatives, etc.)?  
All of  
the time  Most of  
the time  Some of  
the time  A little of  
the time  None of 
the time       
   1    2    3    4    5 
 
  All of  
the time  Most of  
the time  Some of  
the time  A little of  
the time  None of 
the time  
      
 a Did you feel full of life?  ..................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 b Have you been very nervous? ..........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 c Have you felt so down in the  
dumps that nothing could  cheer you up? ...................................
 1 ..............  2 ..............  3 ..............  4 ..............  5 
 d Have you felt calm and  
peace ful? ................................ ..........  1 ..............   2 ..............  3 ..............  4 ..............  5 
 e Did you have a lot of energy? ..........  1 ..............  2 ..............  3 ..............  4 ..............  5 
 f Have you felt downhearted   
and depressed?  ................................ . 1 ..............   2 ..............  3 ..............  4 ..............  5 
 g Did you feel worn out? ....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 h Have you been happy? .....................  1 ..............  2 ..............  3 ..............  4 ..............  5 
 i Did you feel tired? ...........................  1 ..............  2 ..............  3 ..............  4 ..............  5 
SF-36v2® Health Survey  1992, 1996, 2000 Medical Outcomes Trust and QualityMetric Incorporated.  All rights reserved.  
SF-36® is a registered trademark of Medical Outcomes Trust. 
(SF-36v2® Health Survey  Acute, United States (English))  11. How TRUE or FALSE is each  of the following statements for you?
Definitely 
true Mostly 
true Don’t 
know Mostly 
false  Definitely 
false      
a I seem to get sick a little  
easier than other people  ..................  1 ..............  2 .............  3...............  4 ..............  5 
b I am as healthy as 
anybody I know  ..............................   1 ..............  2 .............   3...............   4 ..............   5 
c I exp ect my health to 
get worse  .........................................  1 ..............  2 .............  3...............  4 ..............  5 
d My health is excellent  .....................  1 ..............  2 .............  3...............  4 ..............  5 
Thank you for completing these questions!